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The development of reagents allowing the reversal of the standard reactivity (Umpolung) of small building blocks is an important field of research in 
chemistry, as it allows increasing the flexibility of organic synthesis. Indoles and pyrroles are ubiquitous heterocycles in natural products and drugs. They 
are usually functionalized making use of their high nucleophilicity. In contrast, only few methods are based on the use of electrophilic indole and pyrrole 
synthons, as the needed reagents are highly unstable or can be used only with a very narrow scope. Herein, we report the serendipitous discovery and 
first use in the C-H functionalization of arenes of IndoleBX and PyrroleBX, new thermally highly stable benziodoxol(on)e hypervalent iodine reagents. 
IndoleBX and PyrroleBX could be obtained in one step from the corresponding heterocycles and acetoxy benziodoxolone using a Lewis acid catalyst. The 
mild reactions conditions allowed the introduction of a broad range of functional groups, including ethers, halogens and boronic esters. The new reagents 
could then be used in the rhodium- and ruthenium- catalyzed C-H heteroarylation of arene rings bearing heterocyclic or benzamide directing groups. 
Such transformations could not be realized using previously reported C-H functionalization procedures. 
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Introduction 
Pyrroles and indoles are among the most ubiquitous azoles present in 
nature. These heterocycles can be found in pharmaceuticals,[1] fragrances, 
agrochemicals and natural products (scheme 1a).[2] First discovered in the 
late 19th century by Bayer,[3] their popularity increased when many indole-
containing alkaloids such as Reserpine (1)[4] or Dictyodendrins A-E (2)[5,6] 
were found to be biologically active. Indole and pyrrole rings are also well 
represented in top selling drugs such as Atorvastatin (3) and Fluvastatin 
(4).[7] As a consequence of this interest, countless methods for both 
synthesis and functionalization of indoles and pyrroles were developed.[8–
10] As they are electron-rich heterocycles, they undergo electrophilic 
aromatic substitutions at a higher rate than the benzene ring.[11] Of 
particular interest are arylation methods, as arylated heterocycles have 
found widespread applications in synthetic and medicinal chemistry. The 
most often used approach is cross-coupling, but it requires pre-
functionalized building blocks and generates a significant amount of 
waste.  
Recently, strong interest arouses in direct C-H arylation, as a more direct 
method for heterocyclic functionalization (scheme 1b). Most works have 
made use of the high nucleophilicity of indoles and pyrroles for C-H 
functionalization with activated electrophilic arene partners, such as 
halides.[12] Of particular importance are the works of Sanford,[13] Gaunt,[14] 
and coworkers, in which electron-rich indoles and pyrroles are coupled 
with hypervalent iodonium salts in the presence of catalytic amounts of 
Pd(II) or Cu(I) under mild reaction conditions. Ackermann and coworkers 
also reported a metal free arylation of indoles with aryl iodonium salts.[15] 
These works among others fully establish aryl iodonium salts as 
exceptional reagents for C-H functionalization under mild conditions.[16] 
However, the nearly exclusive focus on the innate nucleophilicity of 
indoles and pyrroles to couple them with electrophilic pre-activated 
arenes fundamentally limits the diversity of accessible structures. In this 
respect, Fagnou and co-workers reported the elegant direct oxidative 
coupling of two C-H bonds between arenes and indoles, which allows also 
the use of electron-rich partners (scheme 1b).[17,18] However, this approach 
required a large excess of the arene and high temperatures, often resulting 
in regioisomeric mixtures of products and low functional group tolerance. 
More efficient processes were possible only in special cases, such as 
coupling with activated azoles[19–24] or perfluorinated benzene rings..[25,26] 
Therefore, the availability of electrophilic indole or pyrrole synthons able to 
react with nucleophilic arene partners by C-H functionalization would 
tremendously enhance the range of accessible arylated heterocycles.  
Nevertheless, accessing such synthons constitutes a formidable challenge. 
Only few successful approaches with a narrow scope of electronically 
biased substrates or relying on reactive electrophilic indolyl intermediates 
generated in situ have been reported.[27] Hypervalent Iodine reagents have 
been frequently applied to achieve the Umpolung of different 
nucleophiles.[28–32] In particular, the Umpolung of indoles and pyrroles was 
realized by Kita and co-workers by in situ generation of non-isolable 
hypervalent iodine intermediates from phenyliodonium ditrifluoroacetate 
(PIDA).[33] This approach was used in the total synthesis of indole 
alkaloids.[34] These reports showed the possibility of nucleophilic 
functionalization of electron-rich heterocycles, via in-situ formation of 
hypervalent iodine intermediates. Nevertheless, the instability of the 
formed intermediates limited the scope and applications of these methods. 
Unfortunately, only few examples of isolable indole and pyrrole-based 
iodonium salts have been reported. 
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Scheme 1. a) Examples of indole- and pyrrole-containing natural products and top selling drugs. b) State of the Art of transition metal catalyzed indole C-H arylation. 
 
Indole-based iodonium salts were first reported in the 70s by Neiland and 
coworkers,[35,36] followed by the groups of Kost,[37,38] and Moriarty.[39] A 
multi-step procedure via a spontaneously self-detonating betaine 
intermediate was required to access these reagents: the obtained salts 
were unstable and could again be used only for a limited range of 
transformations. Only halogenation[37,38] and alkylation[39] with organo-
lithium reagents were reported. Recently, more stable azole-based 
iodonium reagents were reported by Suna and coworkers.[40,41] 
Nevertheless, the azoles needed to be deactivated by electron-
withdrawing groups in order to stabilize the reagents. Suna and coworkers 
reported two applications of these reagents: a Cu(I)-catalyzed azidation in 
which the final product was converted in situ via click chemistry,[40] and an 
amination.[41] More stable iodonium salts were reported by Moriyama,[42,43] 
Kita[44] and coworkers, but again, an electron-withdrawing group on the 
nitrogen was required to stabilize the reagents. Furthermore, a recent 
example of de-aromatization of indoles by using Neiland’s NH-indole 
iodonium salt was reported by Liu et al.[45] This still constitutes the only 
example of metal catalysis involving indole-based iodonium salts not 
stabilized by electron-withdrawing protecting groups. To the best of our 
knowledge, indole and pyrrole iodonium salts have never been used in the 
metal-catalyzed arylation of C-H bonds, probably because of their limited 
stability, especially at higher temperatures. Clearly, the development of 
better indole and pyrrole electrophilic synthons combining high reactivity 
with enhanced stability is urgently needed.  
Since several years, our group has investigated the reactivity of more 
stable cyclic hypervalent iodine reagents in group transfer reactions.[32] In 
particular, EthynylBenziodoXol(on)es (EBX) reagents have been used 
successfully for the Umpolung of alkynes.[46,47] They were especially 
employed by us and others in metal-catalyzed C-H alkynylation of 
(hetero)arenes (scheme 2a).[48–59] Recently, we have reported preliminary 
results on the synthesis and use of new stable indole- and pyrrole- 
benziodoxol(on)e reagents (Indole- and Pyrrole- BX) and their use in the 
Rh(III)- and Ru(II)-catalyzed C-H functionalizations of arenes.[60] Herein, we 
present a full account of this work, including: (1) the serendipitous 
discovery of the reagents when attempting the development of further 
domino transformations for the synthesis of functionalized indoles based 
on our previous work in this area[61–64] (scheme 2b), (2) a detailed report on 
the synthesis and structure analysis of both benziodoxole and 
benziodoxolone heterocyclic reagents and (3) details on the optimization 
and scope of the new C-H functionalization reactions (scheme 2c). 
Results and Discussion 
While direct functionalization methods of heterocyclic rings are well 
developed, they remain limited to more reactive C-H bonds, in particular 
the C2 or C3 positions in heteroarenes (scheme 2a). Metal catalyzed 
domino reactions constitute in this case an interesting alternative, as they 
give access to heterocycles functionalized at other positions. Our group 
reported several domino
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Scheme 2. a) and b) Previous work of the group on the synthesis of alkynylated heterocycles via C-H functionalization or domino processes. c) This work. 
 
approaches for the synthesis of heterocycles alkynylated on the benzene 
ring (scheme 2b). C3-alkynylated furans were obtained starting from α-
allenyl ketones.[62] A gold(III) catalyst was initially used for this 
transformation, but in situ formation of an active gold(I) catalyst was 
proposed later based on computational studies.[65] C5- and C6- alkynylated 
indoles were built starting from alkylated pyrrole precursors: Starting from 
C3-alkylated pyrroles C6-alkynylated indoles were obtained, while C2-
alkylated pyrroles afforded C5-alkynylated indoles.[63] Finally, several C3 
alkynylated benzothiophenes and benzofurans were synthesized from 
aryl-thiols and phenols.[64]  
Based on these results, our initial aim was to expand the scope of domino 
transformations to other hypervalent iodine reagents, in particular 
azidobenziodoxol(on)es (ABX).[66–68] Our choice of ABX was justified by the 
large number of applications and chemical modifications related to azides, 
such as reduction to amines or cycloaddition with alkynes [69] and the 
recent success reported with this reagent for azide transfer reactions.[70–78] 
Best results in the domino cyclization-alkynylation reactions had been 
obtained with hexafluoroisopropanol derived reagent 6. Therefore the 
corresponding reagent 8 containing an azide was synthesized[66] and the 
domino cyclization-azidation of pyrrole 7 was attempted under the 
conditions successful for alkynylation (the solvent was changed to 
solubilize the ABX reagent 8). However, we did not obtain the desired 
azidated indole 9, but we observed the full conversion to a polar 
compound containing 1H NMR signals corresponding to a 2-iodobenzoate 
ring and a substituted pyrrole, without modification of the alkyl 
substituent (Eq. 1). The same result was obtained in absence of the 
platinum catalyst. 
 
To explain the observed NMR spectra, we first hypothesized that a new C-
O bond had been formed between the alcoholate and the pyrrole ring to 
give heterocycle 10. Due to the good leaving group ability of the azide, 
nucleophilic attack of the pyrrole ring followed by re-aromatization and 
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release of hydrazoic acid would give hypervalent iodine reagent 11. At this 
stage, we speculated that this intermediate would be unstable and 
undergo reductive elimination to give 10. Unfortunately, the new 
compound was unstable, and it was not possible to confirm its structure. 
As the new transformation did not involve the alkyne triple bond, we 
decided to study simple commercially available N-methyl pyrrole (12) and 
N-methyl indole (14) as starting materials (Eq. 2) and 3)). For pyrrole 12, we 
again observed the formation of a 1:1 C2:C3-functionalized separable 
mixture of two highly polar regioisomers; these two compounds were 
stable and obtained in a combined excellent yield of 91% (Eq. 2)). In case 
of indole 14, a single C3-functionalized product was obtained in 25% yield 
(Eq. 3).  
 
At this point, we still hypothesized that we had formed a new C-O bond 
with the heterocycle (structures 13 and 15). However, extensive NMR 
analysis performed on the product obtained from indole 14 were not in 
agreement with this assignment, and fitted better with structure 17 still 
containing a hypervalent iodine atom (figure 1). First, the expected proton 
and carbon chemical shifts around the iodine atom were estimated for 
both envisaged structure 15 and 17 based on the reported values for 1-
(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)-2-iodobenzene,[79] indoles 
bearing an oxygen substituent on the C3 position,[80,81] 
hexafluoroisopropanol derived hypervalent iodine reagents[62] and indole 
iodonium salts.[26] The observed indole C2 1H signal at 7.51 ppm is in lower 
field than expected for a compound such as 15, but this fact alone was not 
sufficient to support the hypervalent structure. Hypervalent iodine 
compounds can usually be easily differentiated from the corresponding 
iodines via the 13C chemical shift of the adjacent carbon, which appears in 
about 20-30 ppm in lower field. However, in the specific case of the 
alternative structures 15 and 17, the influence of the iodine atom and the 
indole core on the chemical shift are expected to compensate each other, 
leading in each case to two signals around 80-90 ppm and one signal at 
110-120 ppm for the carbon atoms in proximity to the iodine atom (figure 
1a). The observed values of 81.7, 84.5 and 112.2 ppm are in better 
agreement with the hypervalent iodine structure, but the difference is not 
enough to be sure of the assignment. Fortunately, the positions of the 
aromatic signals in higher field is different for the two proposed structures: 
on the benzene ring for 15 and on the indole for 17.  
 
 
Figure 1. Structure assignment of 17 based on NMR analysis. All values are chemical shifts in ppm. 
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Extensive 2-D NMR experiments allowed a full assignment of the signals[82] 
and unambiguously showed that the signal at 112.2 ppm was on the 
benzene ring and the one at 84.5 ppm on the indole, supporting 
hypervalent structure 17. HMBC correlations between the arene C-H 
signals at 6.96 and 7.86 ppm and the quaternary carbon at 112.2 ppm, as 
well as between the C2 indole C-H signal at 7.54 ppm and the quaternary 
C3 carbon at 84.2 ppm were especially important for the structure 
assignment (Figure 1b).  
Establishing the hypervalent structure of the obtained products was an 
important step, as benziodoxole-based indole or pyrrole reagents had 
never been reported before. We therefore decided to further improve the 
synthesis of these new "Indole-BX" and "Pyrrole-BX" reagents in order to 
study their properties and potential synthetic applications (table 1). Indole 
reagent 17 could be obtained only in 25% yield using azidobenziodoxole 
reagent 8, (table 1, entry 1). The influence of the leaving group on the 
iodine was first investigated. In fact, azido-substituted hypervalent iodine 
reagents are often unstable and toxic azide salts are generated during the 
reaction. We then decided to employ 1-acetoxy-1,3-dihydro-3,3-
bis(trifluoromethyl)-1,2-benziodoxole (18), a more stable and readily 
available reagent.[83] However, no reaction was observed (table 1, entry 2). 
Lewis acids, in particular zinc(II) triflate, have been used by our group and 
others for the activation of benziodoxole reagents.[71,84] In fact, when a 
catalytic amount of zinc(II) triflate was added, a promising 56% yield of 17 
was obtained (table 1, entry 3). As hexafluoroisopropanol-derived 
hypervalent iodine reagents are expensive, we then tested 1-hydroxy-1,2-
benzodioxol-3 -(1H)-one (19)[85] under these conditions, but the desired 
product 21 was not obtained (table 3, entry 4). In contrast, 36% yield of 21 
was isolated starting from acetoxy benziodoxolone 20[86] (table 1, entry 5). 
No product was obtained in absence of zinc(II) triflate (table 1, entry 6). 
Table 1. Optimization of the synthesis of IndoleBX 17 and 21. 
 
Entry Reagent Y X Solvent (M) Additive (mol%) Yield %a 
1 8 (CF3)2  N3 Et2O (0.05) - 25% 
2 18 (CF3)2  OAc Et2O (0.05)  -b 
3 18 (CF3)2  OAc Et2O (0.05) Zn(OTf)2 (10) 56% 
4 19 O  OH Et2O (0.05) Zn(OTf)2 (10) -b 
5 20 O OAc Et2O (0.05) Zn(OTf)2 (10) 36% 
6 20 O OAc Et2O (0.05) - -b 
7 20 O OAc Et2O (0.05) TMSOTf (10) 16% 
8 20 O OAc Et2O (0.05) Cu(OTf)2 (10) 36%c 
9 20 O OAc Et2O (0.05) AgNTf2 (20) -c 
10 20 O OAc Et2O (0.05) TBAF (20) -c 
11 20 O OAc Et2O (0.05) AgF (20) -c 
12 20 O OAc THF (0.05) Zn(OTf)2 (10)  
13 20 O OAc DCM (0.05) Zn(OTf)2 (10) fulld 
14 20 O OAc DCM (0.05) Zn(OTf)2 (20) 97% 
a) Substrate 14 (0.100 mmol), reagents 8, 18-20 (0.110 mmol), additive (10-20 mol%), and solvent (0.05 M) at 25 °C. Isolated yield after flash chromatography 
is given. b) No conversion: starting materials recovered. c) Complete decomposition of the hypervalent iodine reagents. d) 2.2 equiv. of 20 were required. 
 
Other Lewis acid could be also used in this transformation, but with inferior 
results: TMSOTf gave the product in 16% yield only (table 1, entry 7); In the 
case of Cu(II) triflate, although a similar yield was obtained, significant 
decomposition of products 21 into N-methyl-3-iodo-indole was observed 
(table 1, entry 8). No product could be isolated with a silver(I) catalyst (table 
1, entry 9). As fluoride-substituted benziodoxole reagents have been 
successfully used as precursors in previous works,[87] fluoride sources were 
then examined, but without success (table 1, entries 10 and 11). Finally, we 
decided to screen other solvents, as Zn(OTf)2 was only scarcely soluble in 
Et2O. When THF was used, no product was obtained probably due to the 
low solubility of benziodoxolone 20 in this solvent (table 1, entry 12). In 
DCM, full conversion was observed, but it required the use of two 
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equivalents of benziodoxolone 20 (table 2, entry 13). Full conversion and 
an excellent 97% yield could be obtained by raising the amount of zinc(II) 
triflate to 20 mol% (table 1, entry 14). The developed protocol based on the 
catalytic use of a relatively mild Lewis acid is noteworthy, as most 
syntheses of alkynyl, vinyl or aryl benziodoxolone reagents usually require 
a stoichiometric amount of strong Lewis or Brønsted acid.[32,88,89] In fact, 
these reported procedures were not successful for the synthesis of 
IndoleBX 21, as they led to complete decomposition of indole 14. 
Furthermore, IndoleBX 21 displayed excellent thermal stability properties 
when compared to indole iodonium salts. A DSC measurement showed 
that significant decomposition started only at 151 °C, with a peak 
maximum at 183 °C (figure 2). An exothermic decomposition (283 J/g) was 
observed, with a peak height of 17.3 mW and a peak width of 3.7 °C.[90]  
 
Figure 2. DSC measurement of IndoleBX 21. 
When the reaction was scaled up to 0.2 mmol, Indole-BX 21 was obtained 
in 87% yield (eq. 4)). No decrease in yield was observed when scaling up to 
1-10 mmol (gram scale). The developed protocol could also be applied to 
benziodoxole reagents. The yield of hexafluoropropanol-derived 
benziodoxole 17 was also improved under these reaction conditions. The 
dimethyl reagent 23 was also synthesized in 51% yield. The developed 
reaction conditions could not be used for N-unprotected indoles. 
Nevertheless, the use of N-TBS protected indole (24) afforded a mixture of 
unreacted starting material, N-TBS protected reagent in low yield and a 
small amount of NH free indole reagent 25. When 20 mol% of Sc(III) triflate 
was used instead, NH free reagent 25 could be obtained cleanly in 78% 
yield (eq. 5). Reagent 25 showed crystalline properties, unlike other 
reagents that presented a resin-like amorphous character. It was possible 
to obtain high quality crystal for X-ray analysis, which finally confirmed the 
hypervalent structure of the reagents (figure 3). 
 
 
 
 
Figure 3. ORTEP drawing of reagent (25)•H2O  
The method proved to be reliable also in the synthesis of reagents bearing 
different functional groups on the indole ring (figure 4). In case of electron-
donating functional groups such as methyl on the C2 position or methoxy 
on the C5 position, the respective reagents 26 and 27 were obtained in 
excellent yields. Halogen substituents were also tolerated under the 
reaction conditions: fluorine, chlorine and iodine containing reagents 28-
30 were synthesized in 62-85% yield. With a pinacol boronate in C5 
position, reagent 31 was obtained in moderate yield. The tolerance 
towards both halogen and boron substituents sets the stage for further 
functionalization via cross-coupling reactions. All these reagents could be 
synthesized on 1 mmol scale without the need for any re-optimization. We 
then investigated variation of the nitrogen substituent. Different alkyl 
chains were tolerated. While the N-phenyl-propyl reagent 32 and the N-3-
butenyl reagent 33 were isolated in very good yields, the N-triisopropyl-
ethoxy 34 suffered from a slight decrease in yield. 
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Figure 4. Scope of IndoleBXs: variation of the functional groups on indole. Reaction 
conditions: 1.00 mmol heterocycle, 1.10 mmol 20, 0.200 mmol Zn(OTf)2, 0.05 M in 
CH2Cl2, r.t., open air. Isolated yields. 
The synthesis of PyrroleBX reagents was then investigated (figure 5). When 
N-methyl or N-benzyl pyrroles were employed as starting materials, 
separable regioisomeric C2:C3 mixtures of reagents 35 and 36 were 
obtained in high yield. In the case of 36, the steric hindrance of the N-
substituent led to the formation of the C3 isomer as the major one. The 
importance of steric effects was confirmed by the use of a N-TBS group 
which led to the formation of C3-substituted reagent 37 exclusively by 
using Sc(OTf)3 as catalyst. As in the case of indole reagent 25, complete 
deprotection of the silyl group occurred. As for reagent 25, reagent 37 
showed good water solubility and crystalline properties. It was possible to 
obtain an X-ray analysis confirming the substitution at the C3 position 
(figure 6). 
 
Figure 5. Scope of PyrroleBX reagents. Reaction conditions: 1.00 mmol heterocycle, 
1.10 mmol 18, 20 or 22, 0.200 mmol Zn(OTf)2, 0.05 M in CH2Cl2, RT, open air. Isolated 
yields. [a] Sc(OTf)3 was used starting from N-TBS-pyrrole (TBS = tert-butyldimethylsilyl). 
 
  
Figure 6. ORTEP drawing of reagent 37•MeOH  
We then investigated if the nature of the reagent backbone could 
influence the C2:C3 ratio for PyrroleBX reagents. When applying the 
optimized conditions to the synthesis of the hexafluorodimethyl-scaffold, 
reagent 16 was again formed as a 1:1 mixture of isomers. However, when 
we performed the reaction with dimethyl precursor 22, benziodoxole 38 
was obtained as an inseparable 1:9 mixture of C2:C3 regioisomers. At this 
point, the reasons for the higher regioselectivity observed with this 
reagent are not clear. One possible explanation would be lower 
electrophilicity at the iodine center, which would lead to steric effects 
dominating about the higher nucleophilicity of the C2 position. 
In order to confirm this hypothesis, we decided to investigate the influence 
of electron-donating and electron-withdrawing groups when installed on 
the arene ring of the reagents (figure 7).[82] IndoleBX 39 could be obtained 
in 56% yield. The corresponding PyrroleBX reagent 40 was formed as a 1:2 
C2:C3 mixture of regioisomers. The ratio shifted slightly towards the less 
electron-rich and less encumbered C3 position when compared with 
reagent 35. A fluorine in meta position to the iodine did not influence 
massively the outcome of the reaction, as 41 was obtained as a 1:3 ratio of 
C2:C3 isomers. Finally, with a strong electron-withdrawing nitro group in 
para position to the iodine, the ratio reversed in favor of the C2 regioisomer. 
The desired reagent 42 was obtained with a 4:1 C2:C3 ratio in excellent 
yield. In this case, the iodine atom was expected to be highly electrophilic 
and electronic control would become more important than sterics. 
 
Figure 7. Scope of IndoleBXs and PyrroleBXs: modification of the benzene ring. 
Reaction conditions: 0.20 mmol heterocycle, 0.220 mmol acetoxybenziodoxolone, 
0.040 mmol Zn(OTf)2, 0.05 M in CH2Cl2, RT, open air. Isolated yields. 
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Finally, preliminary investigations were done for the synthesis of reagents 
bearing other heterocycles than indole or pyrrole (figure 8). Azaindole-
based reagent 43 was obtained in moderate yield and high C3 
regioselectivity. In case of CarbazoleBX 44, the yield was moderate, but the 
regioselectivity very high, as the iodine was bound exclusively to the 
carbon in para position to the nitrogen. ThiopheneBX 45 and 
DimethylFuranBX 46 were also synthesized in low to moderate yield. In 
this case, the corresponding iodonium salts are already known and have 
been applied in catalytic transformations.[91–96]  
 
Figure 8. Scope of other HeterocyclicBXs. Reaction conditions: 1.00 mmol 
heterocycle, 1.10 mmol 20, 0.200 mmol Zn(OTf)2, 0.05 M in CH2Cl2, RT, open air. 
Isolated yields. 
At this point only a highly speculative mechanism can be proposed for the 
formation of the IndoleBX reagents (scheme 3a). Activation of 
benziodoxole 20 by zinc(II) triflate would first give highly electrophilic 
iodonium intermediate I.[84] Nucleophilic attack of N-methyl indole (14) on 
the iodine center will then give intermediate II. The acetate ligand could 
then act as an internal base to re-aromatize the indole ring, leading to the 
formation of acetic acid and closing of the benziodoxole ring. Activation of 
the acetate as a leaving group by zinc(II) triflate followed by the acetate 
acting as an external base could also be considered. In previous 
mechanism studies involving the activation of heterocycles with 
hypervalent iodine reagents, the formation a charge-transfer (CT) complex 
between the hypervalent iodine reagent and the heterocycle had been 
proposed.[97,98] Single electron transfer would then give a radical cation 
intermediate that would recombine with the formed iodine radical. This 
mechanism appeared less probable to rationalize the formation of 
IndoleBX 21, based on the fact that (1) Moriarty and co-workers had 
observed a fast fragmentation of the radical formed from indole iodonium 
salt to give 3-iodo-indole and the benzene radical;[39] No 3-iodo indole was 
observed in our work; And (2) the high selectivity observed for the C3 
position is difficult to rationalize for a radical pathway. Formation of a C2-
bond iodine intermediate followed by migration can also be excluded, as 
the C2-enriched deuterium reagent 48 was obtained without the loss of 
any deuterium enrichment (scheme 3b). 
 
Scheme 3. Speculative mechanism and deuterium labelling experiment. For 
simplification, the exact geometry at the iodine center including the lone pairs is not 
drawn. 
With a broad range of new IndoleBX and PyrroleBX in hand, we started 
investigating possible applications. As previously stated in the 
introduction, arylated pyrroles and indoles constitute a class of versatile 
molecules, but their synthesis based on arene C-H functionalization has 
not been realized so far. In particular, (hetero)-arylated aryl-pyridines such 
as 52 (scheme 4) would be useful as key intermediates for the synthesis of 
optoelectronic materials.[99] However, no synthesis via direct ortho C-H 
functionalization has ever been reported, despite the tremendous recent 
progress in this area.[100] We first investigated if the indolation of pyridine 
49 would be possible using state-of-the-art C-H functionalization methods 
(scheme 4). Reported catalytic systems based on palladium(0) (A, B)[101,102] 
or palladium(II) (C, D)[59,103] precursors in combination with iodo- and 
bromo-indoles, did not lead to the formation of the desired product 52. 
Using a palladium(II)/copper(I) mixed system was also unsuccessful (E).[102] 
Oxidative methods reported for the direct C-H coupling of indoles were 
then examined. However, neither palladium (F, G)[18,104] or rhodium (H)[105]-
based methods, nor direct oxidation with hypervalent iodine reagents 
activated by Lewis acids (I) [92] worked efficiently. All the reported catalytic 
methods were screened at different temperatures, starting from 50 °C and 
increasing up to a maximum of 140 °C, in order to take into account 
different reaction kinetics.  
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Scheme 4. Attempted synthesis of 2-indolyl pyridine 52 using reported C-H 
functionalization methods. 
We then turned to the use of the new Indole-BX reagent 21. Although no 
product could be obtained using reported palladium-catalyzed protocols 
(A-E, scheme 4), 52 was obtained in 55% yield when using the mild 
conditions developed by Li and coworkers for the rhodium-catalyzed 
alkynylation of arenes with EBX reagents (Eq. 6)).[52] The product was 
obtained as a single C3 regioisomer with complete chemoselectivity, as 
the benzoate group was not transferred on the aryl-pyridine. This is 
noteworthy, as controlling the selectivity of aryl transfer from iodonium 
salts is generally challenging.[106] Furthermore, transfer of the benzoic acid 
is usually observed in the reaction of aryl benziodoxolones with 
nucleophiles.[89] Under these conditions, no product was obtained with 
either iodo- or bromo- indoles 50 and 51. Indolyl benzyl iodonium salt 
53[35] was also not successful. 
  
Based on this promising result (table 2, entry 1), we started to optimize the 
transformation. First, control experiments showed that no reaction 
occurred with Lewis acids only (table 2, entry 2), even using the conditions 
specifically developed by Kita and coworkers for the activation of 
hypervalent iodine reagents (TMSBr in HFIP, table 2, entry 3).[92] Several 
solvents were then screened (table 2, entries 4-7). In DCM, a lower yield 
was obtained (table 2, entry 4) and no product was observed in methanol 
or toluene (table 2, entries 5 and 6). In DMF a good 66% yield of 52 was 
obtained, but only upon heating at 110 °C (table 2, entry 7).  
Table 2. Optimization of the C-H indolation of pyridine 50.  
 
Entry Solvent (M) Base (mol%) Additive (mol%) Rh (mol%) T (°C)  Yield %a 
1 DCE - Zn(OTf)2 (10) [Rh(Cp*Cl2)2] (5) RT 55% 
2 DCE - Zn(OTf)2 (10) - RT - 
3 HFIP - TMSBr - RT - 
4 DCM - Zn(OTf)2 (10) [Rh(Cp*Cl2)2] (5) RT. 25% 
5 MeOH - Zn(OTf)2 (10) [Rh(Cp*Cl2)2] (5) RT - 
6 Toluene - Zn(OTf)2 (10) [Rh(Cp*Cl2)2] (5) RT - 
7 DMF - Zn(OTf)2 (10) [Rh(Cp*Cl2)2] (5) 110 66% 
8 DCE K2CO3 (10) - [Rh(Cp*Cl2)2] (5) RT 28% 
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9 DCE KOAc (10) - [Rh(Cp*Cl2)2] (5) RT 37% 
10 DCE KOPiv  [Rh(Cp*Cl2)2] (5) RT 49% 
11 DCE NaOAc (10) - [Rh(Cp*Cl2)2] (5) RT 69% 
12 DCE NaOPiv (10) - [Rh(Cp*Cl2)2] (5) RT 72% 
13 DCE - AgNTf2 (10) [Rh(Cp*Cl2)2] (5) RT -b 
14 DCE  AgSbF6 (10) [Rh(Cp*Cl2)2] (5) RT 17% 
15 DCE NaOPiv (10) AgSbF6 (10) [Rh(Cp*Cl2)2] (5) RT 90% 
16 DCE NaOPiv (10) AgSbF6 (10) [Rh(Cp*Cl2)2] (2.5) RT 78% 
17 DCE NaOPiv (10) AgSbF6 (10) [Rh(Cp*Cl2)2] (2.5) 50 82% 
18 DCE NaOPiv (10) AgSbF6 (10) [Rh(Cp*Cl2)2] (1.25) 50 37% 
a) Pyridine 49 (0.100 mmol), IndoleBX 21 (0.110 mmol), [Rh(Cp*Cl2)]2 (X mol%), base (X mol%), additive (X mol%) and solvent (0.1 M) at T °C. Isolated yield after flash 
chromatography is given. b) Decomposition of the hypervalent iodine reagent 21 was observed. 
 
To further facilitate a possible CMD (concerted metalation-deprotonation) 
at room temperature, we then screened carbonate and carboxylate salts 
instead of zinc(II) triflate.[107] While potassium salts gave moderate yields 
(table 2, entries 8-10), sodium salts worked better. NaOAc afforded 52 in 
69% yield and NaOPiv in 72% yield (table 2, entries 11-12). As Ag(I) salts are 
known to play a pivotal role in activating the catalyst by chloride 
abstraction to give ionic active species,[108] AgNTf2 and AgSbF6 were then 
examined as additive. In absence of a base, the former led to 
decomposition of the hypervalent iodine reagent 21, whereas the latter 
gave the desired product in 17% only (table 2, entries 13 and 14). 
Nevertheless, the combination of carboxylate bases and AgSbF6 increased 
the yield up to 90% (table 2, entry 15). Lowering the catalyst to 2.5 mol% 
unfortunately led to lower yield at room temperature (table 2, entry 16), 
but 82 % could be obtained when the temperature was increased to 50 °C 
(table 2, entry 17). When further lowering the catalyst loading, no full 
conversion could be obtained (table 2, entry 18). 
We then proceeded with the investigation of the scope of the new C-H 
functionalization (scheme 5). Differently substituted IndoleBX were first 
used and gave the desired heteroarylated-arylpyridines in very good yields 
(scheme 5A). In particular, NH-free indole product 54 could be accessed in 
74%, provided methanol was used as co-solvent for enhancing the 
solubility. A larger alkyl substituent on the nitrogen was also well tolerated 
(product 55). On the C5-indole position, an electron-donating methoxy 
group as well as electron-withdrawing halogens were well tolerated, and 
the products 56-59 were isolated in 74-89% yields. We were also delighted 
to see that the pinacol boronate group was compatible with our method, 
as boronic ester 60 could be accessed in 59% yield. When different 
PyrroleBX reagents were employed, the regioselective synthesis of 
products 61-65 became possible based on the availability of the pure 
reagent isomers (scheme 5B). In this case again, it was possible to access N 
unprotected pyrrole 65 in 79% yield. The presence of various functional 
groups on the aryl-pyridine substrate was then investigated (scheme 5C). 
Again, methoxy and halogen groups were well tolerated (products 66-68). 
We were pleased to see that a cyano group could also be introduced, as 69 
was obtained just by increasing the temperature to 80 °C. Ester 70 was 
formed in nearly quantitative yield.  Different other heterocyclic directing 
groups such as pyrimidines, pyrazoles and benzoquinolines could also be 
used (scheme 5D): products 71-73 were obtained in 72-81% without the 
need for re-optimization of the reaction conditions. A pyrimidine directing 
group could also be used for the synthesis of C2-C3 indole dimer 74. Finally, 
with the double amount of IndoleBX 21, di-indolated product 75 was 
isolated in 53% yield (scheme 5E). 
Quinolones and purines are other classes of important heterocycles in 
bioactive compounds. As shown in Figure 9, quinolone 76 could be 
synthesized in 38% yield. In this case, quinoline N-oxide was used as 
starting material. Functionalized purine base-containing nucleoside 77 
could be also obtained via C-H functionalization in 41% yield.[109] 
The obtained C-H functionalization products based on heterocyclic 
directing groups are highly useful building blocks for medicinal chemistry 
or organic materials. Nevertheless, they constitute “synthetic end points”, 
as the directing group cannot be easily removed. In order to enhance the 
synthetic versatility of the new C-H arylation, we therefore turned to the 
recently developed ruthenium catalyzed C-H functionalization of arenes 
using methoxy-amides directing groups (scheme 6).[56] This directing 
group is simple to install and easily transformable. Moreover, ruthenium is 
a cheaper and more abundant metal. In this case, similar targeted products 
were already synthesized in the past, but only via cross-coupling reactions 
requiring pre-functionalization of the arene ring.[110] Gratifyingly, when the 
conditions developed by Cheng and coworkers for C-H alkynylation with 
EBX reagents[56] were used with amide 78 and IndoleBX 21, the desired 
product 79 was obtained in 55% yield (scheme 6). Control experiments 
showed that no direct C-H coupling with N-methyl indole (14) was feasible 
under palladium- or rhodium-catalyzed conditions reported for this 
substrate (scheme 6, conditions A-C).[18,105,111]  
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Scheme 5. Scope of the Rh-catalyzed C-H (hetero)arylation. a) Reaction conditions: substrate (0.300 mmol), reagent (0.330 mmol), [Rh(Cp*Cl2)]2 (2.5 mol%), NaOPiv (10 mol%), 
AgSbF6 (10 mol%) and DCE (0.1 M) at 50 °C. Isolated yields. b) At 80 °C. c) At 100 °C. d) 0.1 M in DCE:MeOH (1:1 ratio). e) 0.660 mmol of IndoleBX 21 were used. 
 
Based on this promising result, the ruthenium-catalyzed C-H indolation of 
benzamide 78 was further optimized. Screening of solvent showed the 
importance of a fluorinated alcohols, as methanol and ethanol led to lower 
yield of 79 (table 3, entries 1-3). Chlorinated solvents that worked well for 
the rhodium-catalyzed process such as DCM and DCE did not afford any 
conversion (table 3, entry 4). The choice of the base was also fundamental: 
sodium carboxylate bases gave the best result (table 3, entries 5-6), but 
none of the simple carboxylates initially tested were superior to sodium 
acetate (table 3, entry 1). The corresponding potassium salts gave inferior 
results (table 3, entries 7-9). Based on these initial results, we decided to 
screen further sodium carboxylate salts (table 3, entries 10-13). While 
sodium benzoate (80) led to no conversion (table 3, entry 10). 
Adamantane-, xanthene- and diphenyl-based carboxylate salts 81-83 
afforded the desired compound 79 in 65-68% yield (table 3, entries 11-13) 
Although the three bases 81-83 afforded similar yields, adamantyl-
carboxylate base 81 led to a cleaner reaction profile. Different Ag(I) salts 
were also screened to further activate the catalyst,[82] but they prevented 
the reaction to occur (table 3, entry 14).  
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Figure 9. Indole-substituted quinolones and purines obtained by the Rh-catalyzed C-
H functionalization with IndoleBX 21. Reaction conditions: Substrate (0.300 mmol), 
Indole source (0.330 mmol), [Rh(Cp*Cl2)]2 (2.5 mol%), NaOPiv (10 mol%), AgSbF6 (10 
mol%) and DCE (0.1 M) at 50 °C. Isolated yields. a) At 100 °C.  
Finally, the expected active catalyst 84 was synthesized[112] and used in the 
reaction (table 3, entry 15). A similar result was obtained, but the protocol 
was more user friendly, as all reaction components could be added at the 
same time, only one degassing cycle had to be performed and no pre-
mixing was required. Moreover, the active complex was perfectly soluble 
in the reaction medium, allowing us to work under homogeneous 
condition. 
We then performed preliminary investigations on the scope of the new 
ruthenium-catalyzed C-H indolation, focusing this time on functional 
group substitution of the arene ring (figure 10). Substitution in para 
position to the amide was possible with both electron-rich (products 85 
and 86) and electron-poor (products 87 and 88) substituents. A broad 
range of substituents was also tolerated in meta position (products 89-92). 
Double-substitution in both positions was also possible (product 93). 
Functionalized naphthyl amide 94 could also be obtained in 79% yield. The 
fast synthesis of halogenated arenes is especially interesting for 
application in medicinal chemistry, either for further functionalization via 
cross-coupling reactions, or due to the interesting properties of fluorine in 
drugs, especially for blocking metabolism and increasing lipophilicity. 
 
Scheme 6. Lead result for the Ru-catalyzed C-H indolation and control experiments. 
 
 
Table 3. Optimization of the ruthenium-catalyzed C-H indolation.  
 
Entry Solvent (M) Base (mol%) Additive (mol%) Ru (mol%) Yield %a 
1 TFE NaOAc (16) - [Ru(p-CymeneCl2)]2 (4) 55% 
2 MeOH NaOAc (16) - [Ru(p-CymeneCl2)]2 (4) 43% 
3 EtOH NaOAc (16) - [Ru(p-CymeneCl2)]2 (4) 34% 
4 DCM/DCE NaOAc (16) - [Ru(p-CymeneCl2)]2 (4) - 
5 TFE NaOPiv (16) - [Ru(p-CymeneCl2)]2 (4) 50% 
6 TFE MesCOONa (16) - [Ru(p-CymeneCl2)]2 (4) 34% 
7 TFE KOAc (16) - [Ru(p-CymeneCl2)]2 (4) - 
8 TFE KOPiv (16) - [Ru(p-CymeneCl2)]2 (4) - 
9 TFE MesCOOK (16) - [Ru(p-CymeneCl2)]2 (4) 26% 
10 TFE 80 (16) - [Ru(p-CymeneCl2)]2 (4) - 
11 TFE 81 (16) - [Ru(p-CymeneCl2)]2 (4) 68% 
12 TFE 82 (16) - [Ru(p-CymeneCl2)]2 (4) 65%b 
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13 TFE 83 (16) - [Ru(p-CymeneCl2)]2 (4) 66% b 
14 TFE 81 (16) Ag(I)X (16)- [Ru(p-CymeneCl2)]2 (4) - 
15 TFE - - 84 (10) 68% 
 
 
a) Substrate 78 (0.100 mmol), IndoleBX 21 (0.110 mmol), [Ru(p-CymeneCl2)]2 (X mol%), base (X mol%), additive (X mol%) and solvent (0.1 M) at T °C. Isolated yield after flash 
chromatography is given. b) Decomposition was observed. 
 
Conclusions 
In this work, a full account of the synthesis of the hypervalent iodine 
reagents IndoleBX and PyrroleBX as a novel class of bench-stable 
electrophilic indole and pyrrole equivalents and their application in Rh(III) 
and Ru(II) catalyzed C-H (hetero)arylation of different arenes is described. 
In total 33 new hypervalent iodine reagents are reported. A broad range of 
different substituents could be introduced on the heterocycle and on the 
reagents backbone. N-Methyl-IndoleBX 21 was accessible on gram scale 
and presents high thermal stability. Based on the use of these new 
reagents, indoles and pyrroles were transferred directly on the C-H bond 
of various arenes in a mild, chemo- and regio-selective fashion. While Rh(III) 
was employed in combination with a heterocyclic nitrogen donor 
directing group, Ru(II) enabled the functionalization of versatile aryl-
methoxamides. The two methods were robust, and a broad scope was 
obtained as several functional groups were well tolerated. The synthesis 
and novel applications of heterocyclic-based hypervalent iodine reagents 
has just started in our laboratory and important progress can be expected 
in the future.  
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Figure 10. Scope of the Ru-catalyzed C-H (hetero)arylation. Reaction conditions: 
Substrate (0.300 mmol), IndoleBX 21 (0.330 mmol), 84 (10 mol%), and TFE (0.1 M) at 
60 °C.  
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1. Materials and Methods. 
All reactions were carried out in oven dried glassware under an atmosphere of nitrogen, unless 
stated otherwise. For quantitative flash chromatography, technical grade solvents were used. For 
flash chromatography for analysis, HPLC grade solvents from Sigma-Aldrich were used. THF, 
Et2O, CH3CN, toluene, hexane and CH2Cl2 were dried by passage over activated alumina under 
nitrogen atmosphere (H2O content < 10 ppm, Karl-Fischer titration). The solvents were degassed 
through Freeze-Pump-Thaw method when mentioned. All chemicals were purchased from Acros, 
Aldrich, Fluka, VWR, Aplichem, or Merck and used as such unless otherwise stated. 
Chromatographic purification was performed as flash chromatography using Macherey-Nagel 
silica 40-63, 60 Å, with the solvents indicated as eluent under 0.1-0.5 bar pressure. TLC was 
performed on Merck silica gel 60 F254 TLC glass plates or aluminium plates and visualized with 
UV light, permanganate stain, CAN stain, or Anisaldehyde stain. Melting points were measured on 
a Büchi B-540 melting point apparatus using open glass capillaries, the data is uncorrected. 1H-
NMR spectra were recorded on a Brucker DPX-400 400 MHz spectrometer in CDCl3, DMSO-d6 
CD3OD, C6D6 and CD2Cl2, all signals are reported in ppm with the internal chloroform signal at 
7.26 ppm, the internal DMSO signal at 2.50 ppm the internal methanol signal at 3.30 ppm, the 
internal dichloromethane signal at 5.30 ppm as standard. The data is being reported as (s = singlet, 
d = doublet, t = triplet, q = quadruplet, qi = quintet, m = multiplet or unresolved, br = broad signal, 
app = apparent, coupling constant(s) in Hz, integration, interpretation).13C-NMR spectra were 
recorded with 1H-decoupling on a Brucker DPX-400 100 MHz spectrometer in CDCl3, DMSO-d6, 
CD3OD or CD2Cl2, all signals are reported in ppm with the internal chloroform signal at 77.0 ppm, 
the internal DMSO signal at 39.5 ppm, the internal methanol signal at 49.0 ppm and the internal 
dichloromethane signal at 54.0 ppm as standard. Infrared spectra were recorded on a JASCO FT-
IR B4100 spectrophotometer with an ATR PRO410-S and a ZnSe prisma and are reported as cm-1 
(w = weak, m = medium, s = strong, br = broad). High resolution mass spectrometric 
measurements were performed by the mass spectrometry service of ISIC at the EPFL on a 
MICROMASS (ESI) Q-TOF Ultima API.  
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2. Preparation of PyrroleBXs and IndoleBXs.  
The synthesis of the precursors for HeterocyclicBX reagents 21, 25, 26-37, 43-46 and their starting 
materials had been already described before.[1,2] The procedures here reported are taken from the 
cited publications to facilitate reproduction of the results by having all the data in the same file. 
 
2.1 Preparation of Hypervalent Iodine Precursors. 
Following a reported procedure,[1] NaIO4 (7.24 g, 33.8 mmol, 1.05 equiv) and 2-iodobenzoic acids  
(8.00 g, 32.2 mmol, 1.00 equiv) were suspended in 30% (v/v) aq. AcOH (48 mL). The mixture was 
vigorously stirred and refluxed for 4 h. The reaction mixture was then diluted with cold water (180 
mL) and allowed to cool to room temperature, protecting it from light. After 1 h, the crude product 
was collected by filtration, washed on the filter with ice water (3 x 20 mL) and acetone (3 x 20 
mL), and air-dried in the dark to give the pure hydroxylated intermediates. 
Following a reported procedure,[2] hydroxylated intermediates (39.1 mmol, 1.00 equiv.) were 
suspended in acetic anhydride (35 mL) and heated to reflux for 30 minutes. The resulting clear, 
slightly yellow solution was slowly let to warm up to room temperature and then cooled to 0 °C 
for 30 minutes. The white suspension was filtered and the filtrate was again cooled to 0 °C for 30 
minutes. The suspension was once again filtered and the combined two batches of solid product 
were washed with hexane (2 x 20 mL) and dried in vacuo to afford products 20, 95-97. 
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1-Acetoxy-1,2-benziodoxol-3-(1H)-one 20 
1-Acetoxy-1,2-benziodoxol-3-(1H)-one 20 (10.8 g, 35.3 mmol, 90%) as a white 
solid. 1H NMR (CDCl3, 400 MHz) δ 8.24 (dd, J = 7.6, 1.6 Hz, 1H, ArH), 8.00 
(dd, J = 8.3, 1.0 Hz, 1H, ArH), 7.92 (ddd, J = 8.4, 7.2, 1.6 Hz, 1H, ArH), 7.71 
(td, J = 7.3, 1.1 Hz, 1H, ArH), 2.25 (s, 3 H, COCH3). 13C NMR (CDCl3, 100 MHz) δ 176.5, 168.2, 
136.2, 133.3, 131.4, 129.4, 129.1, 118.4, 20.4. NMR values are in accordance with the data reported 
in literature.[3] 
 
5,6-Dimethoxy-3-oxo-1λ3-benzo[d][1,2]iodaoxol-1(3H)-yl acetate (95) 
5,6-Dimethoxy-3-oxo-1λ3-benzo[d][1,2]iodaoxol-1(3H)-yl acetate 95 (12.8 
g, 35.0 mmol, 89%) was obtained as a white solid. 1H NMR (CDCl3, 400 
MHz) δ 7.63 (s, 1H, ArH), 7.36 (s, 1H, ArH), 4.02 (s, 3H, OMe), 4.00 (s, 
3H, OMe), 2.24 (s, 3H, OAc). 13C NMR (CDCl3, 100 MHz) δ 176.4, 168.4, 
155.9, 152.0, 121.8, 113.6, 110.0, 109.0, 56.6, 20.4. NMR values are in 
accordance with the data reported in literature.[4]  
4-Fluoro-3-oxo-1λ3-benzo[d][1,2]iodaoxol-1(3H)-yl acetate (96) 
4-Fluoro-3-oxo-1λ3-benzo[d][1,2]iodaoxol-1(3H)-yl acetate 96 (9.62 g, 29.7 
mmol, 76%) was obtained as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 
7.94 (td, J = 8.2, 4.7 Hz, 1H, ArH), 7.73 (d, J = 8.2 Hz, 1H, ArH), 7.62 (dd, J 
= 10.3, 8.2 Hz, 1H, ArH), 2.24 (s, 3H, OAc). 1H-NMR values are in accordance 
with the data reported in literature.[4]  
1-Acetoxy-5-nitro-1,2-benziodoxol-3(1H)-one ANBX (97) 
1-Acetoxy-5-nitro-1,2-benziodoxol-3(1H)-one 97 (8.71 g, 24.8 mmol, 64%) 
was obtained as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.71 (dt, J 
= 8.9, 2.7 Hz, 1H, ArH), 8.62 – 8.54 (m, 1H, ArH), 8.12 (dd, J = 23.8, 8.8 Hz, 
1H, ArH), 1.90 (s, 3H, OAc). 13C NMR (101 MHz, DMSO-d6) δ 172.0, 166.0, 
149.8, 133.5, 128.3, 128.2, 127.8, 124.9, 21.1. NMR values are in accordance 
with the data reported in literature.[5]  
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1-Chloro-1,3-dihydro-3,3-bis(trifluoromethyl)-1,2-benziodoxole (100)  
 
Following a reported procedure, TMEDA (distilled over KOH) (1.26 mL, 8.20 mmol, 0.200 equiv) 
was added to a solution of nBuLi (2.5 M in hexanes, 36.6 mL, 91.6 mmol, 2.20 equiv). After 15 
min, the cloudy solution was cooled to 0 °C and 98 (7.00 mL, 42.0 mmol, 1 equiv) in THF (6 mL) 
was added dropwise. The reaction was stirred 30 min at 0 °C and then at RT overnight. I2 (11.2 g, 
44.0 mmol, 1.06 equiv) was then added portionwise at 0 °C and the mixture stirred at 0 °C for 30 
min and 4 h at RT. The reaction was quenched with saturated NH4Cl. Et2O (100 mL) was added 
and the layers were separated. The aqueous layer was then extracted twice with Et2O (3 x 50 mL). 
The organic layers were combined, washed twice with saturated NaS2O3 (2 x 50 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure to afford 15.6 g of crude 99 as an brown 
oil which was used without further purification. The crude oil was dissolved in MeCN (40 mL) in 
the dark under air. Trichloroisocyanuric acid (3.42 g, 14.3 mmol, 0.340 equiv.) was then added 
portionwise at r.t. After 30 min, the resulting suspension was filtered to afford 100 (7.30 g, 18.1 
mmol, 43%) as a yellow solid. The mother liquors were carefully reduced to one third and filtered 
to afford more 27 (8.85 g, 21.9 mmol, 52.1% yield) as a yellow solid. Mp: 167 – 169 °C. 1H NMR 
(400 MHz, CDCl3) δ 8.09 (d, 1 H, J = 8.4 Hz, ArH), 7.85 (m, 1 H, ArH), 7.73 (m, 2 H, ArH). 13C 
NMR (101 MHz, CDCl3) δ 133.8, 132.1, 131.6, 129.7, 128.5, 122.8 (q, 289 Hz), 113.4, 84.8. The 
melting point and the 1H NMR correspond to the reported values.[6]  
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1-Acetoxy-1,3-dihydro-3,3-bis(trifluoromethyl)-1,2-benziodoxole (18) 
 
1-Chloro-1,3,-dihydro-3,3-bis(trifluoromethyl)-1,2-benziodoxole 100 (8.85 g, 21.9 mmol) and 
AgOAc (3.65 g, 21.9 mmol, 1 equiv.) were suspended in MeCN (109 mL, 0.2 M). After being 
stirred overnight in the dark, AgCl precipitated and was filtered off. The residue was washed with 
MeCN. The solvent was removed in vacuo to give 18 (9.37 g, 21.9 mmol, 100%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ  7.93 (d, J = 8.4 Hz, 1H, ArH), 7.61–7.79 (m, 3H, ArH), 2.18 (s, 
3H, CH3). The NMR values correspond to the reported ones.[3] 
 
1-Azido-3,3-bis(trifluoromethyl)-3-(1H)-1,2-benziodoxole (8). 
 
To a stirred mixture of 1-hydroxy-3,3-bis(trifluoromethyl)-3-(1H)-1,2- benziodoxole 18 (1.00 g, 
2.60 mmol) in dry CH3CN (20 mL) was added trimethylsilylazide (0.700 mL, 5.20 mmol) under 
nitrogen at room temperature. The reaction mixture was stirred for 18 h, and then the resulting 
yellow solution was evaporated in vacuum to give 8 as a pale crystalline solid (890 mg, yield 0.490 
g (92%); mp 147-150 °C (from CH3CN); IR ν 3076, 2048. 1H NMR (CDCl3:CD3CN 10:1) δ 7.89-
7.66 (m, 4H, ArH). The IR and NMR values correspond to the reported ones.[7] 
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2.2 Preparation of the Starting Materials for the Synthesis of PyrroleBXs and IndoleBXs. 
In this section, only the synthesis of non-commercially available indole compounds is reported. 
The synthesis of the precursors for HeterocyclicBX reagents 11, 16, 17, 21, 23, 26-48 had been 
already described by our group before. The procedures reported here are taken from the cited 
publications to facilitate reproduction of the results by having all the data in the same file.[8,9] 
 
2-(1-Methoxypent-3-yn-1-yl)-1-methyl-1H-pyrrole (105) 
 
A 50 mL two-necked flask was charged with Mg (321 mg, 13.2 mmol, 1.32 equiv), HgCl2 (2.7 mg, 
0.10 mmol, 0.01 equiv) and dry diethyl ether (30 mL), then propargyl bromide was added dropwise 
(2.86 g, 12.0 mmol, 1.20 equiv). When the solution became homogeneous, 103 (1.09 g, 10.0 mmol, 
1.00 equiv) was added dropwise. The reaction was quenched with sat NH4Cl solution (30 mL) 
when TLC (Pentane/EtOAc: 5/1) indicated that the aldehyde was completely consumed after 4 
hours. The aqueous and organic layers were separated; the aqueous layer was extracted with diethyl 
ether (3×20 mL). The combined organic layers were dried over MgSO4 and concentrated under 
vaccum to obtain 1.34 g crude product as brown oil. The crude product was used for the next step 
directly without further purification. Crude propargylic alcohol (1.34 g, 8.98 mmol, 0.89 equiv) in 
THF (18 mL) was added into a suspension of NaH (237 mg, 9.88 mmol, 0.98 equiv) in THF (18 
mL). 15 minutes later, MeI (1.40 g, 9.88 mmol, 1.10 equiv) was added into the mixture. The 
reaction was quenched with sat NH4Cl after 4 h. The aqueous and organic layers were separated 
and the aqueous layer was extracted with ether (3x10 mL). After drying over MgSO4, filtrating 
and concentrating under vacuum, the crude product was purified by column chromatography 
(Pentane:EtOAc= 15:1, 1 % Et3N) to afford 104 as brown oil (1.00 g, 6.13 mmol, 61 % over two 
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steps). Rf : 0.6 (Pentane:EtOAc 25:1). 1H NMR (400 MHz, CDCl3) δ 6.62 (m, 1 H, ArH), 6.18 
(dd, 1 H, J = 3.6, 1.8 Hz, ArH), 6.10 (dd, 1 H, J = 3.6, 2.7 Hz, ArH), 4.58 (t, 1 H, J = 6.9 Hz, CHO), 
3.68 (s, 3 H, NCH3), 3.27 (s, 3 H, OCH3), 2.79 (ddd, 2 H, J = 16.8, 6.5, 2.7 Hz, CH2), 2.05 (t, 1 H, 
J = 2.7 Hz, CH). 13C NMR (101 MHz, CDCl3) δ 129.9, 123.3, 108.5, 106.4, 80.7, 73.9, 69.8, 54.7, 
34.0, 24.0.  
448 mg of crude 104 (3.00 mmol), NaH (144 mg, 6.00 mmol, 2 equiv) and CH3I (1.06 g, 7.50 
mmol, 2.5 equiv) were used for the methylation with the same method as before. 105 was obtained 
as yellow oil (384 mg, 1.83 mmol, 48% over two steps). Rf: 0.5 (Pentane:EtOAc = 15:1). 1H NMR 
(400 MHz, CDCl3) δ 6.59 (m, 1 H, ArH), 6.15 (dd, 1 H, J = 3.6, 1.8 Hz, ArH), 6.08 (dd, 1 H, J = 
3.6, 2.7 Hz, ArH), 4.50 (m, 1 H, CHOCH3), 3.66 (s, 3 H, NCH3), 3.25 (s, 3 H, OCH3), 2.72 (m, 2 
H, CH2), 1.79 (t, 3 H, J = 2.6 Hz, CH3). 13C NMR (101 MHz, CDCl3) δ 130.4, 123.1, 108.2, 106.4, 
76.9, 75.4, 74.4, 54.6, 33.9, 24.3, 3.3. 
 
General Procedure GP1 for the N-Methylation of Indoles. 
 
The corresponding indole (1.00 - 5.00 mmol, 1.00 equiv.) was dissolved in dry THF (0.3 M). 
Sodium hydride (60% suspension in mineral oil; 1.50 equiv.) was slowly added under N2 flow at 0 
°C. After being stirred at 0 °C for 15 min,the reaction mixture was allowed to warm to r.t for 1.5 
h. It was then cooled back to 0 °C and methyl iodide (1.30 equiv.) was added. The mixture was 
warmed to r.t. and stirred overnight. After cooling again to 0° C, the reaction was quenched with 
water (10 mL), extracted with Et2O (3 x 10 mL), the combined organic layers were dried over 
MgSO4, and the solvent removed under reduced pressure. The resulting crude product was purified 
via flash column chromatography (Pentane:EtOAc 9:1-4:1), to give the desired N-methylated 
indole. 
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1,2-Dimethyl-1H-indole (106) 
Starting from commercially available 2-methylindole (656 mg, 5.00 mmol), 
1,2-dimethyl-1H-indole 106 (683 mg, 4.70 mmol, 94% yield) was obtained as 
an off-white solid. IR ν (neat) 3050 (w), 3020 (w), 2970 (m), 1610 (w), 1400 
(s), 1340 (m), 1240 (m), 930 (m), 910 (w), 780 (m), 750 (m), 730 (s). 1H NMR 
(400 MHz CDCl3) δ 7.69 (d, J = 7.8 Hz, 1H, ArH), 7.41 (dd, J = 8.1, 1.0 Hz, ArH), 7.32 (m, 1H, 
ArH), 7.24 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, ArH), 6.42 (s, 1H, NC(CH3)CH), 3.79 (s, 3H, NCH3), 
2.57 (d, J = 1.0 Hz, 3H, NCCH3). 13C NMR (125 MHz, CDCl3) δ  138.1, 136.9, 128.1, 120.6, 
119.8, 119.4, 108.8, 99.7, 29.5, 12.9. 1H NMR values are in accordance with the data reported in 
literature.[10] 
 
5-Methoxy-1-methyl-1H-indole (107) 
Starting from commercially available 5-methoxy-1H-indole (736 mg, 5.00 
mmol), 5-methoxy-1-methyl-1H-indole 107 (730 mg, 4.53 mmol, 91% yield) 
was obtained as a colorless crystalline solid. IR ν 2952 (w), 2918 (w), 2834 
(w), 1622 (m), 1608 (w), 1577 (w), 1496 (s), 1459 (w), 1450 (m), 1449 (m), 
1421 (s), 1347 (w), 1293 (w), 1243 (s), 1191 (m), 1152 (s), 1102 (w), 1026 (m), 942 (w), 855 (m), 
845 (w), 805 (s). 1H NMR (400 MHz, CDCl3) δ 7.30 (d, 1H, J = 8.5 Hz, ArH) 7.13 (s, 1H, ArH), 
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7.05 (s, 1 H, ArH), 6.92 (d, 1H, J = 8.8 Hz, ArH), 6.43 (d, 1H, J = 1.0 Hz, ArH), 3.90 (s, 3H, NMe), 
3.80 (s, 3H, OMe). 13C NMR (101 MHz, CDCl3) δ 154.0, 132.2, 129.3, 128.8, 111.9, 109.9, 102.5, 
100.4, 55.9, 33.0.  
 
5-Fluoro-1-methyl-1H-indole (108) 
Starting from commercially available 5-fluoro-1H-indole (676 mg, 5.00 mmol), 
5-fluoro-1-methyl-1H-indole 108 (683 mg, 4.58 mmol, 92% yield) was 
obtained as a colorless solid. IR 3104 (w), 2946 (w), 2922 (w), 2907 (w), 2887 
(w), 2362 (w), 2343 (w), 1626 (w), 1576 (w), 1514 (m), 1492 (s), 1449 (m), 
1423 (m), 1340 (m), 1283 (m), 1238 (s), 1228 (s), 1140 (m), 1129 (m), 1122 (m), 1100 (m), 1081 
(m), 1013 (w), 949 (m), 859 (m), 811 (s). 1H NMR (400 MHz, CDCl3) δ 7.31 (dd, J = 9.7, 2.4 Hz, 
1H, ArH), 7.26 (m, 1H, ArH), 7.12 (d, J = 3.1 Hz, 1H, ArH), 7.01 (dt, J = 9.1, 2 Hz, 1H, ArH), 
6.48 (dd, J = 3.1, 0.7 Hz, 1H, ArH). 3.81 (s, 3H, NCH3) 13C NMR (101 MHz, CDCl3) δ 158.0 (d, 
J-F6 = 232 Hz), 133.4, 130.4, 128.7 (d, J-F6 = 10 Hz), 109.9 (d, J-F6 = 15 Hz), 109.8, 105.5 (d, J-
F6 = 23 Hz), 100.8 (d, J-F6 = 5.0 Hz), 33.1.  
 
5-Chloro-1-methyl-1H-indole (109) 
Starting from commercially available 5-chloro-1H-indole (758 mg, 5.00 
mmol), 5-chloro-1-methyl-1H-indole 109 (800 mg, 4.83 mmol, 97% yield) was 
obtained as a colorless solid. IR ν 3102 (w), 2943 (w), 2913 (w), 2881 (w), 
2817 (w), 1567 (w), 1513 (m), 1475 (s), 1441 (m), 1421 (s), 1379 (w), 1331 
(m), 1278 (s), 1241 (s), 1199 (m), 1146 (m), 1106 (w), 1082 (m), 1063 (s), 1009 (m), 909 (m), 870 
(m), 869 (m). 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 2.1 Hz, 1H, ArH), 7.30 – 7.19 (m, 2H, 
ArH), 7.10 (d, J = 3.1 Hz, 1H, ArH), 6.47 (dd, J = 3.1, 0.7 Hz, 1H, ArH), 3.80 (s, 3H, NCH3). 13C 
NMR (101 MHz, CDCl3) δ 135.1, 130.1, 130.1, 125.1, 121.8, 120.2, 110.2, 100.6, 33.1.  
 
5-Iodo-1H-indole (110) 
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Starting from commercially available 5-iodo-1H-indole (257 mg, 1.00 mmol), 
5-iodo-1-methyl-1H-indole 110 (380 mg, 0.755 mmol, 76% yield) was obtained 
as a colorless solid. IR ν 3093 (w), 3053 (w), 2940 (w), 2919 (w), 2886 (w), 
2876 (w), 2856 (w), 1557 (m), 1510 (s), 1473 (s), 1432 (m), 1420 (s), 1379 (w), 
1329 (m), 1277 (s), 1242 (s), 1193 (w), 1151 (w), 1103 (m), 1079 (m), 1045 (w), 1007 (m), 888 
(s), 868 (m). 1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1 H, ArH), 7.49 (d, J = 8.6 Hz, 1H, ArH), 7.13 
(d, J = 8.6 Hz, 1H, ArH), 7.04 (s, 1H, ArH), 6.43 (s, 1H, ArH), 3.80 (s, 3H, NCH3). 13C NMR (101 
MHz, CDCl3) δ 135.8, 131.0, 129.8, 129.7, 129.6, 111.3, 100.3, 82.9, 33.0.   
 
N-Functionalized Indoles 
 
 
 
1-(1-(tert-Butyldimethylsilyl)-1H-pyrrole (111) 
S14 
 
 
Following a reported procedure,[5] commercially available 1H-pyrrole 115 (700 µl, 10.0 mmol) was 
dissolved in dry THF (30 ml, 0.3 M). Sodium hydride (60% suspension in mineral oil; 600 mg, 
15.0 mmol, 1.50 equiv.) was slowly added under N2 flow at 0 °C. After being stirred at 0°C for 15 
min, the reaction mixture was allowed to warm to r.t for 1.50 h. Then it was cooled back to 0°C 
and tert-butylchlorodimethylsilane (1.96 g, 13.0 mmol, 1.30 equiv.) was added. The mixture was 
warmed to r.t. and stirred overnight. The reaction was quenched by addition of water (10 mL) at 
0°C. The aqueous layer was extracted with Et2O (3 x 10 mL), the combined organic layers were 
dried over MgSO4, and the solvent was removed under reduced pressure. The crude product was 
purified via flash column chromatography (Pentane:EtOAc 8:1), to give the desired 1-(tert-
butyldimethylsilyl)-1H-pyrrole 111 (1.30 g, 7.17 mmol, 72% yield). IR ν 3100 (w), 2956 (m), 2931 
(m), 2858 (m), 1707 (w), 1473 (m), 1364 (w), 1259 (s), 1222 (w), 1190 (s), 1084 (s), 1048 (s), 1008 
(w), 942 (w), 839 (s). 1H NMR (400 MHz, CDCl3) δ 6.86 – 6.62 (m, 2H, ArH), 6.39 – 6.21 (m, 
2H, ArH), 0.86 (s, 9H, SiC(CH3)3), 0.41 (s, 6H, Si(CH3)2). 1H NMR values are in accordance with 
the data reported in literature.[11] 
 
1-(tert-Butyldimethylsilyl)-1H-Indole (24) 
 
Following a reported procedure,[12] commercially available 1H-indole 34 (586 mg, 5.00 mmol) was 
dissolved in dry THF (10 mL, 0.5 M). Sodium hydride (60% suspension in mineral oil; 300 mg, 
7.50 mmol, 1.50 equiv.) was slowly added under N2 atmosphere at 0 °C. After being stirred at 0 
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°C for 15 min, the reaction mixture was allowed to warm to r.t for 1.5 h. Then it was cooled back 
to 0 °C and tert-butylchlorodimethylsilane (980 mg, 6.50 mmol, 1.30 equiv.) was added. The 
mixture was warmed to r.t. and stirred overnight. After cooling again to 0 °C, the reaction was 
quenched with water (10 mL), extracted with Et2O (3 x 10 mL), the combined organic layers were 
dried over MgSO4, and the solvent was removed under reduced pressure. The residue was purified 
via flash column chromatography (Pentane:EtOAc 4:1), to give the desired 1-(tert-
butyldimethylsilyl)-1H-indole 24 (869 mg, 3.76 mmol, 75% yield). 1H NMR (400 MHz, CDCl3) 
δ 7.79 (m, 1H, ArH), 7.72 (dt, J = 8.2, 1.1 Hz, 1H, ArH), 7.37 (d, J = 3.2 Hz, 1H, ArH), 7.32 (ddd, 
J = 8.3, 7.0, 1.6 Hz, 1H, ArH), 7.25 (m, 1H), 6.78 (dd, J = 3.3, 1.0 Hz, 1H, ArH), 1.11 (s, 9H, 
SiCCH3), 0.78 (s, 6H, Si(CH3)2). IR ν 3064.6 (w), 2950.5 (w), 2929.7 (m), 2855.9 (w), 1512.0 (s), 
1427.6 (s), 1449.9 (m), 1284.3 (s), 1271.6 (s), 1255.8 (m), 1158.9 (s), 1140.9 (s), 984.2 (w), 840.1 
(m). 1H NMR values are in accordance with the data reported in literature.[13] 
 
 
1-(But-3-en-1-yl)-1H-Indole (112) 
 
Following a reported procedure,[14] potassium tertbutoxide (1.24 mg, 11.0 mmol, 1.10 equiv.) was 
added to a solution of 18-crown-6 ether (26.4 mg, 0.100 mmol, 10 mol%.) in dry THF (25 mL, 0.4 
M) under a nitrogen atmosphere. Then, commercially available 1H-indole 116 (1.17 g, 10.0 mmol, 
1.00 equiv.) was added under vigorous stirring. The reaction was cooled to 0°C in an ice bath. A 
solution of 4-bromobut-1-ene (1.20 mL, 11.0 mmol, 1.10 equiv.) in THF (5 mL) was added 
dropwise to the reaction mixture and the latter was stirred overnight. After cooling again to 0 °C, 
the reaction was quenched with water (20 mL), extracted with Et2O (3 x 20 mL), the combined 
organic layers were dried over MgSO4, and the solvent was removed under reduced pressure. The 
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residue was purified via flash column chromatography (Pentane:EtOAc 9:1) to give the desired 1-
(but-3-en-1-yl)-1H-indole 112 (280 mg, 1.64 mmol, 17% yield) as a yellow oil. IR ν 2936 (w), 
1640 (s), 1612 (s), 1508 (m), 1458 (s), 910 (m), 740 (m), 712 (m).  1H NMR (400 MHz, CDCl3) δ 
7.84 (d, J = 8.0 Hz, 1H, ArH), 7.52 (d, J = 8.2 Hz, 1H, ArH), 7.41 (t, J = 7.6 Hz, 1H, ArH), 7.31 
(t, J = 7.4 Hz, 1H, ArH), 7.23 (d, J = 3.2 Hz, 1H, ArH), 6.68 (d, J = 3.2 Hz, 1H, ArH), 5.94 (ddt, J 
= 17.1, 10.2, 6.8 Hz, 1H, ArH), 5.32 – 5.12 (m, 2H, NCH2CH2CH=CH2), 4.31 – 4.27 (m, 2H, CH2), 
2.72 (q, J = 7.1 Hz, 2H, CH2). 1H NMR values are in accordance with the data reported in 
literature.[15] 
 
(2-Iodoethoxy)triisopropylsilane (118)  
 
Following a reported procedure,[16] commercially available 2-iodoethanol 117 (1.10 mL, 10.0 
mmol, 1.00 equiv.) was added to a solution of imidazole (885 mg, 13.0 mmol, 1.30 equiv.) in DMF 
(5 mL, 2.0 M) under nitrogen atmosphere. chloro-triisopropylsilane (2.80 mL, 13.0 mmol, 1.30 
equiv.) was then added dropwise. After 1 h, the reaction turned into a thick suspension and a 
colorless solid precipitated. The mixture was allowed to warm to room temperature removed and 
was stirred for an additional hour. Water (5 mL) was added to dissolve the solid. The organic layer 
was separated and eluted through a SiO2 plug with pentane (100 mL). The solvent was removed 
under reduced pressure to give (2-iodoethoxy)triisopropylsilane 118 (3.15 g, 9.60 mmol, 96% 
yield) as a slightly yellow oil. IR ν 2958 (m), 2942 (m), 2891 (w), 2866 (m), 1464 (m), 1384 (w), 
1275 (w), 1249 (w), 1190 (w), 1169 (w), 1123 (s), 1092 (s), 1069 (s), 1013 (w), 999 (m), 943 (w), 
920 (w), 882 (s), 857 (w). 1H NMR (400 MHz, CDCl3) δ 3.85 (t, J = 6.9 Hz, 2H, OCH2), 3.15 (t, 
J = 7.0 Hz, 2H, ICH2), 1.11-0.88 (m, 21H, TIPS). 13C NMR (101 MHz, CDCl3) δ 64.6, 18.0, 12.1, 
6.9. 
 
1-(2-((Triisopropylsilyl)oxy)ethyl)- 1H-Indole (113) 
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Commercially available 1H-indole 116 (586 mg, 5.00 mmol) was dissolved in N,N-
dimethylformamide (5 mL, 0.5 M in total). Sodium hydride (60% suspension in mineral oil; 144 
mg, 6.00 mmol, 1.20 equiv.) was added at r.t. and the reaction mixture was stirred for one hour. 
N,N-Dimethylformamide (5 mL) was then added to dissolve the resulting colorless precipitate. The 
reaction was cooled to 0 °C and (2-iodoethoxy)triisopropylsilane 118 (1.90 g, 5.50 mmol, 1.10 
equiv.) was added dropwise. The reaction mixture was stirred overnight, allowing it to warm to r.t. 
The reaction was then quenched with water (20 mL) and the reaction mixture was extracted with 
EtOAc (3 x 25 mL). The combined organic layers were washed with water (10 mL), brine (3x10 
mL), and dried over MgSO4. The solvent was then removed under reduced pressure. Flash column 
chromatography (Pentane:EtOAc 9:1) afforded 1-(2-((triisopropylsilyl)oxy)ethyl)- 1H-indole 113 
(1.20 g, 3.78 mmol, 76% yield) as a colorless oil. IR ν 3056 (w), 2891 (m), 2865 (s), 1514 (w), 
1464 (s), 1439 (w), 1387 (w), 1360 (w), 1334 (w), 1317 (m), 1115 (s), 1077 (m), 1013 (m), 923 
(m), 819 (w). 1H NMR (400 MHz, CDCl3) δ 7.66 (m, 1 H, ArH), 7.38 (dd, J = 8.2, 0.8 Hz, 1H, 
ArH), 7.25 - 7.19 (m, 2H, ArH), 7.13 (m, 1H, ArH), 6.52 (dd, J = 3.1, 0.8 Hz, 1H, ArH), 4.30 (t, J 
= 6.0 Hz, 2H, CH2), 4.04 (t, J = 5.8 Hz, 2H, CH2), 1.17 - 0.85 (m, 21H, TIPS). 13C NMR (101 
MHz, CDCl3) δ 136.1, 128.7, 128.6, 121.3, 120.9, 119.2, 109.3, 101.0, 62.8, 48.8, 17.9, 11.9.  
 
1-(3-Phenylpropyl)-1H-indole (114)  
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Following a reported procedure,[17] commercially available 1H-indole 116 (585 mg, 5.00 mmol, 
1.00 equiv.) was dissolved in THF (15 mL). Sodium hydride (60% suspension in mineral oil; 300 
mg, 7.50 mmol, 1.50 equiv.) was added at 0 °C and the reaction mixture was stirred for 30 min. (3-
bromopropyl)benzene (760 µL, 5.00 mmol, 1.00 equiv.) was then added dropwise. After 15 min 
the ice bath was removed and the reaction mixture was stirred for 4 hours at r.t.. The reaction was 
cooled back to 0 °C, quenched with water, diluted with EtOAc (10 mL), extracted with water (2 x 
10 mL), washed with brine (10 mL), and dried over MgSO4. After filtration, the solvent was 
removed under reduced pressure. Flash column chromatography (Pentane:EtOAc 20:1) afforded 
1-(3-phenylpropyl)-1H-indole 114 (1.12 g, 4.76 mmol, 95% yield) as a colorless oil. IR 3085 (w), 
3057 (w), 3026 (w), 3004 (w), 2946 (w), 2945 (w), 2870 (w), 1780 (w), 1738 (s), 1717 (s), 1612 
(w), 1603 (w), 1511 (m), 1497 (m), 1483 (m), 1464 (s), 1455 (s), 1400 (m), 1377 (s), 1354 (s), 
1336 (s), 1315 (s), 1254 (s), 1207 (s), 1179 (m), 1166 (m), 1143 (m), 1143 (m), 1122 (m), 1114 
(m), 1080 (m), 1031 (m), 1020 (m), 1004 (w), 952 (w), 928 (w), 909 (w), 885 (m), 855 (w), 838 
(w), 821 (w), 811 (w), 802 (w). 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 8 Hz, 1H, ArH), 7.53-
7.23 (m, 9H, ArH), 6.72 (dd, J = 3.1, 0.8 Hz, 1H, ArH), 4.26 (t, J = 7.1 Hz, 2H, NCH2), 2.77 (t, J 
= 8 Hz, 2H, CH2Ph), 2.34 (qi, J = 7.8 Hz, 2H, CH2CH2CH2). 13C NMR (101 MHz, CDCl3) δ 141.2, 
136.2, 128.7, 128.7, 128.6, 128.0, 126.3, 121.6, 121.2, 119.5, 109.6, 101.3, 45.8, 33.2, 31.7 (one 
aromatic Carbon signal not resolved).  
2.3 Synthesis of compound 10/11. 
 
A solution of 2-(1-methoxypent-3-yn-1-yl)-1-methyl-1H-pyrrole 7 (0.100 mmol, 1.0 equiv) in THF 
(0.33 mL) was added into a solution of PtBr2 (3.55 mg, 10.0 µmol, 0.10 equiv), NaHCO3 (17.0 mg, 
0.200 mmol, 2.0 equiv) and 1-azido-3,3-bis(trifluoromethyl)-3-(1H)-1,2-benziodoxole 8 (330 mg, 
0.600 mmol, 2.00 equiv) in CH3CN (0.180 mL). The reaction was stopped after 72 hrs, EtOAc was 
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added to solubilize the precipitate and a TLC (Pentane:EtOAc 4:1 for the starting, DCM:MeOH 
9:1 for the product) was taken: full conversion of the starting to 11. The solvent was removed under 
reduced pressure, and a crude NMR (extremely wet of EtOAc) and a MS analysis were taken.  
HR-ESI-MS 546.0372 ([M+H]+, C20H18F6INO2+; calc. for 545.02864) 
The crude 1H-NMR shows a 2:1 ratio between known peaks of iodobenzoic hexafluorodimethyl-
alcohol and the new product. The peak of the new compound are reported here: 
1H NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 6.8, 1.4 Hz, 1H, ArH), 7.75 – 7.70 (m, 1H, ArH), 7.69 
– 7.64 (m, 1H, ArH), 6.59 (d, J = 2.2 Hz, 1H, ArH), 6.14 (dd, J = 3.6, 1.8 Hz, 1H, ArH), 6.06 (dd, 
J = 3.6, 2.7 Hz, 1H, ArH), 4.49 (dd, J = 7.5, 6.3 Hz, 1H, CH), 3.65 (m, 3H, CH3), 3.24 (m, 3H, 
CH3), 2.77 (m, 1H, CH2), 2.64 (m, 1H, CH2), 1.77 (t, J = 2.5 Hz, 3H, CH3). 
Subsequently, the crude was columned over silica using an eluent mixture of 9:1 DCM:MeOH; no 
product was obtained as the compound degraded on silica. 
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2.4 Optimization in the synthesis of IndoleBX 21. 
Table S1: Screening of additives 
 
Entry Y X Additive (mol%) Yield%a 
1 (CF3)2 N3 (8) - 25% 
2 (CF3)2 OAc (18) - - 
3 (CF3)2 OAc (18) Zn(OTf)2 (10) 56% 
4 O OH (19) TMSOTf (10) -b 
5 O OH (19) Zn(OTf)2 (10) -b 
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6 O OAc (20) - -b 
7 O OAc (20) TMSOTf (10) 16% 
8 O OAc (20) Zn(OTf)2 (10) 36%b 
9 O OAc (20) Cu(OTf)2 (10) 36%c 
10 O OAc (20) AgNTf2 (20) -c 
11 O OAc (20) AgF (20) -c 
12 O OAc (20) CsF (20) -c 
13 O OAc (20) TBAF (20) -c 
a) Substrate 14 (0.100 mmol), reagents 8, 18-20 (0.110 mmol), additive (X mol%), and Et2O (0.05 
M) at 25 °C. Isolated yield after flash chromatography is given. b) No conversion: starting materials 
recovered. c) Complete decomposition of the hypervalent iodine reagents. 
 
Table S2: Screening of solvents and additive loading 
Entry Solvent X mol% Zn(OTf)2 Yield%a 
1 THF 10 -b 
2 THF 20 -b 
3 THF 1 equiv. -b 
4 DCM 10 Full conversionc 
5 DCM 20 97% 
6 DCM 1 equiv. decomposition 
a) Substrate 14 (0.100 mmol), AcOBX 20 (0.110 mmol), Zn(OTf)2 (x mol%), and solvent (0.05 M) 
at 25 °C. Isolated yield after flash chromatography is given. b) No conversion: starting materials 
recovered. c) 2 equiv. of OAcBX 20 are needed. 
2.5 Preparation of PyrroleBX and IndoleBX Reagents. 
General Procedure GP2 for the Synthesis of Heterocyclic-BX Reagents 17, 21, 23, 25-47, 49 
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Note: prior to the reaction, the glassware requires to be carefully cleaned with aqua regia to 
remove all metal traces; the commercially available heterocyclic starting material were purified 
through a short plug of silica prior to being used. 
 
Procedure A  for 1.00 mmol: in an open air flask, the corresponding heterocycle (1.00 mmol, 1.00 
equiv.), freshly prepared Acetoxy-benziodoxole 20 (1.10 mmol, 1.10 equiv.) and Zinc(II) 
trifluoromethanesulfonate (72.7 mg, 0.200 mmol, 20 mol%.) were dissolved in DCM (20 mL 0.05 
M). The reaction was stirred while being monitored by TLC (Pentane:EtOAc 9:1 for the starting 
materials, DCM:MeOH 9:1 for the products). Upon consumption of the starting material, the crude 
was directly submitted to short-path flash chromatography (DCM:MeOH 10:1 or EtOAc:MeOH 
10:1 for the separation of pyrrole-based reagents) to afford the desired Heterocyclic-BX 
compounds 17, 21, 23, 25-37, 43-48. 
 
Procedure B for 0.200 mmol: in an open air flask, the corresponding heterocycle (0.200 mmol, 
1.00 equiv.), freshly prepared Acetoxy-benziodoxoles 17, 23, 95-97 (0.220 mmol, 1.10 equiv.) and 
zinc(II) trifluoromethanesulfonate (7.27 mg, 0.040 mmol, 20 mol%.) were dissolved in DCM (4 
mL 0.05 M). The reaction was stirred while being monitored by TLC (Pentane:EtOAc 9:1 for the 
starting materials, DCM:MeOH 9:1 for the products). Upon consumption of the starting material, 
the crude was directly submitted to short-path flash chromatography (DCM:MeOH 10:1 or 
EtOAc:MeOH 10:1 for the separation of pyrrole-based reagents) to afford the desired Heterocyclic-
BX compounds 32-43. 
 
The structure of compounds 25 and 34 was confirmed by X-Ray analysis (see par. 5 of the 
Supplementary Informations). 
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Figure S1: Scope of Heterocyclic-BX reagents (1) 
 
1-(3-1-Methyl-1H-indole)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ3-benzo[d][1,2]iodaoxole 
(17) 
 Following procedure B: starting from commercially available 1-
methyl-1-H-indole 14 (26.2 mg, 0.100 mmol), 1-acetoxy-1,3-
dihydro-3,3-bis(trifluoromethyl)-1,2-benziodoxole 18 (94.0 mg, 
0.220 mmol, 1.10 equiv.) and in Et2O 0.05 M, after 16 hours 1-(3-1-
methyl-1H-indole)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ3-
benzo[d][1,2]iodaoxole 17 (56.1 mg, 0.112 mmol, 56% yield) was 
obtained as a brown foam. Rf: 0.7 (DCM:MeOH 9:1). IR ν 3069 (w), 2922 (w), 2852 (w), 1732 
(w), 1504 (m), 1457 (w), 1263 (s), 1212 (m), 1178 (s), 1157 (s), 1130 (m), 1047 (w), 948 (s). 1H 
NMR (400 MHz, CDCl3) δ 7.86 (m, 1H, ArH), 7.53 (s, 1H, NCHCI), 7.52 – 7.46 (m, 3H, ArH), 
7.41 (ddd, J = 8.3, 7.0, 1.1 Hz, 1H, ArH), 7.28 (m, 1H, ArH), 7.23 (m, 1H, ArH), 6.95 (d, J = 8.3 
Hz, 1H, ArH), 3.96 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 137.5, 137.4, 131.7, 131.4, 
130.1, 129.9, 126.9, 123.9, 123.2 (m), 122.1, 120.4, 112.2, 110.3, 84.2, 81.55 (dt, J = 57.1, 28.5 
Hz), 33.6 (one aromatic Carbon signal not resolved). HR-ESI-MS 499.9946 ([M+H]+, 
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C18H13F6INO+; calc. for 499.9941). The structure of the obtained regioisomer was assigned by 
NMR analysis.[18]  
 
1-(3-1-Methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (21)  
The synthesis of 1-(3-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-
3(2H)-one 21 was scaled up to 10 mmol without reoptimization of the 
protocol. 
Following procedure A: starting from commercially available 1-methyl-
1-H-indole 14 (1.35 g, 10.0 mmol), after 16 hours 1-(3-1-methyl-1H-
indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 21 (3.28 g, 8.70 mmol, 87% yield) was obtained as a 
brown foam. Rf: 0.4 (DCM:MeOH 9:1). IR ν 3107 (w), 3059 (w), 2948 (w), 1599 (s), 1552 (m), 
1506 (m), 1454 (w), 1392 (m), 1277 (s), 1245 (s), 1225 (s), 1166 (s), 1131 (m), 1031 (s), 1004 (w), 
842 (w). 1H NMR (400 MHz, CDCl3) δ 8.40 (dd, J = 7.5, 1.7 Hz, 1H, ArH), 7.82 (s, 1H, NCHCI), 
7.55 – 7.48 (m, 2H, ArH), 7.39 – 7.35 (m, 2H, ArH), 7.34 – 7.23 (m, 2H, ArH + CDCl3), 6.84 (d, 
J = 8.3 Hz, 1H, ArH), 4.02 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 166.8, 138.6, 137.6, 
133.4, 133.3, 132.5, 130.5, 129.3, 125.2, 124.3, 122.6, 119.9, 116.1, 110.7, 78.9, 33.9. HR-ESI-
MS 377.9990 ([M+H]+, C16H13INO2+; calc. for 377.9986). The structure of the obtained 
regioisomer was assigned by NMR correlation to  compound 25. DSC-analysis was performed on 
compound 21: see par.5 of Supplementary informations. 
 
1-(3-1-Methyl-1H-indole)-3,3-dimethyl-1,3-dihydro-1λ3-benzo[d][1,2]iodoxole (23) 
Following procedure B: starting from commercially available 1-
methyl-1-H-indole 14 (26.2 mg, 0.100 mmol) and 3,3-dimethyl-1λ3-
benzo[d][1,2]iodoxol-1(3H)-yl acetate 22 (70.4 mg, 0.220 mmol, 
1.10 equiv.), after 16 hours 1-(3-1-methyl-1H-indole)-3,3-dimethyl-
1,3-dihydro-1λ3-benzo[d][1,2]iodoxole 23 (40.1 mg, 0.102 mmol, 
51% yield) was obtained as a brown foam. Rf: 0.7 (DCM:MeOH 9:1). 
IR ν 3115 (w), 3050 (w), 2986 (w), 1509 (w), 1455 (w), 1372 (w), 1284 (s), 1247 (s), 1225 (m), 
1166 (m), 1110 (w), 1031 (s), 992 (w).1H NMR (400 MHz, CDCl3) δ 7.92 (s, 1H, NCHCI), 7.54 
(m, 1H, ArH), 7.47 (m, 1H, ArH), 7.45 – 7.40 (m, 3H, ArH), 7.34 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H, 
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ArH), 7.08 (ddd, J = 8.7, 5.8, 2.9 Hz, 1H, ArH), 6.87 (m, 1H, ArH), 4.02 (s, 3H, NCH3), 1.75 (s, 
6H, C(CH3)2). 13C NMR (101 MHz, CDCl3) δ 146.3, 140.2, 137.7, 130.9, 130.4, 128.9, 128.7, 
127.0, 124.8, 123.3, 119.6, 111.0, 108.9, 74.6, 72.9, 34.2, 30.5. HR-ESI-MS 392.0510 ([M+H]+, 
C18H19INO+; calc. for 392.0506).  The structure of the obtained regioisomer was assigned by NMR 
correlation to  compound 17. 
 
1-(3-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (25) 
Following procedure A: starting from 1-(tert-butyldimethylsilyl)-1H-
indole 24 (231 mg, 1.00 mmol) and using Sc(OTf)3 as the Lewis acid (20 
mol %), after 16 hours 1-(3-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 
25 (294 mg, 8.10 mmol, 78% yield) was obtained as a brown solid. Rf: 
0.4 (DCM:MeOH 9:1). Mp: 174.2°C (decomposition). IR ν 3302 (w), 
2975 (w), 2903 (w), 1722 (w), 1609 (m), 1584 (m), 1557 (w), 1490 (w), 1457 (w), 1385 (w), 1277 
(s), 1258 (s), 1230 (m), 1174 (m), 1087 (w), 1036 (s), 880 (w), 841 (w). 1H NMR (400 MHz, 
DMSO-d6) δ 12.33 (s, 1H, NH), 8.21 (s, 1H, NCHCI), 8.08 (dd, J = 7.3, 1.7 Hz, 1H, ArH), 7.59 (d, 
J = 8.2 Hz, 1H, ArH), 7.52 (t, J = 7.3 Hz, 1H, ArH), 7.43 (d, J = 7.5 Hz, 1H, ArH), 7.36 (ddd, J = 
8.5, 7.3, 1.7 Hz, 1H, ArH), 7.26 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H, ArH), 7.15 (t, J = 7.5 Hz, 1H, ArH), 
6.72 (d, J = 8.5 Hz, 1H, ArH). 13C NMR (101 MHz, DMSO-d6) δ 166.1, 136.6, 134.5, 133.3, 131.4, 
130.2, 128.5, 126.3, 123.4, 122.3, 121.6, 119.2, 116.1, 112.9, 80.0. HR-ESI-MS 363.9832 
([M+H]+ , C15H11INO2+; calc. for 363.9829). The structure of the reagent was determined through 
X-Ray diffraction of a single crystal (CCDC number: 1540821). 
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Figure S2: Scope of Heterocyclic-BX reagents (2) 
 
1-(3-1,2-Dimethyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (26) 
Following procedure A: starting from 2-methyl-1-methyl-1H-indole 106 
(145 mg, 1.00 mmol), after 16 hours 1-(3-1,2-dimethyl-1H-indole)-1H-
1λ3 -benzo[b]iodo-3(2H)-one 26 (364 mg, 0.930 mmol, 93% yield) was 
obtained as a dark violet foam. Rf: 0.43 (DCM:MeOH 9:1). IR ν 3055 
(w), 2987 (w), 2948 (w), 1717 (w), 1605 (s), 1584 (m), 1553 (m), 1516 
(w), 1472 (w), 1437 (w), 1395 (m), 1378 (m), 1268 (m), 1154 (w), 1032 
(w), 1011 (w), 829 (w).  1H NMR (400 MHz, CDCl3) δ 8.42 (dd, J = 7.3, 1.7 Hz, 1H, ArH), 7.52 
(td, J = 7.3, 0.9 Hz, 1H, ArH), 7.44 (d, J = 8.2 Hz, 1H, ArH), 7.35 (m, 2H, ArH), 7.28 (m, 1H, 
ArH), 7.23 (ddd, J = 8.2, 6.9, 1.0 Hz, 1H, ArH), 6.77 (m, 1H, ArH), 3.91 (s, 3H, CH3N), 2.65 (s, 
3H, ICH=CHCH3). 13C NMR (101 MHz, CDCl3) δ 166.8, 145.3, 137.9, 133.7, 133.2, 132.7, 130.5, 
128.9, 124.7, 123.6, 122.4, 119.2, 115.5, 110.4, 80.1, 31.1, 13.2. HR-ESI-MS 392.0146 ([M+H]+, 
C17H15INO2+; calc. for 392.0142). The structure of the obtained regioisomer was assigned by NMR 
correlation to compound 25. 
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1-(3-5-Methoxy-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (27) 
Following procedure A: starting from 5-methoxy-1-methyl- 1H-indole 
107 (161 mg, 1.00 mmol), after 16 hours 1-(3-5-methoxy-1-methyl-1H-
indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 27 (346 mg, 0.850 mmol, 85% 
yield) was obtained as an orange resin. Rf: 0.42 (DCM:MeOH 9:1). IR 
ν 3110 (w), 3062 (w), 3000 (w), 2944 (w), 2837 (w), 1719 (w), 1604 
(m), 1584 (m), 1556 (w), 1504 (m), 1489 (m), 1439 (w), 1378 (w), 1249 
(s), 1223 (s), 1158 (m), 1031 (s), 970 (w), 845 (m). 1H NMR (400 MHz, CDCl3) δ 8.35 (dd, J = 
7.5, 1.6 Hz, 1H, ArH), 7.82 (s, 1H, NCHCI), 7.48 (t, J = 7.3 Hz, 1H, ArH), 7.40 (d, J = 9.0 Hz, 1H, 
ArH), 7.27 (m, 1H, ArH), 7.04 (dd, J = 9.0, 2.4 Hz, 1H, ArH), 6.84 (d, J = 8.3 Hz, 1H, ArH), 6.79 
(d, J = 2.3 Hz, 1H, ArH), 3.99 (s, 3H, CH3N), 3.78 (s, 3H, OCH3). 13C NMR (101 MHz, CDCl3) δ 
167.1, 156.4, 138.9, 133.3, 132.5, 132.5, 130.5, 130.1, 125.2, 116.0, 114.8, 111.7, 100.8, 77.4, 
55.8, 34.0 (the signal for one aromatic C could not be resolved). HR-ESI-MS 408.0093 ([M+H]+, 
C17H15INO3+ calc. for 408.0091). The structure of the obtained regioisomer was assigned by NMR 
correlation to compound 25. 
1-(3-5-Fluoro-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (28) 
Following procedure A: starting from 5-fluoro-1-methyl-1H-indole 108 
(149 mg, 1.00 mmol), after 16 hours 1-(3-5-fluoro-1-methyl-1H-
indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 28 (336 mg, 0.850 mmol, 85% 
yield) was obtained as an yellow foam. Rf: 0.3 (DCM:MeOH 9:1). IR ν 
3083 (w), 2952 (w), 1717 (w), 1601 (s), 1557 (m), 1503 (m), 1485 (m), 
1438 (w), 1338 (m), 1242 (m), 1193 (m), 1121 (m), 1032 (w), 1005 (w), 
850 (m).  1H NMR (400 MHz, CD3OD) δ 8.14 (dd, J = 7.6, 1.7 Hz, 1H, ArH), 8.01 (s, 1H, NCHCI), 
7.57 (ddd, J = 8.8, 4.2, 0.8 Hz, 1H, ArH), 7.49 (td, J = 7.4, 1.0 Hz, 1H, ArH), 7.30 (ddd, J = 8.3, 
7.2, 1.7 Hz, 1H, ArH), 7.14 – 7.03 (m, 2H, ArH), 6.80 (dd, J = 8.3, 0.9 Hz, 1H, ArH), 3.93 (s, 3H, 
CH3N). 13C NMR (101 MHz, CD3OD) δ 170.3, 160.91 (d, J = 238.2 Hz), 142.6, 135.9, 135.1, 
134.4, 133.2, 131.7, 131.40 (d, J = 10.7 Hz), 127.7, 116.8, 113.71 (d, J = 9.8 Hz), 113.47 (d, J = 
26.7 Hz), 105.67 (d, J = 25.3 Hz), 77.5, 34.3. 19F NMR (376 MHz, CDCl3) δ -119.8.  HR-ESI-
MS 395.9894 ([M+H]+, C16H12FINO2+;  calc. for 395.9891). The structure of the obtained 
regioisomer was assigned by NMR correlation to compound 25. 
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1-(3-5-Chloro-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (29) 
Following procedure A: starting from 5-chloro-1-methyl-1H-indole 109 
(166 mg, 1.00 mmol), after 16 hours 1-(3-5-chloro-1-methyl-1H-
indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 29 (256 mg, 0.622 mmol, 62% 
yield) was obtained as an orange amorphous solid. Rf: 0.4 
(DCM:MeOH 9:1). IR ν 3095 (w), 2953 (w), 1605 (s), 1556 (m), 1505 
(m), 1438 (m), 1388 (m), 1370 (m), 1260 (s), 1226 (m), 1164 (m), 1144 
(m), 1115 (w), 1070 (w), 1032 (s), 1004 (w), 837 (w). 1H NMR (400 MHz, CD2Cl2) δ 8.20 (d, J = 
7.4 Hz, 1H, ArH), 7.78 (s, 1H, NCHCI), 7.38 (d, J = 8.7 Hz, 1H, ArH), 7.34 – 7.22 (m, 3H, ArH), 
7.17 (t, J = 7.7 Hz, 1H, ArH), 6.68 (d, J = 8.2 Hz, 1H, ArH), 3.87 (s, 3H, CH3NCHCI). 13C NMR 
(101 MHz, MeOD) δ 170.3, 142.5, 137.8, 135.1, 134.4, 133.2, 131.7, 131.7, 129.6, 127.8, 125.4, 
120.0, 116.8, 113.7, 77.5, 34.2. HR-ESI-MS 411.9603 ([M+H]+, C16H12ClINO2+; calc. for 
411.9596). The structure of the obtained regioisomer was assigned by NMR correlation to 
compound 25. 
1-(3-5-Iodo-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (30) 
Following procedure A: starting from 5-iodo-1-methyl-1H-indole 110 
(257 mg, 1.00 mmol), after 16 hours 1-(3-5-iodo-1-methyl-1H-indole)-
1H-1λ3 -benzo[b]iodo-3(2H)-one 30 (380 mg, 0.755 mmol, 76% yield) 
was obtained as a yellow amorphous solid. NB: the reagent is unstable 
in acidic deuterated solvents and it decompose in short time, we 
recommend the immediate use after the synthesis. The proton NMR 
presents about 21% of the open protonated form. Rf: 0.3 (DCM:MeOH 9:1). IR ν 3092 (w), 3061 
(w), 1600 (s), 1584 (m), 1557 (m), 1503 (m), 1436 (w), 1422 (w), 1371 (m), 1265 (s), 1245 (s), 
1225 (m), 1163 (m), 1113 (w), 1031 (s), 1004 (w), 836 (w). 1H NMR (400 MHz, CDCl3) δ 8.24 
(m, 1H, ArH), 7.83 (s, 1H, NCHCI), 7.58 – 7.47 (m, 2H, ArH), 7.26 (m, 1H, ArH + CDCl3 ), 7.21 
- 7.18 (m, 2H, ArH), 6.67 (d, J = 8.1 Hz, 1H, ArH), 3.87 (s, 3H, CH3N). 13C NMR (101 MHz, 
CDCl3) δ 168.6, 140.5, 136.8, 133.7, 132.6, 132.3, 131.4, 130.3, 128.1, 126.0, 122.3, 119.1, 115.7, 
112.9, 86.1, 34.0. HR-ESI-MS 503.8952 ([M+H]+, C16H12I2NO2+; calc. for 503.8952). The 
structure of the obtained regioisomer was assigned by NMR correlation to compound 25. 
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1-(3-1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole)-1H-1λ3 -
benzo[b]iodo-3(2H)-one (31) 
Following procedure A: starting from commercially available 1-methyl-
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole (149 mg, 
1.00 mmol), after 16 hours 1-(3-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 31 
(276 mg, 0.549 mmol, 54% yield) was obtained as an orange amorphous 
solid. Rf: 0.46 (DCM:MeOH 9:1). IR ν 3095 (w), 2979 (w), 1611 (s), 
1558 (w), 1507 (w), 1436 (w), 1360 (s), 1303 (w), 1263 (w), 1142 (s), 1114 (w), 1074 (w), 970 
(w), 861 (w). 1H NMR (400 MHz, CD2Cl2) δ 8.32 (dd, J = 7.5, 1.7 Hz, 1H, ArH), 7.93 (s, 1H, 
NCHCI), 7.81 (dd, J = 8.4, 1.1 Hz, 1H, ArH), 7.74 (s, 1H, CCHCBPin), 7.59 – 7.48 (m, 2H, ArH), 
7.31 (ddd, J = 8.6, 7.1, 1.7 Hz, 1H, ArH), 6.85 (dd, J = 8.3, 0.9 Hz, 1H, ArH), 3.99 (s, 3H, NCH3), 
1.30 (s, 12H, CBPin). 13C NMR (101 MHz, CD2Cl2) δ 167.0, 140.1, 139.6, 134.1, 133.8, 132.6, 
131.0, 130.5, 129.5, 127.6, 126.0, 117.1, 110.7, 84.5, 80.3, 34.4, 25.2 (one aromatic Carbon signal 
not resolved). HR-ESI-MS 504.0835 ([M+H]+, C22H24BINO4+; calc. for 504.0838). The structure 
of the obtained regioisomer was assigned by NMR correlation to compound 25. 
 
Figure S3: Scope of Heterocyclic-BX reagents (3) 
1-(3-1-(3-Phenylpropyl)-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (32) 
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Following procedure A: starting from 1-(3-phenylpropyl)--
indole 114 (235 mg, 1.00 mmol), after 16 hours 1-(3-1-(3-
phenylpropyl)-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 
32 (436 mg, 0.906 mmol, 91% yield) was obtained as an orange 
resin. Rf: 0.45 (DCM:MeOH 9:1). IR ν 3060 (w), 3026 (w), 
2939 (w), 1717 (w), 1601 (s), 1551 (m), 1498 (m), 1455 (w), 
1364 (w), 1245 (w), 1165 (w), 1005 (w), 828 (m). 1H NMR (400 MHz, CDCl3) δ 8.37 (dd, J = 7.5, 
1.7 Hz, 1H, ArH), 7.86 (s, 1H, NCHCI), 7.54 – 7.36 (m, 4H, ArH), 7.33 – 7.19 (m, 5H, ArH), 7.18 
– 7.14 (m, 2H, ArH), 6.79 (dd, J = 8.3, 0.8 Hz, 1H, ArH), 4.34 (t, J = 7.2 Hz, 2H, NCH2), 2.73 (t, 
J = 7.5 Hz, 2H, CH2Ph), 2.35 (m, 2H, CH2-CH2-CH2). 13C NMR (101 MHz, CDCl3) δ 166.8, 140.0, 
137.8, 136.8, 133.4, 133.2, 132.4, 130.4, 129.3, 128.6, 128.3, 126.4, 125.2, 124.1, 122.5, 120.0, 
116.1, 110.9, 78.9, 46.7, 32.8, 31.1. HR-ESI-MS 482.0614 ([M+H]+, C24H21INO2+; calc. for 
482.0612). The structure of the obtained regioisomer was assigned by NMR correlation to 
compound 25. 
1-(3-1-(But-3-en-1-yl)-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (33) 
Following procedure A: starting from 1-(but-3-en-1-yl)-1H-
indole 112 (171 mg, 1.00 mmol), after 16 hours 1-(3-1-(but-3-
en-1-yl)-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 33 (359 
mg, 0.860 mmol, 86% yield) was obtained, as a yellow 
amorphous solid. Rf: 0.44 (DCM:MeOH 9:1). IR ν 3082 (w), 
1607 (s), 1557 (m), 1500 (m), 1456 (w), 1437 (w), 1389 (w), 
1358 (m), 1262 (w), 1160 (w), 1005 (w), 919 (w), 830 (w).  1H NMR (400 MHz, CDCl3) δ 8.35 
(dd, J = 7.4, 1.7 Hz, 1H, ArH), 7.91 (s, 1H, NCHCI), 7.54 (m, 1H, ArH), 7.49 (td, J = 7.3, 0.9 Hz, 
1H, ArH), 7.46 – 7.39 (m, 2H, ArH), 7.32 – 7.19 (m, 2H, ArH), 6.73 (dd, J = 8.3, 0.9 Hz, 1H, ArH), 
5.82 (ddt, J = 17.1, 10.3, 6.9 Hz, 1H, NCH2CH2CH=CH2), 5.12 – 4.97 (m, 2H, 
NCH2CH2CH=CH2), 4.41 (t, J = 6.9 Hz, 2H, NCH2), 2.71 (m, 2H, CH2). 13C NMR (101 MHz, 
CDCl3) δ 166.8, 137.9, 136.7, 133.6, 133.4, 133.2, 132.5, 130.5, 129.4, 125.2, 124.2, 122.5, 120.0, 
118.6, 116.2, 110.9, 79.0, 46.9, 34.2. HR-ESI-MS 418.0294 ([M+H]+, C19H17INO2+; calc. for 
418.0299). The structure of the obtained regioisomer was assigned by NMR correlation to 
compound 25. 
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1-(3-1-(2-((Triisopropylsilyl)oxy)ethyl)-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (34) 
Following procedure A: starting from 1-(2-
((triisopropylsilyl)oxy)ethyl)-1H-indole 113 (318 mg, 1.00 
mmol), after 16 hours 1-(3-1-(2-((triisopropylsilyl)oxy)ethyl)-
1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 34 (873 mg, 
0.929 mmol, 60% yield) was obtained as an orange oil. Rf: 
0.40 (DCM:MeOH 9:1). IR ν 2942 (w), 2890 (w), 2865 (m), 
1716 (w), 1604 (s), 1555 (w), 1500 (w), 1458 (w), 1358 (m), 1249 (m), 1169 (w), 1115 (w), 1015 
(w), 883 (m), 831 (m). 1H NMR (400 MHz, CDCl3) δ 8.47 (d, J = 7.5 Hz, 1H, ArH), 7.99 (s, 1H, 
NCHCI), 7.65 (d, J = 8.5 Hz, 1H, ArH), 7.59 (t, J = 7.5 Hz, 1H, ArH), 7.51 – 7.45 (m, 2H, ArH), 
7.35 (m, 2H, ArH), 6.94 (d, J = 8.3 Hz, 1H, ArH), 4.54 (t, J = 5.0 Hz, 2H, CH2), 4.20 (t, J = 5.0 
Hz, 2H, CH2), 1.09 (dd, J = 8.7, 5.6 Hz, 3H, SiCH(CH3)2), 1.01 (d, J = 7.1 Hz, 18H, SiCH(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 167.0, 138.8, 137.1, 133.2, 133.2, 132.4, 130.4, 129.1, 125.3, 
124.0, 122.4, 119.7, 115.8, 111.0, 78.3, 62.3, 49.8, 17.7, 11.6. HR-ESI-MS 564.1431 ([M+H]+, 
C26H35INO3Si+; calc. for 564.1425). The structure of the obtained regioisomer was assigned by 
NMR correlation to compound 25. 
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Figure S4: Scope of Heterocyclic-BX reagents (4) 
 
1-(2-1-Methyl-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (35a) and 1-(3-1-methyl-1H-
pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (35b). 
Following procedure A: starting from 
commercially available 1-methyl-1H-
pyrrole 12 (0.890 ml, 1.00 mmol), after 12 
hours 1-(2-1-methyl-1H-pyrrole)-1H-1λ3 -
benzo[b]iodo-3(2H)-one 35a and 1-(3-1-
methyl-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-
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3(2H)-one 35b were obtained as a 1:1 mixture (310 mg, 0.948 mmol, overall yield 95%) as an off-
white, sticky amorphous solid. Rf: 0.5 (DCM:MeOH 9:1). The two compounds were separated by 
slow flash column chromatography (EtOAc:MeOH 9:1). The structure of the obtained 
regioisomers were assigned by NMR correlation to compound 37.  
1-(2-1-methyl-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 35a (152 mg, 
0.465 mmol, 47% yield; off-white, sticky amorphous solid) Rf: 0.3 
(EtOAc:MeOH 9:1). IR ν 3415 (w), 3105 (w), 3049 (w), 2950 (w), 1604 
(s), 1584 (m), 1558 (w), 1508 (w), 1437 (w), 1346 (m), 1288 (m), 1223 (w), 
1149 (w), 1091 (w), 1047 (w), 1005 (w), 829 (m). 1H NMR (400 MHz, 
CD3OD) δ 8.24 (dd, J = 7.5, 1.6 Hz, 1H, ArH), 7.65 (td, J = 7.4, 1.0 Hz, 1H, 
ArH), 7.55 (m, 1H, ArH), 7.27 (t, J = 2.1 Hz, 1H, ArH), 7.01 (dd, J = 3.9, 1.6 Hz, 1H, ArH), 6.72 
(dd, J = 8.3, 1.0 Hz, 1H, ArH), 6.43 (dd, J = 3.9, 2.1 Hz, 1H, ArH), 3.78 (s, 1H, NCH3). 13C NMR 
(101 MHz, CD3OD) δ 170.1, 135.5, 134.2, 133.2, 131.9, 131.4, 127.7, 126.6, 119.4, 112.9, 96.0, 
37.4. HR-ESI-MS 327.9842 ([M+H]+ , C12H11INO2+; calc. for 327.9829). DSC-analysis was 
performed on compound 35a: see par.5 of Supplementary informations. 
1-(3-1-methyl-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 35b (158 
mg, 0.483 mmol, 48% yield; off-white, sticky amorphous solid). Rf: 
0.25 (EtOAc:MeOH 9:1). IR ν 3447 (w), 3106 (w), 2947 (w), 2863 (w), 
1603 (s), 1591 (m), 1558 (m), 1512 (m), 1437 (w), 1354 (m), 1294 (w), 
1110 (m), 1083 (w), 1007 (w), 829 (m). 1H NMR (400 MHz, CD3OD) 
δ 8.15 (dd, J = 7.5, 1.7 Hz, 1H, ArH), 7.53 (td, J = 7.3, 1.1 Hz, 1H, ArH), 7.49 – 7.40 (m, 2H, 
ArH), 7.04 – 6.98 (m, 2H, ArH), 6.58 (d, J = 1.2 Hz, 1H, ArH), 3.85 (s, 3H, NMe). 13C NMR (101 
MHz, CD3OD) δ 170.0, 134.9, 134.2, 133.4, 132.8, 131.5, 127.9, 127.7, 117.4, 116.6, 82.8, 37.1. 
HR-ESI-MS 327.9831 ([M+H]+ , C12H11INO2+; calc. for 327.9829). DSC-analysis was performed 
on compound 35b: see par.5 of Supplementary informations. 
 
1-(2-1-benzyl-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (36a) and 1-(3-1-benzyl-1H-
pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (36b) 
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Following procedure A: starting from 
commercially available 1-benzyl-1H-
pyrrole (0.890 ml, 1.00 mmol), after 12 
hours 1-(2-1-benzyl-1H-pyrrole)-1H-
1λ3 -benzo[b]iodo-3(2H)-one 36a and 1-
(3-1-benzyl-1H-pyrrole)-1H-1λ3 -
benzo[b]iodo-3(2H)-one 36b were 
obtained in 3:1 mixture (345 mg, 0.856 mmol, overall yield 86%), as a colorless amorphous solid. 
Rf: 0.7 (DCM:MeOH 9:1). The two compounds were separated by slow flash column 
chromatography (EtOAc:MeOH 9:1). The structure of the obtained regioisomers were assigned by 
NMR correlation to compound 37. 
 
1-(2-1-benzyl-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 36a (85.0 mg, 
0.211 mmol, 21% yield); colorless foam. Rf: 0.5 (EtOAc:MeOH 9:1). IR ν 
3109 (w), 3064 (w), 2968 (w), 2875 (w), 1609 (s), 1585 (m), 1558 (w), 1503 
(w), 1456 (w), 1440 (w), 1357 (m), 1277 (w), 1103 (m), 1079 (w), 1032 (w), 
1031 (w), 830 (w). 1H NMR (400 MHz, 2:1 mixture CD3OD:C6D6, 
referered to CD3OD) δ 8.18 (dd, J = 7.5, 1.6 Hz, 1H, ArH), 7.28 (t, J = 7.4 
Hz, 1H, ArH), 7.10 (t, J = 2.2 Hz, 1H, ArH), 6.92 (m, J = 7.6, 2.9 Hz, 6H, 
ArH + C6D6), 6.71 (dd, J = 3.9, 1.7 Hz, 1H, ArH), 6.35 (t, J = 3.4 Hz, 1H, ArH), 6.23 (d, J = 8.3 
Hz, 1H, ArH), 4.90 (s, 2H, NCH2Ph). 13C NMR (101 MHz, 2:1 mixture CD3OD:C6D6, referered 
to CD3OD) δ 169.8, 136.9, 134.6, 132.7, 131.2, 131.1, 129.5, 129.0, 128.5, 127.2, 119.2, 112.9, 
94.8, 54.7 (two Carbon signals under the deuterated benzene). HR-ESI-MS 404.0140 ([M+H]+, 
C18H15INO2+; calc. for 404.0142). 
 
1-(3-1-benzyl-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 
36b (260 mg, 0.645 mmol, 65% yield); colorless foam. Rf: 0.46 
(EtOAc:MeOH 9:1). IR ν 3409 (w), 3114 (w), 2971 (w), 1609 
(s), 1585 (m), 1558 (w), 1456 (w), 1438 (w), 1365 (m), 1277 (s), 
1160 (w), 1079 (w), 1032 (m), 835 (w). 1H NMR (400 MHz, 
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2:1 mixture CD3OD:C6D6, refered to CD3OD) δ 8.29 (dd, J = 7.5, 1.7 Hz, 1H, ArH), 7.36 (t, J = 
7.3 Hz, 1H, ArH), 7.30 – 7.20 (m, 3H ArH + C6D6), 7.18 – 7.08 (m, 3H, ArH), 6.97 (d, J = 2.0 Hz, 
1H, ArH), 6.83 – 6.78 (m, 2H, ArH), 6.30 (dd, J = 3.0, 1.7 Hz, 1H, ArH), 4.93 (s, 2H, NCH2Ph). 
13C NMR (101 MHz, 2:1 mixture CD3OD:C6D6, refered to CD3OD) δ 168.7, 136.8, 133.5, 133.0, 
131.8, 130.9, 130.3, 128.8, 128.1, 127.4, 126.2, 125.5, 116.3, 115.3, 82.4, 53.5. HR-ESI-MS 
404.0140 ([M+H]+, C18H15INO2+; calc. for 404.0142). 
 
1-(3-1H-Pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (37) 
Following procedure A: starting from 1-(tert-butyldimethylsilyl)-1H-
pyrrole 111 (181 mg, 1.00 mmol) and using Sc(OTf)3 as the Lewis Acid 
(20 mol%), after 16 hours 1-(3-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-
one 9n (225 mg, 0.719 mmol, 72% yield) was obtained  as a slightly brown 
solid. Rf: 0.5 (DCM:MeOH 9:1). Mp: 147°C (decomposition). IR ν 3484 
(w), 1607 (w), 1558 (w), 1439 (w), 1397 (w), 1260 (s), 1236 (s), 1174 (s), 1084 (w), 1050 (m), 
1038 (m), 903 (w), 882 (w). 1H NMR (400 MHz, MeOD) δ 8.40 (dd, J = 7.5, 1.7 Hz, 1H, ArH), 
7.72 (d, J = 7.4 Hz, 1H, ArH), 7.68 – 7.59 (m, 2H, ArH), 7.23 (t, J = 2.4 Hz, 1H, ArH), 7.14 (d, J 
= 8.2 Hz, 1H, ArH), 6.74 (dd, J = 2.8, 1.5 Hz, 1H, ArH) (NH signal exchanges with MeOD). 13C 
NMR (101 MHz, MeOD) δ 170.3, 135.0, 134.4, 132.9, 131.5, 130.4, 128.0, 123.7, 117.3, 115.9, 
83.4. HRMS (ESI) calcd for C11H9INO2+ [M+H]+ 313.9673; found 313.9673.  The structure of the 
reagent was assigned based on X-Ray diffraction (CCDC number 1541174). 
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Figure S5: Scope of Heterocyclic-BX reagents (5) 
 
1-(2-1-Methyl-1H-pyrrole)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ3-benzo[d][1,2]iodaoxole 
(16a) and 1-(3-1-methyl-1H-pyrrole)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ3-
benzo[d][1,2]iodaoxole (16b) 
 Following procedure B: starting from 
commercially available 1-methyl-1H-
pyrrole 12 (17.8 µl, 0.200 mmol) and 1-
acetoxy-1,3-dihydro-3,3-
bis(trifluoromethyl)-1,2-benziodoxole 
18 (94.0 mg, 0.220 mmol, 1.10 equiv.), 
after 12 hours 1-(2-1-methyl-1H-pyrrole)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ3-
benzo[d][1,2]iodaoxole 16a  and 1-(3-1-methyl-1H-pyrrole)-3,3-bis(trifluoromethyl)-1,3-dihydro-
1λ3-benzo[d][1,2]iodaoxole 16b were obtained in 1:1 mixture (81.5 mg, 182 mmol, overall yield 
90%), as a slightly grey amorphous solid. Rf: 0.5 (DCM:MeOH 9:1). The two compounds were 
separated by slow flash column chromatography (EtOAc:MeOH 20:1). The structure of the 
obtained regioisomers were assigned by NMR correlation to compound 37. 
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1-(2-1-methyl-1H-pyrrole)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ3-
benzo[d][1,2]iodaoxole 16a (41.2 mg, 92.0 µmol, 45% yield); colorless 
foam. Rf: 0.50 (EtOAc:MeOH 9:1). IR ν 3734 (w), 3702 (w), 3628 (w), 
1716 (w), 1509 (w), 1459 (w), 1288 (m), 1265 (s), 1214 (m), 1181 (s), 
1158 (s), 966 (m), 951 (m), 914 (w). 1H NMR (400 MHz, CDCl3) δ 7.86 
(dd, J = 7.7, 1.3 Hz, 1H, ArH), 7.57 (td, J = 7.4, 1.1 Hz, 1H, ArH), 7.41 
(ddd, J = 8.5, 7.1, 1.5 Hz, 1H, ArH), 6.97 (dd, J = 2.7, 1.6 Hz, 1H, ArH), 6.78 (dd, J = 3.8, 1.6 Hz, 
1H, ArH), 6.63 (dd, J = 8.3, 1.1 Hz, 1H, ArH), 6.34 (dd, J = 3.8, 2.7 Hz, 1H, ArH), 3.68 (s, 3H, 
NCH3).  13C NMR (101 MHz, CDCl3) δ 132.3, 131.3, 130.5, 130.2, 128.3, 126.4, 124.2, 122.6 (m), 
114.3, 111.3, 102.5, 81.40 (dt, J = 57.9, 29.6 Hz), 37.0. HR-APCI-MS 449.9771 ([M+H]+, 
C14H11F6INO+; calc. for 449.9784). The structure of the obtained regioisomer was assigned by 
NMR correlation to  compound 37. 
1-(3-1-methyl-1H-pyrrole)-3,3-bis(trifluoromethyl)-1,3-dihydro-
1λ3-benzo[d][1,2]iodaoxole 16b (40.3 mg, 90.0 µmol, 45% yield); 
slightly grey amorphous foam. Rf: 0.48 (EtOAc:MeOH 9:1). IR ν 
2938 (w), 2929 (w), 1718 (w), 1510 (w), 1464 (w), 1264 (s), 1181 (s), 
1161 (s), 1108 (w), 966 (m), 949 (m). 1H NMR (400 MHz, CDCl3) δ 
7.82 (m, 1H, ArH), 7.52 (ddd, J = 7.8, 7.1, 1.1 Hz, 1H, ArH), 7.37 
(ddd, J = 8.5, 7.1, 1.5 Hz, 1H, ArH), 7.08 (dd, J = 8.3, 1.1 Hz, 1H, ArH), 6.99 (t, J = 1.9 Hz, 1H, 
ArH), 6.76 (dd, J = 2.7, 2.1 Hz, 1H, ArH), 6.42 (dd, J = 2.8, 1.7 Hz, 1H, ArH), 3.80 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 131.6, 131.3, 130.4, 129.9, 129.8, 126.9, 125.38, 124.19 (q, J = 
291.5 Hz), 115.77, 112.69, 89.21, 81.47 (p, J = 28.7 Hz), 36.65. HR-APCI-MS 449.9771 ([M+H]+, 
C14H11F6INO+; calc. for 449.9784). The structure of the obtained regioisomer was assigned by 
NMR correlation to  compound 37. 
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1-(2-1-Methyl-1H-pyrrole)-3,3-dimethyl-1,3-dihydro-1λ3-benzo[d][1,2]iodoxole (38a) and 1-
(3-1-methyl-1H-pyrrole)-3,3-dimethyl-1,3-dihydro-1λ3-benzo[d][1,2]iodoxole (38b) 
 Following procedure B: starting from 
commercially available 1-methyl-1H-
pyrrole 12 (17.8 µl, 0.200 mmol) and 3,3-
dimethyl-1λ3-benzo[d][1,2]iodoxol-1(3H)-
yl acetate 22 (70.4 mg, 0.220 mmol, 1.10 
equiv.), after 12 hours 1-(2-1-Methyl-1H-
pyrrole)-3,3-dimethyl-1,3-dihydro-1λ3-benzo[d][1,2]iodoxole 38a and 1-(3-1-methyl-1H-
pyrrole)-3,3-dimethyl-1,3-dihydro-1λ3-benzo[d][1,2]iodoxole 38b were obtained in 1:9 
unseparable mixture (62.0 mg, 0.182 mmol, overall yield 91%), as a slightly grey amorphous solid. 
Rf: 0.4 (DCM:MeOH 20:1). NB: the reagent is unstable in acidic deuterated solvents and it 
decompose in short time, we recommend the immediate use after the synthesis. The proton and 
carbon NMRs present about 2% of the open protonated alcohol form.  IR ν 3115 (w), 2986 (w), 
1614 (w), 1509 (w), 1455 (w), 1372 (w), 1284 (s), 1247 (s), 1225 (m), 1163 (m), 1110 (w), 1031 
(s), 992 (w). 1H NMR (400 MHz, CD2Cl2) on a maj:min (9:1) δ 7.53 (m, 0.26H, 2 ArH min), 7.50 
(dd, J = 7.0, 1.0 Hz, 1H, ArH maj), 7.45 (dd, J = 7.8, 1.8 Hz, 1H, ArH maj), 7.33 (t, J = 2.0 Hz, 
1H, ArH maj), 7.28 (dtd, J = 8.7, 7.0, 6.5, 1.8 Hz, 1.24H, ArH maj + 2H ArH min), 7.23 (dd, J = 
2.9, 1.7 Hz, 0.12H, ), 7.04 (dd, J = 8.4, 1.1 Hz, 1H, ArH maj), 6.94 (dd, J = 2.9, 2.1 Hz, 1H, ArH 
maj), 6.66 (dd, J = 8.4, 0.9 Hz, 0.12H, ArH min), 6.57 (dd, J = 3.0, 1.8 Hz, 1H, ArH maj), 6.48 
(dd, J = 4.1, 2.8 Hz, 0.12H, ArH min), 3.85 (s, 3.32H, NCH3 maj+min), 1.68 (s, 6.73H, N(CH3)2 
maj+min). Major regioisomer C3 X: 13C NMR (101 MHz, CD2Cl2) δ 146.4, 133.4, 131.5, 131.0, 
129.0, 127.7, 127.7, 116.5, 109.9, 77.8, 75.1, 37.8, 30.8. Minor regioisomer C2 X: 13C NMR (101 
MHz, CD2Cl2) δ 146.6, 132.6, 131.9, 129.5, 128.4, 127.4, 122.6, 119.4, 113.6, 89.3, 75.4, 37.9, 
30.8. (the last two overlap with the major regioisomers). HR-ESI-MS 342.0350 ([M+H]+, 
C14H17INO+; calc. for 342.0349). The structure of the obtained regioisomer was assigned by NMR 
correlation to  compound 37. 
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Figure S6: Scope of Heterocyclic-BX reagents (6) 
5,6-Dimethoxy-1-(3-1-Methyl-1H-indole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one (39) 
 Following procedure B: starting from commercially available 1-methyl-
1-H-indole 14 (26.2 mg, 0.100 mmol) and 5,6-dimethoxy-3-
oxobenzo[d][1,2]iodaoxol-1(3H)-yl acetate 95 (81.0 mg, 0.220 mmol, 
1.10 equiv.), after 16 hours 1-(3-1-methyl-1H-indole)-3,3-dimethyl-1,3-
dihydro-1λ3-benzo[d][1,2]iodoxole 39 (49.0 mg, 0.112 mmol, 56% yield) 
was obtained as a brown foam. Rf: 0.7 (DCM:MeOH 9:1). IR ν 3113 
(w), 2942 (w), 1603 (s), 1499 (s), 1455 (m), 1394 (s), 1330 (s), 1270 (s), 
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1212 (s), 1131 (m), 1017 (m). 1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H, ArH), 7.73 (s, 1H, ArH), 
7.53 – 7.47 (m, 1H, ArH), 7.43 (m, 1H, ArH), 7.40 (dd, J = 8.2, 1.2 Hz, 1H, ArH), 7.29 (ddd, J = 
8.0, 7.1, 1.0 Hz, 1H, ArH), 6.12 (s, 1H, ArH), 4.03 (s, 3H, Me), 3.87 (s, 3H, Me), 3.20 (s, 3H, Me). 
13C NMR (101 MHz, CDCl3) δ 167.2, 153.2, 150.9, 139.3, 137.4, 129.1, 126.4, 124.2, 122.5, 
119.9, 113.3, 110.6, 107.3, 104.9, 79.0, 56.3, 55.7, 33.9. HR-ESI-MS 438.0197 ([M+H]+, 
C18H17INO4+; calc. for 438.0197). The structure of the obtained regioisomer was assigned by NMR 
correlation to  compound 25. 
 
5,6-Dimethoxy-1-(2-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one (40a) and 5,6-
dimethoxy-1-(3-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one (40b) 
 Following procedure B: starting from 
commercially available 1-methyl-1H-pyrrole 
12 (17.8 µl, 0.200 mmol) and 5,6-dimethoxy-3-
oxobenzo[d][1,2]iodaoxol-1(3H)-yl acetate 95 
(81.0 mg, 0.220 mmol, 1.10 equiv.), after 12 
hours 5,6-dimethoxy-1-(2-1-methyl-1H-
pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one 40a 
and 5,6-dimethoxy-1-(3-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one 40b were 
obtained in 1:2 mixture (77.0 mg, 0.199 mmol, overall yield 99%), as a yellow foam. Rf: 0.40 
(DCM:MeOH 9:1). The two compounds were separated by slow flash column chromatography 
(EtOAc:MeOH 20:1). The structure of the obtained regioisomers were assigned by NMR 
correlation to compound 37. 
5,6-dimethoxy-1-(2-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-
3(2H)-one 40a (26.0 mg, 67.0 µmol, 33% yield); yellow foam. Rf: 0.40 
(EtOAc:MeOH 9:1). IR ν 3104 (w), 2942 (w), 2848 (w), 1607 (s), 1562 
(s), 1498 (s), 1392 (s), 1270 (s), 1212 (s), 1182 (m), 1019 (m).  1H NMR 
(400 MHz, CDCl3) δ 7.88 (s, 1H, ArH), 7.07 (dd, J = 2.8, 1.6 Hz, 1H, 
ArH), 6.92 (dd, J = 3.9, 1.6 Hz, 1H, ArH), 6.42 (dd, J = 3.9, 2.8 Hz, 1H, 
ArH), 5.83 (s, 1H, ArH), 3.95 (s, 3H, Me), 3.76 (s, 3H, Me), 3.57 (s, 3H, 
Me). 13C NMR (101 MHz, CDCl3) δ 166.8, 154.1, 151.5, 129.3, 126.5, 125.3, 113.6, 112.1, 107.6, 
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106.2, 98.0, 56.6, 56.1, 37.4. HR-ESI-MS 388.0034 ([M+H]+, C14H15INO4+; calc. for 388.0040). 
The structure of the obtained regioisomer was assigned by NMR correlation to  compound 37. 
 
5,6-dimethoxy-1-(3-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-
3(2H)-one 40b (51.0 mg, 0.132 mmol, 66% yield); yellow foam. Rf: 
0.38 (EtOAc:MeOH 9:1). IR ν 3109 (w), 2941 (w), 2850 (w), 1609 (m), 
1562 (s), 1498 (s), 1392 (s), 1326 (m), 1270 (s), 1212 (s), 1182 (w), 1128 
(w), 1019 (m). 1H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H, ArH), 7.25 
(d, J = 1.9 Hz, 1H, ArH), 6.84 (s, 1H, ArH), 6.54 (m, 1H, ArH), 6.36 (s, 
1H, ArH), 3.94 (s, 3H, Me), 3.85 (s, 3H, Me), 3.62 (s, 3H, Me).13C NMR 
(101 MHz, CDCl3) δ 167.0, 153.3, 151.0, 131.3, 126.6, 125.9, 115.7, 113.4, 107.3, 105.6, 85.0, 
56.4, 56.0, 37.0. HR-ESI-MS 388.0035 ([M+H]+, C14H15INO4+; calc. for 388.0040). The structure 
of the obtained regioisomer was assigned by NMR correlation to  compound 37. 
4-Fluoro-1-(2-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one (41a) and 4-Fluoro-1-
(3-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one (41b) 
 
 Following procedure B: starting from 
commercially available 1-methyl-1H-pyrrole 12 
(17.8 µl, 0.200 mmol) and 4-fluoro-3-oxo-1λ3-
benzo[d][1,2]iodaoxol-1(3H)-yl acetate 96 (71.3 
mg, 0.220 mmol, 1.10 equiv.), after 12 hours 4-
Fluoro-1-(2-1-methyl-1H-pyrrole)- 1H-1λ3 -
benzo[b]iodo-3(2H)-one 41a and -Fluoro-1-(3-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-
3(2H)-one 41b were obtained in 1:3 mixture (44.1 mg, 0.128 mmol, overall yield 64%), as a yellow 
foam. Rf: 0.40 (DCM:MeOH 9:1). The two compounds were separated by slow flash column 
chromatography (EtOAc:MeOH 20:1). The structure of the obtained regioisomers were assigned 
by NMR correlation to compound 37. 
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4-Fluoro-1-(2-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one 41b 
(11.1 mg, 32.0 µmol, 16% yield); yellow foam. Rf: 0.36 (EtOAc:MeOH 9:1). 
IR ν 3105 (w), 2918 (w), 2851 (w), 1636 (s), 1593 (m), 1564 (w), 1515 (w), 
1449 (m), 1422 (w), 1325 (m), 1242 (m), 1112 (m).  1H NMR (400 MHz, 
CDCl3) δ 7.45 – 7.28 (m, 2H, ArH), 7.07 (dd, J = 2.8, 1.6 Hz, 1H, ArH), 6.91 
(dd, J = 3.9, 1.6 Hz, 1H, ArH), 6.48 (dt, J = 7.9, 1.0 Hz, 1H, ArH), 6.42 (dd, 
J = 3.9, 2.8 Hz, 1H, ArH), 3.74 (s, 3H, NMe). 13C NMR (101 MHz, CDCl3) δ 152.6, 134.0, 133.9, 
129.9, 125.6, 121.6, 120.7, 120.6, 120.3, 120.0, 112.3, 37.3. HR-ESI-MS 345.9730 ([M+H]+, 
C12H10FINO2+; calc. for 345.9735).  The structure of the obtained regioisomer was assigned by 
NMR correlation to  compound 37. 
 
4-Fluoro-1-(3-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one 
41a (33.0 mg, 96.0 µmol, 48% yield); yellow foam. Rf: 0.38 
(EtOAc:MeOH 9:1). IR ν 2919 (m), 2851 (w), 1638 (s), 1612 (s), 1592 
(m), 1452 (w), 1339 (w), 1311 (w), 1287 (m), 1233 (w).  1H NMR (400 
MHz, CDCl3) δ 7.32 (td, J = 8.1, 4.6 Hz, 1H, ArH), 7.27 – 7.22 (m, 2H, 
ArH), 6.87 – 6.82 (m, 2H, ArH), 6.50 (dd, J = 2.9, 1.7 Hz, 1H, ArH), 
3.85 (s, 3H, NMe). 13C NMR (101 MHz, CDCl3) δ 164.6 (d, J = 266.7 Hz), 163.2, 133.11 (d, J = 
8.6 Hz), 131.3, 126.2, 121.80 (d, J = 12.7 Hz), 121.36 (d, J = 3.8 Hz), 119.8, 119.5 (d, J = 23.7 
Hz), 115.7, 85.9, 37.0. HR-ESI-MS 345.9731 ([M+H]+, C12H10FINO2+; calc. for 345.9735).  The 
structure of the obtained regioisomer was assigned by NMR correlation to  compound 37. 
5-Nitro-1-(2-1-Methyl-1H-pyrrole)-1H-1λ3-benzo[d][1,2]iodoxol-3-one (42a) and 5-Nitro-1-
(3-1-methyl-1H-pyrrole)-1H-1λ3-benzo[d][1,2]iodoxol-3-one (42b) 
 Following procedure B: starting from 
commercially available 1-methyl-1H-pyrrole 
12 (17.8 µl, 0.200 mmol) and 1-acetoxy-5-
nitro-1,2-benziodoxol-3(1H)-one 97 (77.0 mg, 
0.220 mmol, 1.10 equiv.), after 12 hours 5-
nitro-1-(2-1-methyl-1H-pyrrole)-1H-1λ3-
benzo[d][1,2]iodoxol-3-one (42a) and 5-nitro-
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1-(3-1-methyl-1H-pyrrole)-1H-1λ3-benzo[d][1,2]iodoxol-3-one (42b) were obtained in 4:1 
mixture (69.5 mg, 0.187 mmol, overall yield 93%), as a yellow foam. Rf: 0.50 (DCM:MeOH 9:1). 
The two compounds were separated by slow flash column chromatography (EtOAc:MeOH 20:1). 
The structure of the obtained regioisomers were assigned by NMR correlation to compound 37. 
5-nitro-1-(2-1-Methyl-1H-pyrrole)-1H-1λ3-benzo[d][1,2]iodoxol-3-one 42a 
(54.9 mg, 0.148 mmol, 74% yield); yellow foam. Rf: 0.50 (EtOAc:MeOH 
9:1). NB: the reagent is unstable in acidic deuterated solvents and it 
decompose in short time, we recommend the immediate use after the 
synthesis. The proton NMR presents about 6% of the open protonated 
acidic form.   IR ν 3103 (w), 2935 (w), 2925 (w), 2856 (w), 1785 (w), 1716 
(m), 1617 (m), 1530 (s), 1459 (w), 1346 (s), 1288 (m), 1250 (m).  1H NMR (400 MHz, CDCl3) δ 
9.13 (d, J = 2.6 Hz, 1H, ArH), 8.27 (dd, J = 8.8, 2.5 Hz, 1H, ArH), 7.13 (dd, J = 2.8, 1.5 Hz, 1H, 
ArH), 6.97 (dd, J = 4.0, 1.6 Hz, 1H, ArH), 6.82 (d, J = 8.9 Hz, 1H, ArH), 6.47 (d, J = 1.1 Hz, 1H, 
ArH), 3.80 (s, 3H, NMe).13C NMR (101 MHz, CDCl3) δ 164.9, 150.6, 135.6, 130.4, 127.8, 127.0, 
126.6, 126.0, 124.8, 112.7, 96.6, 37.5. HR-ESI-MS 372.9690 ([M+H]+, C12H10IN2O4++; calc. for 
372.9680).  The structure of the obtained regioisomer was assigned by NMR correlation to  
compound 37. 
 
5-nitro-1-(3-1-Methyl-1H-pyrrole)-1H-1λ3-benzo[d][1,2]iodoxol-3-one 
42b (14.6 mg, 0.039 mmol, 19% yield); yellow foam. Rf: 0.46 
(EtOAc:MeOH 9:1). NB: the reagent is unstable in acidic deuterated 
solvents and it decompose in short time, we recommend the immediate 
use after the synthesis. The proton and carbon NMRs present about 
8% of the open protonated acidic form.   IR ν 3092 (w), 2957 (w), 2928 
(w), 1716 (m), 1623 (m), 1529 (s), 1346 (s), 1303 (w), 1109 (w), 1076 (w). 1H NMR (400 MHz, 
CDCl3) δ 9.18 (d, J = 2.6 Hz, 1H, ArH), 8.24 (dd, J = 8.9, 2.7 Hz, 1H, ArH), 7.23 (t, J = 1.9 Hz, 
1H, ArH), 7.20 (d, J = 8.9 Hz, 1H, ArH), 6.90 (m, 1H, ArH), 6.56 (dd, J = 2.9, 1.7 Hz, 1H, ArH), 
3.89 (s, 3H, NMe).13C NMR (101 MHz, CDCl3) δ 194.4, 150.5, 135.6, 131.3, 127.1, 126.8, 126.7, 
126.6, 122.3, 115.8, 84.2, 37.2. HR-ESI-MS 372.9691 ([M+H]+, C12H10IN2O4++; calc. for 
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372.9680).  The structure of the obtained regioisomer was assigned by NMR correlation to  
compound 37. 
 
Figure S7: Scope of Heterocyclic-BX reagents (6) 
 
1-(3-1-Methyl-1H-pyrrolo[2,3-b]pyridine)-1H-1λ3 -benzo[b]iodo-3(2H)-one (43) 
Following procedure A: starting from commercially available 1-methyl-
1H-pyrrolo[2,3-b]pyridine (132 mg, 1.00 mmol), after 16 hours 1-(3-1-
methyl-1H-pyrrolo[2,3-b]pyridine)-1H-1λ3 -benzo[b]iodo-3(2H)-one 43 
(114 mg, 0.301 mmol, 30% yield) was obtained as a brown amorphous 
solid. Rf: 0.2 (DCM:MeOH 9:1). IR ν 2925 (w), 2852 (w), 1719 (s), 
1599 (m), 1585 (m), 1468 (m), 1408 (w), 1348 (w), 1289 (m), 1262 (s), 
1136 (m), 1103 (w), 1042 (w), 1017 (m), 976 (w).  1H NMR (400 MHz, CD2Cl2) δ 8.37 (dd, J = 
4.7, 1.6 Hz, 1H, ArH), 8.06 (dd, J = 7.9, 1.2 Hz, 1H, ArH), 7.96 (dd, J = 7.9, 1.7 Hz, 1H, ArH), 
7.92 (dd, J = 7.9, 1.7 Hz, 1H, ArH), 7.46 (td, J = 7.7, 1.2 Hz, 1H, ArH), 7.25 – 7.19 (m, 2H, ArH), 
7.14 (dd, J = 7.9, 4.7 Hz, 1H, ArH), 3.86 (s, 3H, CH3N). 13C NMR (101 MHz, CD2Cl2) δ 168.6, 
144.4, 142.3, 134.3, 133.8, 132.1, 128.7, 127.0, 126.3, 118.8, 116.5, 103.2, 94.9, 31.7 (one Carbon 
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signal not resolved). HR-ESI-MS 378.9945 ([M+H]+, C15H12IN2O2+; calc. for 378.9938). The 
structure of the obtained regioisomer was assigned by NMR correlation to compound 9b. 
 
1-(3-9-Methyl-9H-carbazole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (44) 
Following procedure A: starting from commercially available 9-
methyl-9H-carbazole (181 mg, 1.00 mmol), after 16 hours 1-(3-9-
methyl-9H-carbazole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 9m (110 
mg, 0.257 mmol, 33% yield) was obtained as a grey amorphous 
solid. Rf: 0.2 (DCM:MeOH 9:1). IR ν 3082 (w), 2974 (w), 2924 
(w), 2816 (w), 1652 (s), 1588 (w), 1570 (w), 1456 (w), 1440 (m), 1295 (m), 1245 (w), 1139 (w), 
1017 (w), 982 (m), 831 (w).  1H NMR (400 MHz, CDCl3) δ 8.67 (d,  J = 1.6 Hz, 1H, ArH), 8.47 
(dd, J = 7.5, 1.7 Hz, 1H, ArH), 8.14 (d, J = 7.9 Hz, 1H, ArH), 7.96 (dd,  J = 8.5, 1.6 Hz, 1H, ArH), 
7.63 (ddd, J = 8.4, 7.1, 1.2 Hz, 1H, ArH), 7.59 (d, J = 8.5 Hz, 1H, ArH), 7.57 – 7.52 (m, 2H, ArH), 
7.37 (td, J = 7.5, 1.2 Hz, 1H, ArH), 7.30 (ddd, J = 8.5, 7.1, 1.7 Hz, 1H, ArH), 6.69 (dd, J = 8.5, 0.9 
Hz, 1H, ArH), 3.98 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 166.5, 142.4, 141.4, 133.4, 
133.3, 132.7, 130.6, 130.0, 127.7, 125.8, 125.7, 121.4, 120.8, 120.7, 116.3, 112.0, 109.3, 101.8, 
53.4, 29.5. HR-ESI-MS 428.0147 ([M+H]+, C20H15INO2+; calc. for 428.0142). 
 
1-(2-1H-Thiophene)-1H-1λ3-benzo[b]iodo-3(2H)-one (45) 
 
Following procedure A: starting from commercially available thiophene 
(80.0 µL, 1.00 mmol) and using Sc(OTf)3 as the Lewis Acid (20 mol%), after 
16 hours 1-(2-1H-thiophene)-1H-1λ3 -benzo[b]iodo-3(2H)-one (45) (102 
mg, 0.309 mmol, 31% yield) was obtained as a light yellow amorphous solid. 
NB: the reagent is unstable in protic deuterated solvents and it decompose 
in short time, we recommend the immediate use after the synthesis. The 
proton NMR presents about 7% of the open protonated form.  Rf: 0.4 (DCM:MeOH 9:1). IR ν 
3080 (w), 2958 (w), 2925 (m), 2853 (w), 1716 (w), 1622 (s), 1603 (s), 1558 (m), 1438 (w), 1354 
(w), 1341 (w), 1299 (w), 1223 (w), 1006 (w), 951 (w), 834 (w), 830 (w).  1H NMR (400 MHz, 
CD3OD) δ 8.28 (dd, J = 7.5, 1.7 Hz, 1H, ArH), 8.05 (dd, J = 5.2, 1.2 Hz, 1H, ArH), 7.98 (dd, J = 
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3.7, 1.2 Hz, 1H, ArH), 7.70 (td, J = 7.4, 0.9 Hz, 1H, ArH), 7.61 (ddd, J = 8.7, 7.2, 1.7 Hz, 1H, 
ArH), 7.37 (dd, J = 5.3, 3.6 Hz, 1H, ArH), 6.92 (dd, J = 8.3, 0.9 Hz, 1H, ArH). 13C NMR (101 
MHz, CDCl3) δ 166.6, 141.5, 137.1, 134.1, 132.7, 131.0, 130.4, 125.2, 117.8, 104.2 (one aromatic 
Carbon signal not resolved). HR-ESI-MS 330.9291 ([M+H]+, C11H8IO2S+; calc. for 330.9284).  
 
1-(3-1H-2,5-dimethylfuran)-1H-1λ3 -benzo[b]iodo-3(2H)-one (46)  
Following procedure A: starting from commercially available 2,5-
dimethylfuran (107 µL, 1.00 mmol) and using In(OTf)3 as the Lewis 
Acid (20 mol%), after 24 hours 1- (3-1H-2,5-dimethylfuran)-1H-1λ3 -
benzo[b]iodo-3(2H)-one (9t) (47.0 mg, 0.137 mmol, 14% yield) was 
obtained as a brown resin. Rf: 0.3 (DCM:MeOH 9:1). IR ν 3430 (w), 
3111 (w), 3065 (w), 2923 (w), 2854 (w), 1607 (s), 1559 (m), 1438 (m), 
1348 (m), 1298 (w), 1229 (w), 1128 (w), 1039 (w), 1007 (w), 926 (w), 831 (m).  1H NMR (400 
MHz, CDCl3) δ 8.28 (dd, J = 7.4, 1.8 Hz, 1H, ArH), 7.50 (t, J = 7.3 Hz, 1H, ArH), 7.43 (td, J = 7.7, 
7.3, 1.8 Hz, 1H, ArH), 7.00 (d, J = 8.1 Hz, 1H, ArH), 6.21 (s, 1H, ArH), 2.42 (s, 3H, FuraneCH3), 
2.31 (s, 3H, FuraneCH3). 13C NMR (101 MHz, CDCl3) δ 166.9, 158.9, 154.2, 133.5, 133.1, 132.4, 
130.4, 125.4, 115.0, 110.4, 88.0, 13.4, 13.2. HR-ESI-MS 342.9827 ([M+H]+, C13H12IO3+; calc. for 
342.9826).  
2.6 Preparation of Deuterated IndoleBX (49). 
Following a reported procedure,[19] a flame dried flask is charged with freshly distilled 1-methyl-
1H-indole 14 (0.374 ml, 3.00 mmol) and then flushed with argon. Anhydrous THF (9 mL, 0.3 M) 
is added, and the reaction is allowed to stir until all the 1-methylindole is dissolved. The solution 
is cooled to 0 °C, and nBuLi 2.5 M (1.80 mL, 4.50 mmol, 1.5 equiv.) is added dropwise. The 
resulting solution is allowed to warm to ambient temperature, and allowed to stir for an additional 
20 minutes. Then, D2O (1.20 mL, 60.0 mmol, 20.0 equiv.) is added dropwise. After the solution is 
fully quenched with D2O, it is extracted with hexane (5x3 mL). Then the organic phase is dried 
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over Na2SO4 and the solvent is removed in vacuo. The final product 48 was purified by distillation 
from molecular sieves. The product was 88 % enriched with deuterium in the 2-position, as 
determined by 1H NMR. 
Following general procedure A, 1-(2 D 1 methylindole)-1H-1λ3-benzo[b]iodo-3(2H)-one 49 (215 
mg, 0.569 mmol, 56.9 % yield) is obtained as a slightly brown foam. The product was 88 % 
enriched with deuterium in the 2-position, as determined by 1H NMR. Rf: 0.28 (DCM:MeOH 
9:1). IR ν 3057 (w), 2945 (w), 2326 (w), 1601 (s), 1555 (m), 1474 (m), 1415 (m), 1359 (m), 1277 
(m), 1262 (m), 1157 (w), 1032 (m), 899 (m), 832 (m). 1H NMR (400 MHz, CDCl3:AcOH 10:1) δ 
8.22 (dd, J = 7.5, 1.7 Hz, 1H, ArH), 8.02 (s, 0.12H, CH + CD), 7.48 (d, J = 8.3 Hz, 1H, ArH), 7.40 
– 7.33 (m, 2H, ArH), 7.32 (d, J = 7.9 Hz, 1H, ArH), 7.22 (t, J = 7.5 Hz, 1H, ArH), 7.18 (ddd, J = 
8.6, 5.8, 2.3 Hz, 1H, ArH), 6.76 (d, J = 8.3 Hz, 1H, ArH), 4.00 (s, 3H, NCH3). 13C NMR (101 
MHz, CDCl3) δ 167.3, 139.3 (m, C-D), 137.4, 133.2, 133.0, 132.1, 130.2, 129.1, 125.5, 123.9, 
122.3, 119.5, 115.8, 110.7, 77.3, 33.8. HR-ESI-MS 378.9989 ([M+H]+, C16H13INO2+; calc. for 
378.9987). 
2.7 Preparation of β-Phenyliodonioindole Tetrafluoroborate (53). 
 
Following a reported procedure,[20] to a stirred solution of fine crushed KOH (5.61 g, 100 mmol, 
5.00 equiv.) in MeOH (20.0 mL, 1.0 M), 1H-indole 116 (2.34 g, 20.0 mmol, 1.00 equiv.) was added 
in portions at 0 °C. The resulting mixture was left stirring at 0 °C until complete dissolution of the 
1H-indole (1.5 h). Then PIDA (6.44 g, 20.0 mmol, 1.00 equiv.) was added portionwise and the 
reaction mixture left stirring at 0 °C for 1.5 h. Betaine I intermediate (dark yellow green solid in 
suspension) was then removed by filtration over a glass-synthered funnel, washed with cold MeOH 
and CHCl3 and air dried in the dark at 0 °C. Betaine I intermediate (2.20 g, 6.89 mmol, 35% yield) 
was obtained as a dark yellow green amorphous solid. 
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Caution: Betaine I is a highly unstable intermediate, it is reported to detonate at room 
temperature; do NOT grind it, it may explode. The Betaine I intermediate decomposes at -20 °C, 
it is recommended to be used immediately after its preparation. 
HBF4 (450 µL, 6.89 mmol, 1.00 equiv., 48 wt.% solution in H2O) was added to EtOH (10 mL) and 
the resulting solution cooled at -15 °C; then Betaine I intermediate (2.20 g, 6.89 mmol, 1.00 equiv.) 
was added portionwise under vigorous stirring at -15 °C. After all of Betaine I had been added, the 
dark brown resulting reaction mixture was diluted with Et2O (50 mL) and stirred for 1.5 h at -15 
°C. Then stirring was stopped and the reaction left at -15 °C for 30 min. The resulting precipitate 
was then removed by filtration over a glass-synthered funnel and dried at 0 °C to give β-
Phenyliodonioindole Tetrafluoroborate 53 (2.10 g, 5.16 mmol, 75% yield) as a yellowish green 
amorphous solid.  
Caution: β-Phenyliodonioindole Tetrafluoroborate 53 is an unstable salt and it was immediately 
used after its preparation. 
IR ν 3375 (s), 3132 (w), 1561 (m), 1491 (m), 1472 (s), 1411 (s), 1340 (m), 
1328 (m), 1279 (s), 1244 (s). 1H NMR (400 MHz, DMSO-d6) δ 12.32 (brs, 
1H, NH), 8.40 (d, J = 2.7 Hz, 1H, ArH), 8.14 – 8.12 (m, 2H, ArH), 7.74 (m, 
1H, ArH), 7.58 – 7.55 (m, 2H), 7.47 – 7.43 (m, 2H), 7.35 – 7.16 (m, 2H). 
(presence of Et2O residual solvent as the NMR analysis was performed on the 
slightly wet compound to prevent decomposition). 13C NMR (101 MHz, DMSO-d6) δ 135.8, 135.1, 
134.0, 131.5, 127.1, 123.6, 121.9, 118.8, 117.3, 113.0, 78.0. (one aromatic Carbon signal not 
resolved). HR-ESI-MS 319.9932 ([M+], C14H11IN; calc. for 319.9931).  
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3. Rh-Catalyzed C-H Indolization of Arenes via C-H activation.  
All commercially available chemicals were purchased from the suppliers quoted in Paragraph 1.0 
of Supplementary Informations: these chemicals were purified through a short plug of celite prior 
to their use in catalysis. The synthesis of non commercial available compounds is presented below. 
The synthesis of the starting materials 121, 123, 127 the optimization process of compound 52 and 
products 52, 54-75 had been already described before.[1] The procedures here reported are taken 
from the cited publication to facilitate reproduction of the results by having all the data in the same 
file. 
 
3.1 Synthesis of Starting Materials.  
 
Methyl 4-(pyridin-2-yl)benzoate (44) 
  
Following a reported procedure,[21] to a solution of commercially available 2-bromopyridine 119 
(100 µL, 1.00 mmol) in a mixture of 4/1 toluene/EtOH (5 mL, 0.2 M) was added Na2CO3 (106 mg, 
1.00 mmol, 1.00 equiv.) followed by Pd(PPh3)4  (34.7 mg, 30.0 µmol, 3 mol %) and (4-
(methoxycarbonyl)phenyl)boronic acid 120 (234 mg, 1.30 mmol, 1.30 equiv.) under argon 
atmosphere in a 50 mL two-necked flask.  The reaction mixture was refluxed for 12 h, and then 
cooled to room temperature. To the reaction mixture was added sat. aqueous NH4Cl (15 mL), then 
the mixture was extracted by EtOAc (3x5 ml). The combined organic extracts were dried over 
MgSO4, filtered and and concentrated in vacuo. The resulting crude product was purified by flash 
chromatography (Pentane:EtOAc 4:1) to afford methyl 4-(pyridin-2-yl)benzoate 121 (181 mg, 
0.849 mmol, 85% yield) as a white solid. IR ν 2944 (w), 2848 (w), 1708 (s), 1606 (w), 1586 (m), 
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1466 (w), 1435 (m), 1405 (w), 1319 (w), 1274 (s), 1194 (m), 1183 (m), 1153 (w), 1111 (s), 1014 
(m), 965 (m), 868 (w), 830 (w), 797 (w), 754 (vs), 699 (m). 1H NMR (400 MHz, CDCl3) δ 8.64 
(d, J = 4.7 Hz, 1H, ArH), 8.06 (d, J = 8.4 Hz, 2H, ArH), 7.98 (d, J = 8.3 Hz, 2H, ArH), 7.73 – 7.63 
(m, 2H, ArH), 7.19 (q, J = 4.6 Hz, 1H, ArH), 3.85 (s, 3H COOMe). 13C NMR (101 MHz, CDCl3) 
δ 166.8, 156.1, 149.8, 143.4, 136.8, 130.3, 130.0, 126.7, 122.8, 120.9, 52.1. NMR values are in 
accordance with the data reported in literature.[20] 
 
1-(Pyrimidin-2-yl)-1H-indole (123) 
 
Following a reported procedure,[22] commercially available 1H-indole 116 (586 mg, 5.00 mmol) 
was dissolved in N,N-dimethylformamide (15.0 mL, 0.3M) and sodium hydride (60% suspension 
in mineral oil, 300 mg, 7.50 mmol, 1.50 equiv.) was added at r.t. and the reaction mixture was 
stirred for one hour. Upon seizing of gas release, commercially available 2-chloropyrimidine 122 
(573 mg, 5.00 mmol, 1.00 equiv.) was added portionwise. The reaction was heated up to 150 °C 
and stirred overnight. After 10 hours the reaction was allowed cooling to r.t. and was then quenched 
with water (20 mL). The majority of the solvent was removed under reduced pressure, then the 
crude was diluted with Et2O (25 mL), the organic layer washed with brine (3x10 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. Flash column chromatography 
(Pentane:EtOAc 4:1) afforded 1-(pyrimidin-2-yl)-1H-indole 123 (926 mg, 4.74 mmol, 95% yield) 
as a light brown oil. IR ν 3138 (w), 3108 (w), 1575 (s), 1525 (m), 1456 (s), 1309 (m), 1204 (s), 
1080 (m), 970 (s), 776 (m), 750 (w), 731 (w).  1H NMR (400 MHz, CDCl3) δ  8.94 (d, J = 8.4 Hz, 
1H, ArH), 8.75 (d, J = 4.8 Hz, 2H, ArH), 8.40 (d, J = 3.7 Hz, 1H, ArH), 7.75 (d, J = 7.8 Hz, 1H, 
ArH), 7.51 – 7.43 (m, 1H, ArH), 7.37 (t, J = 7.5 Hz, 1H, ArH), 7.07 (t, J = 4.8 Hz, 1H, ArH), 6.83 
(d, J = 3.6 Hz, 1H, ArH). 13C NMR (101 MHz, CDCl3) δ 157.7, 157.4, 135.1, 131.1, 125.6, 123.4, 
121.9, 120.6, 116.2, 115.8, 106.6. NMR values are in accordance with the data reported in 
literature.[23] 
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(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(6-phenyl-9H-purin-9-yl)tetrahydrofuran-3,4-diyl 
diacetate (50) 
 
Following a reported procedure,[24] commercially available (2R,3R,4S,5R)-2-(6-chloro-9H-purin-
9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol 47 (573 mg, 2.00 mmol, 1.00 equiv.) was 
suspended in MeCN (12.5 mL, 0.15 M). Then Triethylamine (2.90 mL, 20.0 mmol, 10.0 equiv.) 
and Acetic Anhydride (1.10 mL µl, 12.00 mmol, 6.00 equiv.) were added at 0° C. After stirring for 
1h at room temperature, the mixture was refluxed for 5 hours. The resulting solution was 
evaporated to dryness and EtOAc (30 mL) and water (30 mL) were added. The organic layer was 
separated, dried over Na2SO4, filtered and concentrated under reduced pressure to give a light 
brown oil, which was recrystallized from EtOAc/Ether to give (2R,3R,4R,5R)-2-(acetoxymethyl)-
5-(6-chloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate 48 (693 mg, 1.68 mmol, 84 % yield)  
 
Subsequently, to a solution of (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(6-chloro-9H-purin-9-
yl)tetrahydrofuran-3,4-diyl diacetate 48 (500 mg, 1.21 mmol) in a mixture of 4/1 toluene (12 mL, 
0.1 M) was added K2CO3 (218 mg, 1.58 mmol, 1.30 equiv.) followed by Pd(PPh3)4  (42.0 mg, 30.0 
µmol, 3 mol %) and phenylboronic acid 49 (192 mg, 1.58 mmol, 1.30 equiv.) under argon 
atmosphere in a 20 mL two-necked flask. The reaction mixture was refluxed for 12 h, and then 
cooled to room temperature. To the reaction mixture was added sat. aqueous NH4Cl (15 mL), then 
the mixture was extracted by EtOAc (3x5 mL). The combined organic extracts were dried over 
MgSO4, filtered and and concentrated in vacuo. The resulting crude product was purified by flash 
chromatography (Pentane:EtOAc 4:1) to afford (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(6-phenyl-
9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate 50 (523 mg, 1.15 mmol, 95% yield) as a white 
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solid. IR ν 2926 (m), 1749 (s), 1583 (s), 1566 (s), 1439 (m), 1220 (s), 1101 (m), 766 (m), 693 (m). 
1H NMR (400 MHz, CDCl3) δ 8.95 (s, 1H, ArH), 8.68 (dd, J = 8.0, 1.8 Hz, ArH), 8.21 (s, 1H, 
ArH), 7.52 – 7.43 (m, 3H, ArH), 6.22 (d, J = 5.3 Hz, 1H, CH), 5.95 (t, J = 5.4 Hz, 1H, CH), 5.64 
(m, 1H, CH), 4.45 – 4.24 (m, 3H, CH + CH2), 2.08 (s, 3H, CH3), 2.05 (s, 3H, CH3), 2.00 (s, 3H, 
CH3. 13C NMR (101 MHz, CDCl3) δ 169.9, 169.2, 169.0, 154.7, 152.1, 151.6, 142.5, 135.0, 131.2, 
130.7, 129.4, 128.2, 86.1, 79.9, 72.7, 70.2, 62.7, 20.3, 20.1, 20.0. NMR values are in accordance 
with the data reported in literature.[23] 
 
3.2 Optimization of the Rh-Catalyzed Indolization of Arenes via C-H activation.     
In a vial, 2-phenylpyridine 49 (14.0 µl, 0.100 mmol), 1-(3-1-methyl-1H-indole)-1H-1λ3 -
benzo[b]iodo-3(2H)-one 21 (1.10 equiv.), the catalyst system (1.25-5 mol%) and the relative 
additive (2.5-20 mol%) were dissolved in the appropriate dry solvent (0.1 M)  under nitrogen. The 
reaction mixture was degassed (freeze-thaw-pump) and then stirred at the reported T in °C 
overnight. The reaction mixture was then allowed to cool to r.t., the organic layer was washed with 
sat. aqueous NaHCO3 (2 mL), and the solvent was removed under reduced pressure. Flash column 
chromatography (Pentane:EtOAc 4:1) afforded the desired product 52 (see compound 52’s 
characterization for all the chemical data). 
Table S3: Screening of solvents 
 
Entry Solvent Yield%a 
1 DCM 25% 
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2 DCE 55% 
3 MeOH - 
4 EtOH - 
5 TFE 16% 
6 Chlorobenzene - 
7 1,2-Chlorobenzene - 
8 Toluene - 
9 DMF (110°C) 66% 
a) Substrate 49 (0.100 mmol), IndoleBX 21 (0.110 mmol), [Rh(Cp*Cl2)]2 
(5 mol%), Zn(OTf)2 (10 mol%) and solvent (0.1 M) at 25 °C. Isolated yield 
after flash chromatography is given. 
Table S4: Screening of additives 
 
Entry Additive Yield%a 
1 - - 
2 Zn(OTf)2 55%b 
3 Sc(OTf)3 56%c 
4 K2CO3 28% 
5 Zn(NTf2)2 56% 
6 AgNTf2 - 
7 AgSbF6d 17% 
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8 NaOAc 69% 
9 KOAc 37% 
10 NaOPiv 72% 
11 KOPiv 49% 
12 CsOPiv 36% 
a) Substrate 49 (0.100 mmol), IndoleBX 21 (0.110 mmol), [Rh(Cp*Cl2)]2 (5 
mol%), additive (10 mol%) and DCE (0.1 M) at 25 °C. Isolated yield after 
flash chromatography is given. b) incomplete conversion, remaining starting 
material completely recovered. c) decomposition observed. d) T of the 
reaction is 50°C. 
Table S5: Screening of the catalyst:additive ratio at different T°C. 
 
Entry Catalyst (mol%) Additive (mol%) T°C Yield%a 
1 [Rh(Cp*Cl2)2] 
(1.25)/AgSbF6 (2.5) 
NaOPiv (2.5) r.t. tracesb 
2 [Rh(Cp*Cl2)2] 
(1.25)/AgSbF6 (10) 
NaOPiv (10) r.t. tracesb 
3 [Rh(Cp*Cl2)2] 
(1.25)/AgSbF6 (10) 
NaOPiv (10) 40°C tracesb 
4 [Rh(Cp*Cl2)2] 
(1.25)/AgSbF6 (10) 
NaOPiv (10) 50°C 37%b 
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5 [Rh(Cp*Cl2)2] 
(2.5)/AgSbF6 (5) 
NaOPiv (5)  r.t. tracesc 
6 [Rh(Cp*Cl2)2] 
(2.5)/AgSbF6 (10) 
NaOPiv (10) r.t. 78% 
7 [Rh(Cp*Cl2)2] 
(2.5)/AgSbF6 (10) 
NaOPiv (10) 50°C 82% 
8 [Rh(Cp*Cl2)2] 
(2.5)/AgSbF6 (10) 
NaOPiv (10) 80°C 85% 
9 [Rh(Cp*Cl2)2] (5)/AgSbF6 
(10) NaOPiv (10) r.t. 90% 
a)Substrate 49 (0.100 mmol), IndoleBX 21 (0.110 mmol), [Rh(Cp*Cl2)]2 (X mol%), NaOPiv (X mol%) and 
DCE (0.1 M) at 25 °C. Isolated yield after flash chromatography is given. b) the reaction time was 48 hours, 
hypervalent iodine decomposition was observed. 
3.3 Control experiments for the Indolization of Arenes via C-H activation.      
In order to assess the superiority of our reagents in catalysis compared to other indole-transfer 
reagents already known in cross-coupling reactions, we tested the latter under different sets of 
conditions. Substrates 14, 50 and 51 are commercially available, while compound 53 needed to be 
prepared and immediately used in the catalytic process. 
 
Substrates 50, 51 and 53 were tested under our optimized conditions (table S6, entries 1-3) at 
different temperatures (r.t.-50-60-110 °C): no conversion was observed. The hypervalent 
indolinium salt 53 was also tested in presence of NaSbF6 (table S6, entry 4) as an alternative salt to 
promote the exchange of BF4- counteranion with SbF6-, but no conversion was observed. Substrates 
50 and 51 were then tested under established conditions for Pd-catalyzed cross couplings of C3-
halogenated indoles. 3- Bromo-N-methylindole 50 was tested under Hartwig Pd-catalyzed 
amination conditions[25] (table S6, entry 5), carbonylative Sonogashira conditions[26] (table S6, 
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entry 6) and Heck conditions[27] (table S6, entry 7): the desired product was never observed. 
Furthermore, when 3-Iodo-N-methylindole 51 was tested under Suzuki and Sonogashira cross 
coupling conditions[28] (table S6, entries 8-9) no product was detected.  
In Table S7 oxidative methods were examined (table S7, entries 1,4),[29] Shi conditions (table S7, 
entries 2,5),[30] and Fagnou conditions (table S7, entries 3,6);[31] the desired compound was never 
observed.  
Table S6: Control experiments (I) 
 
Entry X Catalyst (mol%) Additive (mol%) Solvent (M) Yield%a 
1 H (14) [Rh(Cp*Cl2)2] (2.5)/AgSbF6 (10) 
NaOPiv (10) DCE (0.1 M) - 
 
2 
 
I (51) 
 
[Rh(Cp*Cl2)2] 
(2.5)/AgSbF6 (10) 
 
NaOPiv (10) 
 
DCE (0.1 M) 
 
- 
 
3 
 
I(III) (53) 
 
[Rh(Cp*Cl2)2] 
(2.5)/NaSbF6 (10) 
 
NaOPiv (10) 
 
DCE (0.1 M) 
 
- 
 
4 
 
I(III) (53) 
 
[Rh(Cp*Cl2)2] 
(2.5)/AgSbF6 (10) 
 
NaOPiv (10) 
 
DCE (0.1 M) 
 
- 
 
5 
 
Br (50) 
 
Pd(dba)2 (5)/ 
PPh3 (5) 
 
- 
 
Toluene (0.2 M) 
 
- 
 
6 
 
Br (50) 
 
PdCl2 (5)/ 
XanthPhos (5) 
 
TEA (3 equiv.) 
 
Dioxane (0.2 M) 
 
- 
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7 Br (50) Pd(OAc)2(20)/ 
P(o-Tol)3 (20) 
TEA (3 equiv.) Toluene (0.2 M) - 
 
8 
 
I (51) 
 
PdCl2PPh3 (5) 
 
CuI (10)/ TEA (3 
equiv.) 
 
DMF (0.1 M) 
 
- 
 
9 
 
I (51) 
 
Pd(PPh3)3 (2.5) 
 
Na2CO3 (1 equiv.) 
 
DMF (0.1 M) - 
a)Substrate 49 (0.100 mmol), Indole source (0.110 mmol), Catalyst (X mol%), Additive (X mol%) and Solvent (0.1 
M) at 50°-80°-110°C.T  
Table S7: Control experiments (II) 
 
Entry Substrate Equiv.  Equiv. 8a Catalyst (mol%) Additive (mol%) 
Solvent (M)/  
T °C Yield%
a 
1 1 20 [Rh(Cp*Cl2)2]  (2.5)/CsOPiv(20) 
 
PivOH (50) 
2.0 equiv. 
C6Br6/2.2 equiv. 
Cu(OAc)2 
2Cl-p-xylene 
(0.33 M)/140 °C - 
2 1 6.0 Pd(OAc)2(10) 
 
Cu(OTf)2 (20) 
O2 1 atm. 
EtCOOH  
(0.2 M)/120°C - 
3 60 1 Pd(TFA)2(5) 
 
3.0 equiv. 
Cu(OAc)2/6.0 
equiv. PivOH 
 
neat in arene 
(0.15 M) - 
4 1 20 [Rh(Cp*Cl2)2]  (2.5)/CsOPiv(20) 
 
PivOH (50) 
2.0 equiv. 
C6Br6/2.2 equiv. 
Cu(OAc)2 
 
2Cl-p-xylene 
(0.33 M)/140 °C - 
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5 
 
1 6.0 Pd(OAc)2(10) Cu(OTf)2 (20) O2 1 atm. 
EtCOOH  
(0.2 M)/120 °C - 
6 60 1 Pd(TFA)2(5) 
 
3.0 equiv. 
Cu(OAc)2/6.0 
equiv. PivOH 
 
neat in arene 
(0.15 M)/110 °C - 
a)Reaction performed on 0.1 mmol of the limiting reagent; substrate (X mmol), Indole 14 (X mmol), Catalyst (X 
mol%), Additive (X mol%) and Solvent (X M) at T °C.  
 
Finally, in Table S8 are reported control experiments employing conditions suitable for hypervalent 
iodine reagents such as Kita conditions (table S8, entry 1),[32] Sanford conditions (table S8, entry 
2),[33] and Daugulis conditions (table S8, entry 3);[34] the desired compounds was not observed also 
in this case; All conditions screened in Tables S6, S7 and S8 failed to afford the desired product, 
thus demonstrating the unique reactivity of our reagents. 
 
Table S8: Control experiments (III) 
 
Entry Substrate Equiv. Equiv. 8a Catalyst (mol%) Additive (mol%) 
Solvent (M)/ 
T °C Yield%
a 
 
1 1.5 1 - 
2.0 equiv. TMSBr 
 HFIP (0.1 M) - 
2 1 1.5 Pd(OAc)2 (5) 
 
- 
MeCOOH 
(0.1 M)/110 °C - 
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3 
 
1 5 Pd(OAc)2 (5) - MeCOOH  (1.5 M)/90 °C - 
a)Reaction performed on 0.1 mmol of the limiting reagent; substrate (X mmol), Indole source 21 (X mmol), Catalyst 
(X mol%), Additive (X mol%) and Solvent (X M) at T °C.  
 
3.4 Scope of the Rh-Catalyzed Indolization via C-H activation.  
General Procedures GP3-GP4 for Rh-Catalyzed Hetero-arylation via C-H activation   
 
GP3: In a vial, the corresponding aryl-pyridine (0.300 mmol, 1 .00 equiv.), the relative heterocyclic 
hypervalent iodine reagent (0.330 mmol, 1.10 equiv.), [Rh(Cp*Cl2)]2 (4.60 mg, 7.50 µmol, 2.5 
mol%), AgSbF6 (10.3 mg, 30.0 µmol, 10 mol%) and NaOPiv (3.70 mg, 30.0 µmol, 10 mol%) were 
dissolved in dry 1,2-DCE (3 ml, 0.1 M) under nitrogen. the reaction mixture was degassed (freeze-
thaw-pump) and stirred at the reported T in °C overnight. The reaction mixture was then allowed 
to cool to r.t., the organic layer was washed with sat. aquoeus NaHCO3 (2ml), and the solvent was 
removed under reduced pressure. Flash column chromatography (Pentane:EtOAc) afforded the 
desired products 52-70, 75. 
 
S60 
 
 
GP4: In a screw capped vial, the corresponding heterocycle (0.300 mmol, 1.00 equiv.), the relative 
heterocyclic hypervalent iodine reagent 21 (0.330 mmol, 1.10 equiv.), [Rh(Cp*Cl2)]2 (4.60 mg, 
7.50 µmol, 2.5 mol%), AgSbF6 (10.3 mg, 30.0 µmol, 10 mol%) and NaOPiv (3.70 mg, 30.0 µmol, 
10 mol%) were dissolved in dry 1,2-DCE (3 ml, 0.1M) under nitrogen. the reaction mixture was 
degassed (freeze-thaw-pump) and stirred at the reported T in °C overnight. The reaction mixture 
was then allowed to cool to r.t., the organic layer was washed with sat. aqueous NaHCO3 (2 mL), 
and the solvent was removed under reduced pressure. Flash column chromatography 
(Pentane:EtOAc) afforded the desired products 71-74, 76-77. 
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Figure S8: Scope with Aryl-pyridines. 
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Figure S9: Scope with Aryl-pyridines (I). 
1-Methyl-3-(2-(pyridin-2-yl)phenyl)-1H-indole (52) 
Starting from commercially available 2-phenylpyridine 49 (43.0 µl, 0.300 
mmol, 1.00 equiv.) and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -
benzo[b]iodo-3(2H)-one 21 (124 mg, 0.330 mmol, 1.10 equiv.) at 50 °C, 2-
(2-(1-methyl-1H-pyrrol-2-yl)phenyl)pyridine 52 (60.0 mg, 0.256 mmol, 
85% yield) was obtained as a pale yellow oil. Rf: 0.48 (Pentane:EtOAc 4:1). 
IR ν 3057 (w), 2934 (w), 1725 (w), 1586 (s), 1545 (m), 1461 (s), 1425 (s), 
1377 (s), 1330 (m), 1219 (m), 1162 (w), 1091 (w), 1024 (w), 942 (w), 910 (w).1H NMR (400 MHz, 
CDCl3) δ 8.65 (m, 1H, ArH), 7.73 (dd, J = 7.4, 1.7 Hz, 1H, ArH), 7.59 (m, 1H, ArH), 7.52 – 7.38 
(m, 3H, ArH), 7.35 – 7.22 (m, 2H, ArH), 7.19 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H, ArH), 7.11 – 6.94 (m, 
3H, ArH), 6.71 (s, 1H, NCHC), 3.70 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 159.9, 149.3, 
139.8, 136.8, 135.1, 133.3, 131.0, 130.5, 128.4, 128.2, 127.0, 126.7, 124.9, 121.6, 121.2, 119.9, 
119.5, 115.4, 109.1, 32.7. HR-ESI-MS 285.1388 ([M+H]+, C20H17N2+; calc. for 285.1386).  
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3-(2-(pyridin-2-yl)phenyl)-1H-indole (54) 
Starting from commercially available 2-phenylpyridine 8 (43.0 µl, 0.300 
mmol, 1.00 equiv.) and with 1-(3-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-
one 25 (120 mg, 0.330 mmol, 1.10 equiv.) at 50 °C, 2-(2-(1-methyl-1H-
pyrrol-2-yl)phenyl)pyridine 54 (60.3 mg, 0.223 mmol, 74% yield) was 
obtained as a slightly brown foam. Rf: 0.30 (Pentane:EtOAc 4:1). IR ν 3409 
(w), 3170 (w), 3058 (w), 2921 (w), 1668 (w), 1600 (m), 1589 (s), 1544 (w), 
1489 (w), 1464 (s), 1332 (w), 1245 (m), 1153 (w), 1098 (w), 910 (m).  1H NMR (400 MHz, CDCl3) 
δ 8.63 (m, 1H, ArH), 8.40 (s, 1H, NH), 7.72 (dd, J = 7.3, 1.8 Hz, 1H, ArH), 7.60 (dd, J = 7.3, 1.8 
Hz, 1H, ArH), 7.51 – 7.39 (m, 3H, ArH), 7.33 – 7.22 (m, 2H, ArH), 7.14 (ddd, J = 8.2, 6.9, 1.2 Hz, 
1H, ArH), 7.02 (m, 3H, ArH), 6.76 (d, J = 2.5 Hz, 1H, NHCHC). 13C NMR (101 MHz, CDCl3) δ 
159.8, 149.0, 139.8, 135.9, 135.3, 133.3, 131.0, 130.5, 128.5, 126.9, 126.6, 125.0, 123.7, 122.0, 
121.3, 119.9, 119.7, 116.7, 111.0. HR-ESI-MS 271.1233 ([M+H]+, C19H15N2+; calc. for 271.1230). 
1-(3-Phenylpropyl)-3-(2-(pyridin-2-yl)phenyl)-1H-indole (55) 
Starting from commercially available 2-phenylpyridine 49 (43.0 
µl, 0.300 mmol) and with 1-(3-1-(3-phenylpropyl)-1H-indole)-
1H-1λ3 -benzo[b]iodo-3(2H)-one 32 (159 mg, 0.330 mmol, 1.10 
equiv.) at 80 °C, 1-(3-phenylpropyl)-3-(2-(pyridin-2-yl)phenyl)-
1H-indole 55 (86.0 mg, 0.221 mmol, 74% yield) was obtained as 
an orange oil. Rf: 0.48 (Pentane:EtOAc 4:1). IR ν 3059 (w), 3027 
(w), 2932 (w), 1602 (w), 1585 (m), 1547 (w), 1496 (w), 1462 (s), 1424 (w), 1392 (w), 1372 (w), 
1334 (w), 1167 (w), 1024 (w), 911 (w). 1H NMR (400 MHz, CDCl3) δ 8.67 (m, 1H, ArH), 7.76 
(dd, J = 7.4, 1.7 Hz, 1H, ArH), 7.67 (dd, J = 7.4, 1.5 Hz, 1H, ArH), 7.58 (d, J = 7.9 Hz, 1H, ArH), 
7.51 (td, J = 7.4, 1.7 Hz, 1H, ArH), 7.47 (td, J = 7.4, 1.5 Hz, 1H, ArH), 7.34 – 7.19 (m, 6H, ArH), 
7.09 (m, 3H, ArH), 7.06 – 7.01 (m, 2H, ArH), 6.71 (s, 1H, CH2NCHC), 4.04 (t, J = 6.8 Hz, 2H, 
PhCH2CH2CH2N), 2.48 (dd, J = 8.6, 6.7 Hz, 2H, PhCH2CH2CH2N), 2.08 (dq, J = 9.0, 6.9 Hz, 2H, 
PhCH2CH2CH2N). 13C NMR (101 MHz, CDCl3) δ 160.0, 149.1, 140.8, 139.8, 136.0, 135.2, 133.3, 
130.9, 130.5, 128.5, 128.3, 127.4, 127.3, 126.7, 126.1, 125.1, 121.6, 121.3, 119.9, 119.6, 115.2, 
109.3, 45.4, 32.7, 31.3 (one Carbon signal not resolved). HR-ESI-MS 389.2016 ([M+H]+, 
C28H25N2+; calc. for 389.2012).  
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5-Methoxy-1-methyl-3-(2-(pyridin-2-yl)phenyl)-1H-indole (56) 
Starting from commercially available 2-phenylpyridine 49 (43.0 µl, 0.300 
mmol) and with 1-(3-5-methoxy-1-methyl-1H-indole)-1H-1λ3 -
benzo[b]iodo-3(2H)-one 27 (134 mg, 0.330 mmol, 1.10 equiv.) at 50 °C, 
5-methoxy-1-methyl-3-(2-(pyridin-2-yl)phenyl)-1H-indole 56 (84.0 mg, 
0.267 mmol, 89% yield) was obtained as a yellow oil. Rf: 0.40 
(Pentane:EtOAc 4:1). IR ν 3051 (w), 2946 (w), 1585 (m), 1489 (s), 1463 
(m), 1424 (m), 1295 (w), 1266 (s), 1228 (m), 1210 (s), 1181 (w), 1136 (m), 1088 (w), 1031 (m), 
866 (m).  1H NMR (400 MHz, CDCl3) δ 8.67 (dd, J = 4.9, 0.9 Hz, 1H, ArH), 7.76 (dd, J = 7.2, 1.9 
Hz, 1H, ArH), 7.56 (dd, J = 7.2, 1.9 Hz, 1H, ArH), 7.57 – 7.42 (m, 2H, ArH), 7.26 (td, J = 7.7, 1.9 
Hz, 1H, ArH), 7.14 (d, J = 8.9 Hz, 1H, ArH), 7.10 – 7.02 (m, 2H, ArH), 6.84 (s, 1H, NCHC), 6.79 
(dd, J = 8.9, 2.4 Hz, 1H, ArH), 6.67 (d, J = 2.4 Hz, 1H, CCHCOMe), 3.71 (s, 3H, NCH3), 3.64 (s, 
3H, OCH3). 13C NMR (101 MHz, CDCl3) δ 159.9, 153.9, 149.3, 139.4, 135.2, 133.4, 132.0, 131.0, 
130.5, 128.5, 128.3, 126.9, 126.8, 124.9, 121.3, 115.3, 112.2, 109.8, 100.8, 55.6, 32.9. HR-ESI-
MS 315.1493 ([M+H]+, C21H19N2O+; calc. for 315.1492). 
5-Fluoro-1-methyl-3-(2-(pyridin-2-yl)phenyl)-1H-indole (57) 
Starting from commercially available 2-phenylpyridine 49 (43.0 µl, 0.300 
mmol) and with 1-(3-5-fluoro-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-
3(2H)-one 28 (130 mg, 0.330 mmol, 1.10 equiv.) at 50 °C, 5-fluoro-1-
methyl-3-(2-(pyridin-2-yl)phenyl)-1H-indole 57 (66.0 mg, 0.218 mmol, 
73% yield) was obtained as a yellow oil. Rf: 0.40 (Pentane:EtOAc 4:1). IR 
ν 3063 (w), 2930 (w), 1624 (m), 1585 (m), 1488 (s), 1464 (m), 1425 (m), 
1292 (w), 1192 (s), 1123 (m), 1060 (w), 873 (s). 1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 4.9 
Hz, 1H, ArH), 7.71 (d, J = 7.2 Hz, 1H, ArH), 7.55 (d, J = 7.2 Hz, 1H, ArH), 7.51 – 7.38 (m, 2H), 
7.33 (t, J = 7.7 Hz, 1H, ArH), 7.17 (dd, J = 9.0, 4.3 Hz, 1H, ArH), 7.08 (t, J = 6.3 Hz, 1H, ArH), 
7.08 – 6.97 (m, 2H, ArH), 6.91 (t, J = 9.0 Hz, 1H, ArH), 6.77 (s, 1H, NCHC), 3.70 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 159.8, 158.0 (d, J = 234.6 Hz), 149.3, 139.7, 135.2, 133.4, 132.9, 
130.8, 130.6, 129.7, 128.5, 127.3 (d, J = 9.9 Hz), 126.9, 124.8, 121.3, 115.5 (d, J = 4.9 Hz), 110.0 
(d, J = 26.5 Hz), 109.7 (d, J = 9.7 Hz), 104.7 (d, J = 24.2 Hz), 33.0. 19F NMR (376 MHz, CDCl3) 
δ -125.1. HR-ESI-MS 303.1295 ([M+H]+, C20H16FN2+; calc. for 303.1292).  
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5-Chloro-1-methyl-3-(2-(pyridin-2-yl)phenyl)-1H-indole (58) 
Starting from commercially available 2-phenylpyridine 49 (43.0 µl, 0.300 
mmol) and with 1-(3-5-chloro-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-
3(2H)-one 29 (136 mg, 0.330 mmol, 1.10 equiv.) at 50°C, 5-fluoro-1-methyl-
3-(2-(pyridin-2-yl)phenyl)-1H-indole 58 (77.0 mg, 0.242 mmol, 81% yield) 
was obtained as a yellow oil. Rf: 0.36 (Pentane:EtOAc 4:1). IR ν 3055 (w), 
3014 (w), 2924 (w), 1586 (w), 1543 (w), 1477 (s), 1424 (m), 1374 (w), 1288 
(w), 1218 (w), 1152 (w), 1096 (w), 1058 (w), 953 (w). 1H NMR (400 MHz, CDCl3) δ 8.65 (m, 1H, 
ArH), 7.72 (dd, J = 7.3, 1.8 Hz, 1H, ArH), 7.55 (m, 1H, ArH), 7.46 (pd, J = 7.3, 1.8 Hz, 2H, ArH), 
7.38 – 7.31 (m, 2H, ArH), 7.17 (d, J = 8.6 Hz, 1H, ArH), 7.14 – 7.07 (m, 2H, ArH), 7.04 (m, 1H, 
ArH), 6.75 (s, 1H, NCHC), 3.69 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 159.6, 149.0, 
139.5, 135.6, 135.2, 132.7, 131.0, 130.6, 129.4, 128.7, 128.0, 127.1, 125.5, 124.9, 121.9, 121.4, 
119.3, 115.2, 110.2, 33.0. HR-ESI-MS 319.1006 ([M+H]+, C20H16ClN2+; calc. for 319.0997).  
 
5-Iodo-1-methyl-3-(2-(pyridin-2-yl)phenyl)-1H-indole (59) 
Starting from commercially available 2-phenylpyridine 49 (43.0 µl, 0.300 
mmol) and with 1-(3-5-iodo-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-
3(2H)-one 30 (166 mg, 0.330 mmol, 1.10 equiv.) at 50 °C, 5-Iodo-1-methyl-
3-(2-(pyridin-2-yl)phenyl)-1H-indole 59 (91.0 mg, 0.222 mmol, 74% yield) 
was obtained as a yellow oil. Rf: 0.45 (Pentane:EtOAc 4:1). IR ν 3058 (w), 
2920 (w), 1606 (w), 1585 (m), 1474 (s), 1422 (m), 1371 (w), 1287 (w), 1266 
(w), 1217 (w), 1148 (w), 1092 (w), 1024 (w), 943 (w), 874 (w). 1H NMR (400 MHz, CDCl3) δ 
8.66 (dd, J = 5.0, 0.9 Hz, 1H, ArH), 7.71 (m, 1H, ArH), 7.65 (d, J = 1.6 Hz, 1H, ArH), 7.53 (m, 
1H, ArH), 7.50 – 7.42 (m, 2H, ArH), 7.39 (dd, J = 8.5, 1.6 Hz, 1H, ArH), 7.32 (td, J = 7.7, 1.9 Hz, 
1H, ArH), 7.08 (ddd, J = 7.7, 5.0, 1.1 Hz, 1H, ArH), 7.07 – 6.97 (m, 2H, ArH), 6.70 (s, 1H, NCHC), 
3.67 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 159.7, 149.3, 139.8, 135.7, 135.2, 132.5, 130.9, 
130.5, 129.8, 129.2, 128.7, 128.7, 128.5, 127.0, 124.7, 121.4, 114.9, 111.1, 83.2, 32.9. HR-ESI-
MS 411.0348 ([M+H]+, C20H16IN2+; calc. for 411.0353).  
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1-Methyl-3-(2-(pyridin-2-yl)phenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-
indole (60) 
Starting from commercially available 2-phenylpyridine 49 (43.0 µl, 0.300 
mmol) and with 1-(3-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 31 (166 mg, 0.330 
mmol, 1.10 equiv.) at 50 °C, 1-Methyl-3-(2-(pyridin-2-yl)phenyl)-5-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole 60 (73.0 mg, 
0.178 mmol, 59% yield) was obtained as a yellow oil. Rf: 0.30 
(Pentane:EtOAc 4:1). IR ν 3063 (w), 2978 (w), 2940 (w), 2245 (w), 2214 (w), 1608 (m), 1605 (m), 
1568 (w), 1463 (m), 1438 (m), 1383 (s), 1349 (s), 1311 (s), 1273 (m), 1142 (s), 1097 (m), 967 (m), 
910 (s), 866 (m). 1H NMR (400 MHz, CDCl3) δ 8.64 (d, J = 5.0 Hz, 1H, ArH), 8.00 (s, 1H, ArH), 
7.71 (d, J = 7.5 Hz, 1H, ArH), 7.64 (dd, J = 8.3, 1.1 Hz, 1H, ArH), 7.61 (m, 1H, ArH), 7.46 (td, J 
= 7.4, 1.7 Hz, 1H, ArH), 7.41 (td, J = 7.4, 1.6 Hz, 1H, ArH), 7.29 – 7.26 (m, 2H, ArH), 7.00 (ddd, 
J = 7.5, 4.9, 1.2 Hz, 1H, ArH), 6.95 (dt, J = 7.9, 1.0 Hz, 1H, ArH), 6.62 (s, 1H, ArH), 3.68 (s, 3H, 
NCH3), 1.34 (s, 12H, BPin). 13C NMR (101 MHz, CDCl3) δ 159.9, 149.1, 140.0, 138.6, 135.0, 
133.1, 131.2, 130.3, 128.4, 128.2, 127.7, 127.7, 126.9, 126.7, 124.9, 121.1, 116.0, 108.5, 83.3, 
32.6, 24.8 (one aromatic Carbon signal not resolved). HR-ESI-MS 411.2248 ([M+H]+, 
C26H28BN2O2+; calc. for 411.2238).  
 
2-(2-(1-methyl-1H-pyrrol-2-yl)phenyl)pyridine (61) 
Starting from commercially available 2-phenylpyridine 49 (43.0 µl, 0.300 mmol, 
1.00 equiv.) and with 1-(2-1-methyl-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-
one 35a (108 mg, 0.330 mmol, 1.10 equiv.) at 80 °C, 2-(2-(1-methyl-1H-pyrrol-
2-yl)phenyl)pyridine 61 (60.0 mg, 0.256 mmol, 85% yield) was obtained as a 
pale yellow oil. Rf: 0.42 (Pentane:EtOAc 4:1). IR ν 3098 (w), 3059 (w), 2926 
(m), 2854 (w), 1707 (w), 1585 (s), 1473 (s), 1429 (s), 1310 (s), 1239 (w), 1090 
(m), 1056 (m), 1024 (m). 1H NMR (400 MHz, CDCl3) δ 8.67 (m, 1H, ArH), 7.86 (d, J = 7.5 Hz, 
1H, ArH), 7.55 – 7.40 (m, 4H, ArH), 7.14 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H, ArH), 6.80 (m, 1H, ArH), 
6.51 (t, J = 2.3 Hz, 1H, ArH), 6.18 – 6.15 (m, 2H, ArH), 2.90 (s, 3H, NCH3). 13C NMR (101 MHz, 
CDCl3) δ 158.6, 149.5, 140.0, 135.7, 133.2, 131.8, 131.5, 130.1, 128.5, 128.4, 123.7, 122.2, 121.5, 
109.2, 107.7, 33.8. HR-ESI-MS 235.1233 ([M+H]+, C16H15N2+; calc. for 235.1230).  
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2-(2-(1-Methyl-1H-pyrrol-3-yl)phenyl)pyridine (62) 
Starting from commercially available 2-phenylpyridine 49 (43.0 µl, 0.300 
mmol, 1.00 equiv.) and with 1-(3-1-methyl-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-
3(2H)-one 35b (108 mg, 0.330 mmol, 1.10 equiv.) at 80°C, 2-(2-(1-Methyl-
1H-pyrrol-3-yl)phenyl)pyridine 62 (60.0 mg, 0.256 mmol, 85% yield) was 
obtained as a yellow oil. Rf: 0.38 (Pentane:EtOAc 4:1). IR ν 3056 (w), 3007 
(w), 2943 (w), 1586 (s), 1551 (m), 1508 (m), 1463 (s), 1424 (s), 1361 (m), 1260 
(w), 1202 (s), 1150 (w), 1087 (w), 1024 (w), 990 (w), 926 (w). 1H NMR (400 MHz, CDCl3) δ 8.67 
(d, J = 5.0 Hz, 1H, ArH), 7.57 – 7.46 (m, 3H, ArH), 7.37 (t, J = 7.5 Hz, 1H, ArH), 7.31 (d, J = 7.5 
Hz, 1H, ArH), 7.22 (d, J = 7.9 Hz, 1H, ArH), 7.18 (dd, J = 7.4, 5.1 Hz, 1H, ArH), 6.43 (t, J = 2.5 
Hz, 1H, ArH), 6.30 (d, J = 1.6 Hz, 1H, ArH), 5.80 (d, J = 1.6 Hz, 1H, ArH), 3.54 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 160.6, 149.1, 138.7, 135.2, 134.8, 130.2, 129.3, 128.3, 125.8, 
125.2, 123.8, 121.5, 121.3, 120.6, 109.2, 36.1. HR-ESI-MS 235.1230 ([M+H]+, C16H15N2+; calc. 
for 235.1230).   
 
2-(2-(1-benzyl-1H-pyrrol-2-yl)phenyl)pyridine (63) 
Starting from commercially available 2-phenylpyridine 49 (43.0 µl, 
0.300 mmol, 1.00 equiv.) and with 1-(2-1-benzyl-1H-pyrrole)-1H-1λ3 -
benzo[b]iodo-3(2H)-one 36a (133 mg, 0.330 mmol, 1.10 equiv.) at 80 
°C, 2-(2-(1-benzyl-1H-pyrrol-2-yl)phenyl)pyridine 63 (63.0 mg, 0.203 
mmol, 68% yield) as an pale yellow oil. Rf: 0.32 (Pentane:EtOAc 4:1). 
IR ν 3062 (m), 3029 (w), 2925 (w), 1585 (s), 1471 (s), 1427 (s), 1311 
(m), 1298 (m), 1236 (m), 1153 (w), 1076 (m), 1024 (m), 989 (w).  1H NMR (400 MHz, CDCl3) δ 
8.68 (d, J = 4.9 Hz, 1H, ArH), 7.85 (m, 1H, ArH), 7.53 – 7.42 (m, 2H, ArH), 7.42 – 7.33 (m, 2H, 
ArH), 7.17 – 7.13 (m, 4H, ArH), 6.83 (d, J = 7.9 Hz, 1H, ArH), 6.72 (dd, J = 6.6, 2.9 Hz, 2H, ArH), 
6.52 (m, 1H, ArH), 6.24 – 6.13 (m, 2H, ArH), 4.45 (s, 2H, NCH2Ph). 13C NMR (101 MHz, CDCl3) 
δ 158.7, 149.5, 140.2, 138.1, 135.8, 133.2, 132.1, 131.7, 130.3, 128.6, 128.6, 128.4, 127.3, 127.2, 
124.2, 121.7, 110.1, 108.3, 50.6. (2 Cs overlapping at 121.7, shown by HSQC). HR-ESI-MS 
311.1542 ([M+H]+, C22H19N2+; calc. for 311.1543).  
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2-(2-(1-Benzyl-1H-pyrrol-3-yl)phenyl)pyridine (64) 
Starting from commercially available 2-phenylpyridine 49 (43.0 µl, 0.300 mmol, 
1.00 equiv.) and with 1-(3-1-benzyl-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-
one 36b (133 mg, 0.330 mmol, 1.10 equiv.) at 80 °C, 2-(2-(1-Benzyl-1H-pyrrol-
3-yl)phenyl)pyridine 64 (54.0 mg, 0.174 mmol, 58% yield) was obtained as an 
pale yellow oil. Rf: 0.30 (Pentane:EtOAc 4:1). IR ν 3062 (m), 2925 (m), 2854 
(w), 1708 (m), 1586 (s), 1562 (m), 1498 (s), 1463 (s), 1425 (s), 1355 (m), 1190 
(m), 1082 (m), 1025 (m).  1H NMR (400 MHz, CDCl3) δ 8.62 (m, 1H, ArH), 7.51 
– 7.45 (m, 3H, ArH), 7.38 (td, J = 7.5, 1.6 Hz, 1H, ArH), 7.34 – 7.26 (m, 4H, ArH), 7.20 (d, J = 
7.9 Hz, 1H, ArH) 7.13 (ddd, J = 7.4, 4.9, 1.2 Hz, 1H, ArH), 7.03 – 6.97 (m, 2H, ArH), 6.54 (t, J = 
2.5 Hz, 1H, ArH), 6.25 (t, J = 1.8 Hz, 1H, ArH), 5.99 (dd, J = 2.5, 1.8 Hz, 1H, ArH), 4.92 (s, 2H, 
NCH2Ph). 13C NMR (101 MHz, CDCl3) δ 160.5, 149.1, 138.8, 137.9, 135.2, 134.8, 130.1, 129.4, 
128.6, 128.3, 127.6, 126.9, 126.0, 125.2, 123.9, 121.3, 121.0, 120.4, 109.4, 53.3. HR-ESI-MS 
311.1545 ([M+H]+, C22H19N2+; calc. for 311.1543).  
 
2-(2-(1H-Pyrrol-3-yl)phenyl)pyridine (65) 
Starting from commercially available 2-phenylpyridine 49 (43.0 µl, 0.300 mmol, 
1.00 equiv.) and with 1-(3-1H-pyrrole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 37 
(103 mg, 0.330 mmol, 1.10 equiv.) in a mixture of 1,2-DCE:MeOH (2:1, 0.1M) 
at 50 °C, 2-(2-(1H-pyrrol-3-yl)phenyl)pyridine 65 (52.0 mg, 0.236 mmol, 79% 
yield) was obtained as a light brown foam. Rf: 0.42 (Pentane:EtOAc 4:1). IR ν 
3191 (m), 3054 (m), 2928 (w), 1601 (s), 1589 (s), 1562 (m), 1505 (m), 1464 (s), 
1426 (s), 1267 (w), 1152 (w), 1078 (w), 1028 (m), 996 (w), 917 (w). 1H NMR (400 MHz, CDCl3) 
δ 8.67 (m, 1H, ArH), 8.29 (m, 1H, NH), 7.57 – 7.47 (m, 3H, ArH), 7.40 (dd, J = 8.2, 6.8 Hz, 1H, 
ArH), 7.32 (t, J = 7.3 Hz, 1H, ArH), 7.23 – 7.15 (m, 2H, ArH), 6.62 (d, J = 2.6 Hz, 1H, ArH), 6.43 
(d, J = 2.6 Hz, 1H, ArH), 5.95 (dd, J = 2.9, 1.6 Hz, 1H, ArH). 13C NMR (101 MHz, CDCl3) δ 
160.6, 149.2, 139.0, 135.2, 134.7, 130.2, 129.6, 128.4, 126.1, 125.2, 123.8, 121.4, 117.6, 116.8, 
109.3. HR-ESI-MS 221.1077 ([M+H]+, C15H13N2+; calc. for 221.1073).  
3-(5-Methoxy-2-(pyridin-2-yl)phenyl)-1-methyl-1H-indole (66) 
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Starting from commercially available 2-(4-methoxyphenyl)pyridine (55.6 
mg, 0.300 mmol) and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-
3(2H)-one 21 (124 mg, 0.330 mmol, 1.10 equiv.) at 50 °C, 3-(5-methoxy-2-
(pyridin-2-yl)phenyl)-1-methyl-1H-indole 66 (83.0 mg, 0.264 mmol, 88% 
yield) was obtained as a yellow oil. Rf: 0.38 (Pentane:EtOAc 4:1). IR ν 3049 
(w), 2933 (w), 2834 (w), 1602 (s), 1568 (m), 1463 (s), 1426 (m), 1278 (s), 
1232 (s), 1210 (m), 1062 (m), 1017 (m), 844 (w).  1H NMR (400 MHz, 
CDCl3) δ 8.64 (d, J = 5.0 Hz, 1H, ArH), 7.70 (d, J = 8.5 Hz, 1H, ArH), 7.45 (d, J = 8.0 Hz, 1H, 
ArH), 7.31 – 7.23 (m, 2H, ArH), 7.20 (t, J = 7.6 Hz, 1H, ArH), 7.13 (d, J = 2.7 Hz, 1H, ArH), 7.06 
– 6.95 (m, 4H, ArH), 6.73 (s, 1H, CH3NCHC), 3.89 (s, 3H, NCH3), 3.71 (s, 3H, OCH3). 13C NMR 
(101 MHz, CDCl3) δ 159.6, 159.4, 148.9, 136.7, 135.2, 134.6, 132.3, 131.9, 128.2, 126.8, 125.0, 
121.6, 120.8, 119.9, 119.5, 115.9, 115.3, 112.6, 109.1, 55.3, 32.8. HR-ESI-MS 315.1494 ([M+H]+, 
C21H19N2O+; calc. for 315.1492).  
3-(5-Chloro-2-(pyridin-2-yl)phenyl)-1-methyl-1H-indole (67) 
Starting from commercially available 2-(4-chlorophenyl)pyridine (57.0 mg, 
0.300 mmol) and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-
3(2H)-one 21 (124 mg, 0.330 mmol, 1.10 equiv.) at 50 °C, 3-(5-chloro-2-
(pyridin-2-yl)phenyl)-1-methyl-1H-indole 67 (81.2 mg, 0.255 mmol, 85% 
yield) was obtained as a yellow oil. Rf: 0.40 (Pentane:EtOAc 4:1). IR ν 3055 
(w), 2926 (w), 1595 (s), 1566 (m), 1476 (m), 1461 (s), 1427 (w), 1329 (m), 
1219 (w), 1163 (w), 1100 (m), 1026 (w), 913 (w), 830 (w). 1H NMR (400 MHz, CDCl3) δ 8.65 
(m, 1H, ArH), 7.68 (d, J = 8.3 Hz, 1H, ArH), 7.59 (d, J = 2.2 Hz, 1H, ArH), 7.40 (dd, J = 8.3, 2.2 
Hz, 1H, ArH), 7.37 (dd, J = 8.0, 1.0 Hz, 1H, ArH), 7.30 (dd, J = 7.7, 1.7 Hz, 1H, ArH), 7.27 (m, 
1H, ArH), 7.19 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H, ArH), 7.08 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H, ArH), 7.04 
– 6.99 (m, 2H, ArH), 6.75 (s, 1H, NCHC), 3.71 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 
158.7, 149.2, 137.9, 136.8, 135.4, 135.1, 134.3, 132.0, 130.7, 128.4, 126.7, 126.6, 124.9, 121.8, 
121.5, 119.8, 119.7, 114.3, 109.2, 32.8. HR-ESI-MS 319.0999 ([M+H]+, C20H16ClN2+; calc. for 
319.0997).  
 
3-(5-Bromo-2-(pyridin-2-yl)phenyl)-1-methyl-1H-indole (68) 
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Starting from commercially available 2-(4-bromophenyl)pyridine (70.2 mg, 
0.300 mmol) and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-
3(2H)-one 21 (124 mg, 0.330 mmol, 1.10 equiv.) at 50 °C, 3-(5-methoxy-2-
(pyridin-2-yl)phenyl)-1-methyl-1H-indole 68 (91.0 mg, 0.251 mmol, 84% 
yield) was obtained as a yellow oil. Rf: 0.40 (Pentane:EtOAc 4:1). IR ν 2956 
(w), 2929 (w), 2851 (w), 1678 (w), 1592 (m), 1510 (m), 1453 (m), 1453 (m), 
1434 (s), 1399 (s), 1364 (s), 1264 (m), 1108 (m), 1031 (m), 956 (m).  1H NMR (400 MHz, CDCl3) 
δ 8.66 (m, 1H, ArH), 7.75 (d, J = 2.0 Hz, 1H, ArH), 7.63 (d, J = 8.3 Hz, 1H, ArH), 7.56 (dd, J = 
8.3, 2.0 Hz, 1H, ArH), 7.36 – 7.31 (m, 2H, ArH), 7.28 (dt, J = 8.2, 0.9 Hz, 1H, ArH), 7.19 (ddd, J 
= 8.2, 6.9, 0.9 Hz, 1H, ArH), 7.11 (t, J = 6.3 Hz, 1H, ArH), 7.04 (d, J = 8.0 Hz, 1H, ArH), 6.99 (m, 
1H, ArH), 6.77 (s, 1H, NCHC), 3.72 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 158.7, 149.3, 
138.5, 136.7, 135.4, 135.2, 133.5, 132.1, 129.6, 128.3, 126.5, 124.7, 122.4, 121.8, 121.5, 119.7, 
119.6, 114.2, 109.2, 32.7. HR-ESI-MS 363.0490 ([M+H]+, C20H1679BrN2+; calc. for 363.0491).  
3-(1-Methyl-1H-indol-3-yl)-4-(pyridin-2-yl)benzonitrile (69) 
Starting from commercially available 4-(pyridin-2-yl)benzonitrile (54.0 mg, 
0.300 mmol) and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-
3(2H)-one 21 (124 mg, 0.330 mmol, 1.10 equiv.) at 80 °C, 3-(1-methyl-1H-
indol-3-yl)-4-(pyridin-2-yl)benzonitrile 69 (72.0 mg, 0.233 mmol, 78% 
yield) was obtained as a yellow oil. Rf: 0.35 (Pentane:EtOAc 4:1). IR ν 3053 
(w), 2932 (w), 2230 (m), 1587 (m), 1558 (w), 1475 (m), 1463 (m), 1330 (w), 
1266 (s), 1224 (w), 1160 (w), 1091 (w), 1026 (w), 902 (w), 839 (m). 1H NMR (400 MHz, CDCl3) 
δ 8.70 (m, 1H, ArH), 7.88 (d, J = 1.7 Hz, 1H, ArH), 7.83 (d, J = 8.0 Hz, 1H, ArH), 7.69 (dd, J = 
8.0, 1.7 Hz, 1H, ArH), 7.36 – 7.27 (m, 3H, ArH), 7.21 (ddd, J = 8.3, 7.0, 1.1 Hz, 1H, ArH), 7.13 
(ddd, J = 7.5, 4.9, 1.2 Hz, 1H, ArH), 7.05 (d, J = 8.0 Hz, 1H, ArH), 7.02 (ddd, J = 8.0, 7.0, 1.1 Hz, 
1H, ArH), 6.77 (s, 1H, NCHC), 3.73 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 157.9, 149.6, 
143.6, 136.7, 135.6, 134.8, 134.5, 131.5, 129.8, 128.4, 126.3, 124.7, 122.2, 122.0, 120.1, 119.3, 
118.9, 113.3, 112.1, 109.4, 32.9. HR-ESI-MS 310.1344 ([M+H]+, C21H16N3+; calc. for 310.1339).  
 
 
Methyl 3-(1-methyl-1H-indol-3-yl)-4-(pyridin-2-yl)benzoate (70) 
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Starting from methyl 4-(pyridin-2-yl)benzoate 121 (64.0 mg, 0.300 mmol) 
and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 21 
(124 mg, 0.330 mmol, 1.10 equiv.) at 50°C, methyl 3-(1-methyl-1H-indol-
3-yl)-4-(pyridin-2-yl)benzoate 70 (94.0 mg, 0.275 mmol, 92% yield) was 
obtained as an orange oil. Rf: 0.33 (Pentane:EtOAc 4:1). 1H NMR (400 
MHz, CDCl3) δ 8.61 (dd, J = 5.1, 1.6 Hz, 1H, ArH), 8.20 (d, J = 1.7 Hz, 1H, 
ArH), 7.99 (dd, J = 8.1, 1.8 Hz, 1H, ArH), 7.72 (d, J = 8.1 Hz, 1H, ArH), 7.26 (d, J = 8.0 Hz, 1H, 
ArH), 7.24 – 7.16 (m, 2H, ArH), 7.09 (t, J = 7.6 Hz, 1H, ArH), 7.03 – 6.96 (m, 2H, ArH), 6.90 (t, 
J = 7.5 Hz, 1H, ArH), 6.71 (s, 1H, NCHC), 3.85 (s, 3H, COOMe), 3.61 (s, 3H, NCH3). 13C NMR 
(101 MHz, CDCl3) δ 167.0, 158.8, 149.4, 143.8, 136.8, 135.3, 133.7, 132.3, 130.7, 129.9, 128.3, 
127.6, 126.7, 124.7, 121.8, 121.7, 119.7, 114.7, 109.1, 52.1, 32.8 (two aromatic Carbon signals 
overlapping at 119.7). IR ν 3052 (w), 2950 (w), 2252 (w), 2218 (w), 1718 (s), 1587 (m), 1436 (m), 
1365 (m), 1330 (m), 1286 (s), 1251 (s), 1162 (m), 1113 (m), 994 (w), 911 (s). HR-ESI-MS 
343.1438 ([M+H]+, C22H19N2O2+; calc. for 343.1441).  
 
1-Methyl-3-(2-(pyrimidin-2-yl)phenyl)-1H-indole (71) 
Starting from commercially available 2-phenylpyrimidine (47.0 mg, 0.300 
mmol) and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-
one 21 (124 mg, 0.330 mmol, 1.10 equiv.) at 80 °C, 1-methyl-3-(2-
(pyrimidin-2-yl)phenyl)-1H-indole 71 (69.0 mg, 0.242 mmol, 81% yield) 
was obtained as a yellow oil. Rf: 0.40 (Pentane:EtOAc 4:1). IR ν 3048 (w), 
2932 (w), 1599 (w), 1568 (s), 1554 (m), 1473 (w), 1414 (s), 1377 (w), 1330 
(w), 1268 (w), 1221 (w), 1162 (w), 1135 (w), 1015 (w), 943 (w), 822 (w). 1H NMR (400 MHz, 
CDCl3) δ 8.58 (d, J = 4.9 Hz, 2H, PyrimidineH), 7.84 (dd, J = 7.7, 1.5 Hz, 1H, ArH), 7.59 (dd, J = 
7.7, 1.5 Hz, 1H, ArH), 7.51 (m, 1H, ArH), 7.44 (td, J = 7.5, 1.5 Hz, 1H, ArH), 7.24 (d, J = 8.2 Hz, 
1H, ArH), 7.10 (dd, J = 9.3, 7.5 Hz, 2H, ArH), 7.03 (s, 1H, NCHCI), 7.00 (t, J = 4.9 Hz, 1H, ArH), 
6.84 (t, J = 7.5 Hz, 1H, ArH), 3.76 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 168.5, 156.7, 
138.1, 136.7, 134.1, 131.3, 130.7, 129.4, 127.5, 126.8, 126.5, 121.3, 119.3, 119.2, 118.2, 116.2, 
109.0, 32.8 (two aromatic Carbon signals overlapping at 156.7). HR-ESI-MS 286.1344 ([M+H]+, 
C19H16N3+; calc. for 286.1339).  
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3-(2-(1H-Pyrazol-1-yl)phenyl)-1-methyl-1H-indole (72) 
Starting from commercially available 1-phenyl-1H-pyrazole (43.0 mg, 0.300 
mmol) and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 
21 (124 mg, 0.330 mmol, 1.10 equiv.) at 80 °C, 3-(2-(1H-pyrazol-1-
yl)phenyl)-1-methyl-1H-indole 72 (59.0 mg, 0.216 mmol, 72% yield) was 
obtained as a yellow oil. Rf: 0.40 (Pentane:EtOAc 4:1). IR ν 3049 (w), 2926 
(m), 2853 (w), 1680 (w), 1615 (w), 1604 (w), 1548 (m), 1518 (s), 1473 (s), 1423 (w), 1394 (s), 
1378 (s), 1329 (s), 1264 (w), 1221 (m), 1089 (m), 1045 (s), 1019 (m), 936 (s). 1H NMR (400 MHz, 
CDCl3) δ 7.69 (dd, J = 7.8, 1.6 Hz, 1H, ArH), 7.67 (d, J = 1.7 Hz, 1H, ArH), 7.62 (dd, J = 7.8, 1.6 
Hz, 1H, ArH), 7.52 – 7.44 (m, 2H, ArH), 7.40 (td, J = 7.8, 1.6 Hz, 1H, ArH), 7.31 (d, J = 8.2 Hz, 
1H, ArH), 7.25 – 7.20 (m, 2H, ArH), 7.07 (m, 1H, ArH), 6.60 (s, 1H, NCHC), 6.15 (m, 1H, ArH), 
3.72 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 139.9, 138.5, 136.7, 131.1, 131.0, 130.6, 128.2, 
127.6, 127.0, 126.9, 126.6, 121.8, 119.9, 119.3, 112.0, 109.3, 106.2, 32.8. HR-ESI-MS 274.1343 
([M+H]+, C18H16N3+; calc. for 274.1339).   
 
10-(1-Methyl-1H-indol-3-yl)benzo[h]quinoline (73) 
Starting from commercially available benzo[h]quinoline (54.0 mg, 0.300 
mmol) and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-
one 21 (124 mg, 0.330 mmol, 1.10 equiv.) at 50 °C, 10-(1-methyl-1H-
indol-3-yl)benzo[h]quinoline 73 (70.0 mg, 0.227 mmol, 76% yield) was 
obtained as a light yellow oil. Rf: 0.40 (Pentane:EtOAc 4:1). IR ν 3046 
(m), 2929 (m), 1677 (w), 1615 (w), 1588 (m), 1569 (m), 1475 (s), 1418 
(s), 1375 (s), 1323 (s), 1263 (w), 1230 (s), 1161 (w), 1129 (w), 1014 (w), 910 (m). 1H NMR (400 
MHz, CDCl3) δ 8.27 (d, J = 2.4 Hz, 1H, ArH), 8.10 (dd, J = 8.0, 1.9 Hz, 1H, ArH), 7.93 – 7.90 (m, 
1H, ArH), 7.88 (d, J = 8.7 Hz, 1H, ArH), 7.75 – 7.65 (m, 3H, ArH), 7.37 (d, J = 8.2 Hz, 1H, ArH), 
7.29 (m, 1H, ArH), 7.24 (m, 1H, ArH), 7.16 (ddd, J = 8.2, 4.7, 3.5 Hz, 1H, ArH), 6.79 (s, 1H, 
NCHC), 6.78 (t, J = 1.1 Hz, 1H, ArH), 3.93 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 147.0, 
146.8, 137.0, 135.4, 135.3, 133.9, 132.8, 129.7, 128.5, 128.4, 127.8, 127.5, 127.4, 127.1, 126.2, 
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125.7, 121.0, 120.8, 120.7, 118.5, 108.9, 32.9. HR-ESI-MS 309.1398 ([M+H]+, C22H17N2+; calc. 
for 309.1386).   
1'-Methyl-1-(pyrimidin-2-yl)-1H,1'H-2,3'-biindole (74) 
Starting from 1-(pyrimidin-2-yl)-1H-indole 123 (59.0 mg, 0.300 
mmol) and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-
3(2H)-one 21 (124 mg, 0.330 mmol, 1.10 equiv.) at 50 °C, 1'-methyl-
1-(pyrimidin-2-yl)-1H,1'H-2,3'-biindole 74 (80.0 mg, 0.247 mmol, 
82% yield) was obtained as a yellow oil. Rf: 0.38 (Pentane:EtOAc 
4:1). IR ν 3049 (w), 2931 (w), 1592 (w), 1563 (m), 1454 (m), 1423 
(s), 1372 (w), 1350 (w), 1309 (m), 1258 (w), 1217 (w), 910 (w).  1H NMR (400 MHz, CDCl3) δ 
8.51 (d, J = 4.8 Hz, 2H, ArH), 8.01 (m, 1H, ArH), 7.56 (dd, J = 7.9, 1.3 Hz, 1H, ArH), 7.22 – 7.14 
(m, 3H, ArH), 7.13 (s, 1H, ArH), 7.06 (dd, J = 8.3, 6.9 Hz, 2H, ArH), 6.93 (t, J = 4.8 Hz, 1H, ArH), 
6.82 (td, J = 7.4, 0.9 Hz, 1H, ArH), 6.69 (s, 1H, CH3NCHC), 3.71 (s, 3H, NCH3). 13C NMR (101 
MHz, CDCl3) δ 158.2, 158.2, 137.5, 136.8, 134.6, 129.6, 127.8, 126.8, 122.6, 121.8, 121.7, 120.0, 
119.8, 119.5, 117.5, 112.4, 109.3, 108.9, 106.5, 32.9. HR-ESI-MS 325.1452 ([M+H]+, C21H17N4+; 
calc. for 325.1448).  
 
Methyl 3,5-bis(1-methyl-1H-indol-3-yl)-4-(pyridin-2-yl)benzoate (75) 
Starting from methyl 4-(pyridin-2-yl)benzoate 121 (64.0 mg, 
0.300 mmol) and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -
benzo[b]iodo-3(2H)-one 21 (249 mg, 0.660 mmol, 2.20 equiv.) 
at 50 °C, methyl 3,5-bis(1-methyl-1H-indol-3-yl)-4-(pyridin-2-
yl)benzoate 75 (75.0 mg, 0.159 mmol, 53% yield) was obtained 
as a yellow oil. Rf: 0.30 (Pentane:EtOAc 4:1). IR ν 3056 (w), 
2950 (w), 2247 (w), 1720 (m), 1571 (m), 1477 (m), 1427 (m), 1325 (m), 1293 (s), 1247 (s), 1161 
(m), 1119 (m), 1004 (m), 908 (s).  1H NMR (400 MHz, CDCl3) δ 8.47 (m, 1H, ArH), 8.32 (s, 2H, 
ArH), 7.68 (d, J = 8.0 Hz, 2H, ArH), 7.29 – 7.15 (m, 5H, ArH), 7.08 (ddd, J = 8.2, 6.5, 1.5 Hz, 2H, 
ArH), 6.99 – 6.93 (m, 2H, ArH), 6.52 (s, 2H, ArH), 3.94 (s, 3H, COOMe), 3.58 (s, 6H, NMe). 13C 
NMR (101 MHz, CDCl3) δ 167.2, 159.8, 147.9, 143.2, 136.4, 135.6, 135.4, 129.7, 128.9, 127.3, 
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125.7, 121.6, 121.5, 119.8, 119.5, 114.5, 109.0, 52.1, 32.6. HR-ESI-MS 472.2021 ([M+H]+, 
C31H25N3O2+; calc. for 472.1998).  
8-(1-Methyl-1H-indol-3-yl)quinolin-2(1H)-one (76) 
Starting from commercially available quinoline 1-oxide (44.0 mg, 0.300 
mmol) and with 1-(3-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 
21 (124 mg, 0.330 mmol, 1.10 equiv.) at 100 °C, 8-(1-methyl-1H-indol-3-
yl)quinolin-2(1H)-one 76 (31.0 mg, 0.113 mmol, 38% yield) was obtained as 
a yellow oil. Rf: 0.58 (EtOAc:MeOH 10:1). IR ν 3367 (w), 3053 (w), 2923 
(m), 2853 (w), 1715 (w), 1651 (s), 1608 (m), 1541 (w), 1467 (m), 1372 (w), 
1333 (w), 1234 (w), 1135 (w), 1014 (w), 840 (m). 1H NMR (400 MHz, CDCl3) δ 9.02 (s, 1H, 
NHCO), 7.83 (d, J = 9.5 Hz, 1H, ArH), 7.61 – 7.54 (m, 2H, ArH), 7.45 (dd, J = 8.3, 6.7 Hz, 2H, 
ArH), 7.34 (m, 1H, ArH), 7.30 (d, J = 7.6 Hz, 1H, ArH), 7.23 (s, 1H, NCHC), 7.20 – 7.15 (m, 1H, 
IndoleH), 6.66 (d, J = 9.3 Hz, 1H, ArH), 3.91 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 162.4, 
141.0, 136.3, 132.2, 127.8, 127.7, 126.9, 126.7, 122.9, 122.4, 121.9, 121.6, 120.6, 120.0, 119.4, 
109.8, 109.4, 33.1. HR-ESI-MS 275.1185 ([M+H]+, C18H15N2O+; calc. for 275.1179).  
 
(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(6-(2-(1-methyl-1H-indol-3-yl)phenyl)-9H-purin-9-
yl)tetrahydrofuran-3,4-diyl diacetate (77) 
Starting from (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(6-
phenyl-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate 127 
(136 mg, 0.300 mmol) and with 1-(3-1-methyl-1H-indole)-
1H-1λ3 -benzo[b]iodo-3(2H)-one 21 (124 mg, 0.330 mmol, 
1.10 equiv.) at 50 °C, (2R,3R,4R,5R)-2-(Acetoxymethyl)-5-
(6-(2-(1-methyl-1H-indol-3-yl)phenyl)-9H-purin-9-
yl)tetrahydrofuran-3,4-diyl diacetate 77 (72 mg, 0.123 mmol, 
41% yield)) was obtained as a yellow oil. Rf: 0.65 (EtOAc 
100%). IR ν 3056 (w), 2934 (w), 2825 (w), 2254 (w), 1749 (s), 1586 (m), 1505 (w), 1484 (w), 
1435 (w), 1377 (m), 1332 (m), 1219 (s), 1101 (m), 1048 (m), 912 (m), 817 (w). 1H NMR (400 
MHz, CDCl3) δ 8.81 (s, 1H, ArH), 8.04 (s, 1H, ArH), 7.76 (dd, J = 7.6, 1.4 Hz, 1H, ArH), 7.70 (dd, 
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J = 7.6, 1.3 Hz, 1H, ArH), 7.56 (td, J = 7.6, 1.5 Hz, 1H, ArH), 7.46 (td, J = 7.5, 1.3 Hz, 1H, ArH), 
7.30 – 7.23 (m, 1H, ArH + CDCl3), 7.18 (d, J = 8.3 Hz, 1H, ArH), 7.08 (ddd, J = 8.1, 7.0, 1.1 Hz, 
1H, ArH), 6.90 (s, 1H, ArH), 6.86 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H, ArH), 6.18 (d, J = 5.1 Hz, 1H, 
CH), 5.89 (t, J = 5.3 Hz, 1H, CH), 5.65 (dd, J = 5.5, 4.5 Hz, 1H, CH), 4.47 – 4.40 (m, 2H, CH + 
CH2), 4.34 (dd, J = 13.1, 5.2 Hz, 1H, CH2), 3.67 (s, 3H, NMe), 2.14 (s, 3H, COCH3), 2.08 (s, 3H, 
COCH3), 2.06 (s, 3H, COCH3). 13C NMR (101 MHz, CDCl3) δ 170.3, 169.5, 169.2, 160.3, 152.3, 
151.0, 142.4, 136.6, 134.7, 134.2, 132.9, 131.3, 131.0, 129.8, 128.2, 126.9, 126.2, 121.4, 119.5, 
119.2, 115.4, 109.0, 86.3, 80.2, 73.0, 70.5, 62.9, 32.7, 20.7, 20.5, 20.4. HR-ESI-MS 584.2138 
([M+H]+, C31H30N5O7+ ; calc. for 584.2140).   
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4. Ru-Catalyzed C-H Indolization of Arenes via C-H activation. 
All commercially available chemicals were purchased from the suppliers quoted in Paragraph 1.0 
of Supplementary Informations: these chemicals were purified through a short plug of celite prior 
to their use in catalysis. The synthesis of non commercial available compounds is presented below. 
The synthesis of the starting materials 14, 53-62 the optimization process of compound 79 and 
products 79, 85-94 had been already described before.[1] The procedures here reported are taken 
from the cited publication to facilitate reproduction of the results by having all the data in the same 
file. 
 
4.1 Preparation of starting materials for Ru-Catalyzed C-H activation. 
 
GP5: Following a reported procedure,[35] O-methylhydroxylamine hydrochloride (0.418 g, 5.00 
mmol, 1.00 equiv.) was added to a solution of K2CO3 (1.38 g, 10.0 mmol, 2.00 equiv) in a mixture 
of EtOAc/H2O (20 mL,1:1 0.25 M) under vigorous stirring. Then the reaction mixture was cooled 
to 0 °C and the corresponding (substituted) benzoyl chloride (5.00 mmol, 1.00 equiv) was added 
dropwise or portionwise. The reaction mixture was warmed to room temperature and stirred for 
additional 2 hours. The organic layer was separated and the aqueous layer was extracted with 
EtOAc (3x10 mL). The combined organic layers were dried over MgSO4, filtered, and the solvent 
removed under reduced pressure. The crude product was purified by flash column chromatography 
(Pentane:EtOAc 2:1) to afford the desired N-methoxy benzamides 78, 129-138. 
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Figure S10: Starting materials for Ru-catalyzed Indolization of Arenes via C-H activation.. 
 
 
 
 
 
 
S78 
 
N-Methoxybenzamide (78) 
The synthesis of N-methoxybenzamide 14 was scaled up to 10 mmol without 
reoptimization of the protocol. 
Starting from commercially available benzoyl chloride (1.15 mL, 10.0 mmol), N-
methoxybenzamide 78 (1.20 g, 7.94 mmol, 79% yield) was obtained as a colorless 
solid. IR ν 3197 (w), 2980 (w), 2935 (w), 1646 (s), 1579 (m), 1516 (m), 1484 (m), 
1310 (m), 1154 (w), 1045 (m), 1026 (m), 945 (w), 881 (s).  1H NMR (400 MHz, CDCl3) δ 10.70 
(s, 1H, NHOCH3), 7.70 (dd, J = 8.3, 1.4 Hz, 2H, ArH), 7.38 (m, 1H, ArH), 7.26 (ddd, J = 8.3, 6.6, 
1.3 Hz, 2H, ArH), 3.69 (s, 3H, NHOCH3). 13C NMR (100 MHz, CDCl3) δ 166.2, 131.7, 128.3, 
127.1, 63.9, 53.3. NMR values are in accordance with the data reported in literature.[34] 
N-Methoxy-4-methylbenzamide (129) 
Starting from commercially available 4-methylbenzoyl chloride (775 mg, 5.00 
mmol), N-methoxy-4-methylbenzamide 129 (822 mg, 4.98 mmol, 100% yield) was 
obtained as a colorless solid. IR ν 3201 (w), 2975 (w), 2935 (w), 1646 (s), 1572 (w), 
1494 (m), 1439 (w), 1308 (m), 1155 (w), 1043 (s), 1020 (m), 943 (w), 883 (s), 833 
(m). 1H NMR (400 MHz, CDCl3) δ 10.73 (brs, 1H, NHOCH3), 7.67 (d, J = 8.2 Hz, 
2H, ArH), 7.10 (d, J = 8.0 Hz, 2H, ArH),  3.74 (s, 3H, NHOCH3), 2.30 (s, 3H, ArCH3). 
13C NMR (100 MHz, CDCl3) δ (ppm) 166.2, 142.1, 128.9, 127.1, 63.8, 21.2 (2 
aromatic Carbon signals overlapping at 128.9). NMR values are in accordance with the data 
reported in literature.[34] 
N,4-dimethoxybenzamide (130) 
Starting from commercially available 4-methoxybenzoyl chloride (853 mg, 5.00 
mmol), 4-fluoro- N,4-dimethoxybenzamide 130 (890 mg, 4.91 mmol, 98% yield) was 
obtained as a white solid. IR ν 3205 (w), 2972 (w), 2938 (w), 1644 (m), 1606 (s), 
1496 (m), 1255 (s), 1181 (m), 1159 (m), 1027 (s), 884 (m), 844 (m).  1H NMR (400 
MHz, CDCl3) δ 10.67 (s, 1H, NHOMe), 7.77 (d, J = 8.9 Hz, 2H, ArH), 6.81 (d, J = 
8.4 Hz, 2H, ArH), 3.77 (s, 3H, NHOMe), 3.76 (s, 3H, ArOMe). 13C NMR (100 MHz, 
CDCl3) δ 162.2, 132.6, 128.9, 114.0, 113.5, 63.8, 55.1. NMR values are in accordance 
with the data reported in literature.[34] 
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4-Fluoro-N-methoxybenzamide (131) 
Starting from commercially available 4-fluorobenzoyl chloride (793 mg, 5.00 mmol), 
4-fluoro-N-methoxybenzamide 131 (643 mg, 3.80 mmol, 76% yield) was obtained as 
a colorless solid. IR ν 3210 (w), 2984 (w), 2941 (w), 1656 (s), 1592 (s), 1481 (s), 
1439 (w), 1318 (w), 1154 (w), 1072 (s), 1012 (s), 944 (w), 879 (s), 841 (m).  1H NMR 
(400 MHz, CDCl3) δ 11.29 (s, 1H, NHOMe), 7.78 (m, 2H, ArH), 6.96 (m, 2H, ArH), 
3.72 (s, 3H, NHOMe).  13C NMR (101 MHz, CDCl3) 165.2, 164.7 (d, J = 252.5 Hz), 
129.6 (d, J = 9.0 Hz), 127.6 (d, J = 3.3 Hz), 115.3 (d, J = 22.0 Hz), 63.7.  NMR data 
is corresponding to the reported values.[34] 
4-Bromo-N-methoxybenzamide (132) 
Starting from commercially available 4-bromobenzoyl chloride (1.09 g, 5.00 mmol), 
4-bromo-N-methoxybenzamide 132 (700 mg, 3.04 mmol, 61% yield) was obtained 
as a colorless solid. IR ν 3059 (w), 3006 (w), 1647 (s), 1604 (s), 1497 (s), 1267 (s), 
1237 (s), 1158 (m), 1041 (m), 885 (m), 850 (s). 1H NMR (400 MHz, CDCl3) δ 10.59 
(brs, 1H, NHOCH3), 7.56 (d, J = 8.5 Hz, 2H, ArH), 7.41 (d, J = 8.6 Hz, 2H), 3.71 (s, 
3H, NHOCH3). 13C NMR (100 MHz, CDCl3) δ 165.4, 131.7, 130.4, 128.8, 126.7, 
64.1. 1H NMR data is corresponding to the reported values.[34] 
 
N-Methoxy-3-methylbenzamide (133) 
Starting from commercially available 3-methylbenzoyl chloride (775 mg, 5.00 
mmol), N-methoxy-3-methylbenzamide 133 (813 mg, 4.92 mmol, 98% yield) 
was obtained as a white solid. IR ν 3004 (w), 2953 (w), 1726 (s), 1650 (m), 1516 
(w), 1439 (m), 1303 (m), 1264 (s), 1156 (m), 1109 (w), 982 (w), 826 (w).  1H 
NMR (400 MHz, CDCl3) δ (ppm) 11.09 (s, 1H, NHOCH3), 8.37 (s, 1H, ArH), 
8.03 (dt, J = 7.8, 1.5 Hz, 1H), 7.98 (dt, J = 7.8, 1.5 Hz, 1H), 7.39 (t, J = 7.8 Hz, 
1H), 3.78 (s, 6H, NHOMe + ArCH3). 13C NMR (101 MHz, CDCl3) δ 166.0, 132.4, 132.0, 131.6, 
130.1, 128.5, 128.1, 63.9, 52.1. NMR values are in accordance with the data reported in 
literature.[34] 
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N-Methoxy-3-(trifluoromethyl)benzamide (134) 
Starting from commercially available 3-(trifluoromethyl)benzoyl chloride (1.04 
g, 5.00 mmol), N-methoxy-4-methylbenzamide 134 (822 mg, 3.75 mmol, 75% 
yield) was obtained as a colorless solid. IR ν 3190 (w), 2995 (w), 1656 (m), 1522 
(w), 1440 (w), 1330 (s), 1283 (m), 1169 (s), 1125 (s), 1075 (m), 909 (w). 1H 
NMR (400 MHz, CDCl3) δ 9.60 (s, 1H, NHOCH3), 8.02 (s, 1H, ArH), 7.95 (d, 
J = 8.1 Hz, 1H, ArH), 7.56 (t, J = 7.8 Hz, 1H, ArH), 3.87 (s, 3H, NHOCH3). 13C 
NMR (100 MHz, CDCl3) δ 168.3, 130.5, 129.3, 128.7, 128.6, 124.2, 124.2, 123.5 (q, JF = 272.6 
Hz), 64.6. NMR values are in accordance with the data reported in literature.[36] 
3-Fluoro-N-methoxybenzamide (135) 
Starting from commercially available 3-fluorobenzoyl chloride (775 mg, 5.00 
mmol), 3-fluoro-N-methoxybenzamide 1351 (710 mg, 4.20 mmol, 84% yield) was 
obtained as a colorless solid. Mp: 67.9°C. IR 2979 (w), 2940 (w), 1652 (s), 1587 
(s), 1519 (m), 1483 (m), 1226 (s), 1046 (m), 937 (m), 816 (s). 1H NMR (400 MHz, 
CDCl3) δ 10.76 (brs, 1H, NHOCH3), 7.57 (m, 1H, ArH), 7.50 (ddd, J = 9.4, 2.6, 
1.6 Hz, 1H, ArH), 7.30 – 7.21 (m, 1H, ArH), 7.08 (t, J = 8.8 Hz, 1H, ArH), 3.73 
(s, 3H, NHOCH3). 13C NMR (101 MHz, CDCl3) δ 165.0, 162.4 (d, J = 247.6 Hz), 133.7 (d, J = 
6.9 Hz), 130.1 (d, J = 7.8 Hz), 122.8, 118.9 (d, J = 21.2 Hz), 114.4 (d, J = 23.3 Hz), 64.0. Mp and 
IR significative values are in accordance with the data reported in literature.[37]  
3-Chloro-N-methoxybenzamide (136) 
Starting from commercially available 3-chlorobenzoyl chloride (875 g, 5.00 
mmol), 3-chloro-N-methoxybenzamide 136 (830 mg, 4.47 mmol, 89% yield) was 
obtained as a white solid. IR ν 3187 (w), 3006 (w), 2937 (w), 1646 (s), 1572 (s), 
1519 (m), 1471 (m), 1298 (m), 1162 (m), 1048 (m), 944 (m), 904 (m). 1H NMR 
(400 MHz, CDCl3): δ 9.90 (br s, 1H, NHOCH3), 7.75 (s, 1H, ArH), 7.64 (d, J = 
7.8 Hz, 1H, ArH), 7.45 (dd, J = 8.1, 2.1 Hz, 1H, ArH), 7.32 (t, J = 7.9 Hz, 1H, 
                                                 
1: Compound 59 is purchaseable via Adlab Chemicals Building Blocks and Aurora Building Blocks. 
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ArH), 3.83 (s, 3H, NHOCH3). 13C NMR (101 MHz, CDCl3): δ 165.1, 134.7, 133.4, 132.0, 129.9, 
127.5, 125.3, 64.4. NMR values are in accordance with the data reported in literature.[38] 
N-Methoxybenzo[d][1,3]dioxole-5-carboxamide (137) 
Starting from commercially available benzo[d][1,3]dioxole-5-carbonyl chloride 
(923 mg, 5.00 mmol), N-methoxybenzo[d][1,3]dioxole-5-carboxamide 137 (865 
mg, 4.43 mmol, 89% yield) was obtained as a white solid. Rf: 0.4 (Pentane:EtOAc 
4:1). IR ν 2982 (w), 2938 (w), 1650 (m), 1605 (m), 1478 (s), 1438 (m), 1300 (m), 
1252 (s), 1093 (m), 1034 (s), 927 (s), 839 (m).  1H NMR (400 MHz, CDCl3) δ 
10.59 (br s, 1H, NHOCH3), 7.31 (d, J = 8.2, 1.8 Hz, 1H, ArH), 7.23 (s, 1H, ArH), 
6.69 (d, J = 8.1, Hz, 1H, ArH), 5.92 (s, 2H, OCH2O), 3.75 (s, 3H, NHOCH3). 13C 
NMR (101 MHz, CDCl3) δ 165.7, 150.4, 147.6, 125.5, 122.1, 107.8, 107.5, 101.5, 63.9. HR-ESI-
MS 196.0604 ([M+H]+, C9H10NO4+ ; calc. for 196.0604).     
N-Methoxy-1-naphthamide (138) 
For this starting material the synthesis was performed on 1.00 mmol scale 
Starting from commercially available 1-naphthoyl chloride (191 mg, 1.00 
mmol), N-methoxy-1-naphthamide 138 (183 mg, 0.909 mmol, 91% yield) was 
obtained as a white solid. IR 2943 (w), 2907 (w), 2827 (w), 1631 (s), 1617 (s), 
1591 (m), 1537 (w), 1318 (w), 1262 (w), 1063 (m), 958 (m), 889 (w). 1H NMR 
(300 MHz, DMSO-d6) δ 8.72 (br s, 1H, NHOCH3), 8.28 (m, 1H, ArH), 8.10–
7.90 (m, 2H, ArH), 7.71–7.41 (m, 4H, ArH), 3.94 (s, 3H, NHOCH3). 13C NMR (75 MHz, CDCl3) 
δ 167.3, 133.6, 131.4, 130.3, 129.6, 128.3, 127.4, 126.6, 125.6, 125.1, 124.5, 64.8. NMR values 
are in accordance with the data reported in literature.[39] 
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4.2 Optimization of the Ru-Catalyzed Indolization of Arenes via C-H activation. 
GP5: In a vial, N-methoxybenzamide 78 (15.0 mg, 0.100 mmol), 1-(3-1-methyl-1H-indole)-1H-
1λ3 -benzo[b]iodo-3(2H)-one 21 (1.10 equiv.), [RuCl2(p-cymene)]2 139 (2.45 mg, 4.00 µmol, 4 
mol%) and the relative additives (16 mol%) were dissolved in the specified dry solvent (0.1 M) 
under nitrogen. the reaction mixture was degassed (freeze-thaw-pump) and stirred at the reported 
T in °C overnight. Then the reaction was stopped, the organic layer washed with a saturated 
solution of NaHCO3 (2 ml) and the solvent removed under reduced pressure. Flash column 
chromatography (Pentane:EtOAc 2:1) afforded the desired product (see compound 79’s 
characterization for all the chemical data).  
 
Table S9: Screening of solvents  
 
Entry Solvent Yield%a 
1 DCM - 
2 DCE - 
3 MeOH 43% 
4 EtOH 34% 
5 t-BuOH - 
6 t-AmylOH - 
7 Toluene - 
8 Xylene - 
9 Dioxane 28% 
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10 MeCN - 
11 DMF - 
12 2,2,2-Trifluoroethanol (TFE) 55% 
13 Hexafluoroisopropanol (HFIP) 30% 
14 Nonafluoroisopropanol (NFIP):HFIP 1:9 - 
15 HFIP:DCE 9:1 - 
16 HFIP:DCE 8:2 35% 
17 HFIP:DCE 1:1 - 
18 Monofluoroethanol (MFE) 21% 
a) Substrate 78 (0.100 mmol), IndoleBX 21 (0.110 mmol), 
[Ru(pCymeneCl2)]2 139 (4 mol%), NaOAc (16 mol%) and solvent (0.1 M) 
at 60 °C. Isolated yield after flash chromatography is given. 
Table S10: Screening of the Temperature 
 
Entry T Yield%a 
1 r.t -b 
2 40 low conversionb 
3 60 55% 
4 80 low conversionc 
5 120 -c 
a) Substrate 78 (0.100 mmol), IndoleBX 21 (0.110 mmol), 
[Ru(pCymeneCl2)]2 139 (4 mol%), NaOAc (16 mol%) and TFE (0.1 M) at T 
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°C. Isolated yield after flash chromatography is given. b) clean reaction, 
starting material recovered. c) decomposition occurred. 
Table S11: Screening of the base  
 
Entry Base Yield%a 
1 LiOPiv - 
2 Li2CO3 - 
3 LiMes -b 
4 NaOAc 55% 
5 Na2CO3 - 
6 NaOPiv 50% 
7 NaMes 34% 
8 63 -b 
9 64 68%c 
10 65 65%b 
11 66 66%b 
12 KOAc - 
13 KOPiv - 
14 KMes 26%b 
15 CsOPiv - 
16 Cs2CO3 - 
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a) Substrate 78 (0.100 mmol), IndoleBX 21 (0.110 mmol), 
[Ru(pCymeneCl2)]2 139 (4 mol%), base (16 mol%) and TFE (0.1 M) at 60 
°C. Isolated yield after flash chromatography is given. b) decomposition 
occurred. c)clean reaction, starting material recovered. 
 
 
Table S12: Screening of the silver(I) additive 
Entry Solvent Yield%a 
1 none 68%c 
2 Ag(NTf2) -b 
3 AgSbF6 -c 
4 AgPF6 -b 
5 AgBF4 -b 
6 AgOTf -b 
7 AgOTs -b 
8 AgOAc -c 
9 AgBenzoate -b 
10 AgTFA -c 
a) Substrate 78 (0.100 mmol), IndoleBX 21 (0.110 mmol), 
[Ru(pCymeneCl2)]2 139 (4 mol%), NaCOOAd (16 mol%), silver(I) 
additive (16 mol%) and TFE (0.1 M) at 60 °C. Isolated yield after flash 
chromatography is given. b) decomposition occurred. c) clean reaction, 
starting material recovered. 
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4.3 Preparation of the Ruthenium Catalyst (84). 
Following a reported procedure,2 [RuCl2(p-cymene)]2 139 (105 mg, 0.163 mmol), adamantane-1-
carboxylic acid (118 mg, 0.652 mmol, 4.00 equiv.) and K2CO3 (225 mg, 1.63 mmol, 10.0 equiv.) 
were suspended in toluene (16.0 mL, 0.01 M) under N2. The resulting suspension was stirred for 3 
hours at r.t.. The solvent was then removed in vacuo and the residue dissolved in dry CH2Cl2 (20 
mL). The resulting suspension was filtered under N2 through a short plug of celite. The solvent was 
removed in vacuo to yield (catalyst) complex 84 (90.0 mg, 0.156 mmol, 96% yield) as an orange 
solid. 1H NMR (300 MHz, CDCl3): δ 5.70 (d, J = 5.7 Hz, 2H, ArH), 5.49 (d, J = 5.7 Hz, 2H, ArH), 
2.88 (hept, J = 7.1 Hz, 1H, ArCH(CH3)2), 2.23 (s, 3H, ArCH3), 1.92 (t, J = 3.3 Hz, 6H, 
ArCH(CH3)2), 1.78 (s, 12H, AdCH2), 1.63 (s, 12H, AdCH2), 1.33 (d, J = 6.9 Hz, 6H, AdCH). 1H-
NMR values are in accordance with the data reported in literature.35 
     
  
                                                 
[2] L. Ackermann, P. Novák, R. Vicente, N. Hofmann, Angew. Chem. Int. Ed. 2009, 48, 6045–6048. 
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4.4 Scope of the Ru-Catalyzed Indolization via C-H activation.   
 
GP6: In a vial, freshly synthetized benzamide 78, 129-138 (50.0 mg, 0.300 mmol), 1-(3-1-methyl-
1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one 21 (0.330 mmol, 1.10 equiv.) and freshly synthetized 
Ruthenium complex 139 (18.2 mg, 30.0 µmol, 10 mol%), were dissolved in dry TFE (3 ml, 0.1 M) 
under nitrogen. the reaction mixture was degassed (freeze-thaw-pump) and stirred at 60 °C 
overnight. It was then allowed to cool down to r.t., washed with a saturated aqueous NaHCO3 (2ml) 
and concentrated under reduced pressure. Flash column chromatography (Pentane:EtOAc) 
afforded the desired products 85-95. 
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Figure S11: Scope with Methoxy-amides. 
 
N-Methoxy-2-(1-methyl-1H-indol-3-yl)benzamide (79) 
Starting from N-methoxybenzamide 78 (45.3 mg, 0.300 mmol), N-
methoxy-2-(1-methyl-1H-indol-3-yl)benzamide 79 (57.0 mg, 0.203 mmol, 
68% yield) was obtained as a yellow oil. Rf: 0.4 (Pentane:EtOAc 2:1). IR 
ν 3209 (w), 3057 (w), 2968 (w), 2934 (m), 2816 (w), 1655 (s), 1599 (w), 
1547 (w), 1482 (s), 1464 (m), 1378 (m), 1329 (m), 1223 (m), 1161 (w), 
1034 (m), 944 (m), 885 (m). 1H NMR (400 MHz, CDCl3) δ 7.98 (br s, 1H, 
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NHOCH3), 7.74 (dd, J = 7.5, 5.9 Hz, 1H, ArH), 7.67 (d, J = 7.9 Hz, 1H, IndoleH), 7.57 (dd, J = 
7.8, 1.4 Hz, 1H, ArH), 7.52 (td, J = 7.5, 1.4 Hz, 1H, ArH), 7.38 (m, 2H, ArH + IndoleH), 7.30 (ddd, 
J = 8.2, 6.9, 1.1 Hz, 1H, IndoleH), 7.24 (s, 1H, CH3NCHC), 7.18 (ddd, J = 7.9, 6.9, 1.0 Hz, 1H, 
IndoleH), 3.85 (s, 3H, NCH3), 3.46 (s, 3H, NHOCH3). 13C NMR (101 MHz, CDCl3) δ 168.4, 137.0, 
132.5, 132.4, 130.8, 130.7, 129.5, 128.1, 126.8, 126.7, 122.5, 120.3, 119.5, 113.5, 109.6, 63.9, 
33.0. HR-ESI-MS 303.1108 ([M+Na]+, C17H16N2NaO2+; calc. for 303.1104).  
N-Methoxy-4-methyl-2-(1-methyl-1H-indol-3-yl)benzamide (85) 
Starting from N-methoxy-4-methylbenzamide 129 (50.0 mg, 0.300 mmol), 
N-methoxy-4-methyl-2-(1-methyl-1H-indol-3-yl)benzamide 85 (30.0 mg, 
0.102 mmol, 34% yield) was obtained as a yellow oil. Rf: 0.44 
(Pentane:EtOAc 2:1). IR ν 3200 (w), 3047 (w), 2936 (w), 1662 (s), 1615 
(m), 1543 (w), 1482 (m), 1370 (w), 1331 (w), 1232 (w), 1160 (w), 1086 (w), 
1040 (w), 1015 (w), 912 (w), 887 (w), 834 (w). 1H NMR (400 MHz, CDCl3) 
δ 7.97 (br s, 1H, NHOCH3), 7.71 – 7.64 (m, 2H, ArH), 7.40 – 7.34 (m, 2H, ArH), 7.30 (ddd, J = 
8.2, 6.9, 1.2 Hz, 1H, ArH), 7.22 – 7.16 (m, 3H, ArH), 3.85 (s, 3H, NCH3), 3.44 (s, 3H, NHOCH3), 
2.42 (s, 3H, ArCH3). 13C NMR (101 MHz, CDCl3) δ 168.5, 141.1, 137.0, 132.4, 131.4, 129.7, 
129.6, 128.0, 127.7, 126.8, 122.5, 120.4, 119.6, 113.8, 109.6, 63.8, 33.0, 21.5. HR-ESI-MS 
317.1264 ([M+Na]+, C18H18N2NaO2+; calc. for 317.1260).   
N,4-Dimethoxy-2-(1-methyl-1H-indol-3-yl)benzamide (86) 
Starting from N,4-dimethoxybenzamide 130 (54.5 mg, 0.300 mmol), N,4-
dimethoxy-2-(1-methyl-1H-indol-3-yl)benzamide 86 (85.0 mg, 0.274 
mmol, 91% yield) was obtained as a yellow oil. Rf: 0.48 (Pentane:EtOAc 
2:1). IR ν 3203 (w), 2961 (w), 2936 (w), 2838 (w), 1661 (s), 1603 (s), 1467 
(m), 1330 (m), 1279 (m), 1238 (m), 1214 (m), 1084 (m), 1030 (m), 886 (w).  
1H NMR (400 MHz, CDCl3) δ 8.02 (br s, 1H, NHOCH3), 7.75 (d, J = 8.6 
Hz, 1H, ArH), 7.66 (dd, J = 8.0, 1.0 Hz, 1H, ArH), 7.38 (d, J = 8.3 Hz, 1H, ArH), 7.30 (ddd, J = 
8.1, 7.0, 1.1 Hz, 1H, ArH), 7.22 (s, 1H, NCHC), 7.18 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H, ArH), 7.03 (d, 
J = 2.6 Hz, 1H, ArH), 6.92 (dd, J = 8.6, 2.6 Hz, 1H, ArH), 3.85 (s, 3H, NCH3), 3.85 (s, 3H, OCH3), 
3.43 (s, 3H, NHOCH3). 13C NMR (101 MHz, CDCl3) δ 168.1, 161.3, 137.0, 134.3, 131.5, 128.0, 
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126.7, 124.8, 122.5, 120.4, 119.6, 115.7, 113.7, 112.5, 109.7, 63.8, 55.4, 33.0. HR-ESI-MS 
333.1210 ([M+Na]+, C18H18N2NaO3+; calc. for 333.1210).   
 
5-Fluoro-N-methoxy-2-(1-methyl-1H-indol-3-yl)benzamide (87) 
Starting from 4-fluoro-N-methoxybenzamide 131 (50.7 mg, 0.300 mmol), 
4-bromo-N-methoxy-2-(1-methyl-1H-indol-3-yl)benzamide 87 (78.0 mg, 
0.243 mmol, 81% yield) was obtained as a yellow oil. Rf: 0.40 
(Pentane:EtOAc 2:1). IR ν 3201 (w), 3055 (w), 2984 (w), 2938 (w), 1932 
(w), 1663 (m), 1551 (w), 1481 (m), 1455 (m), 1374 (m), 1330 (m), 1266 (s), 
1245 (m), 1224 (m), 1161 (w), 1052 (m), 943 (w), 829 (s). 1H NMR (400 
MHz, CDCl3) δ 8.03 (s, 1H, NHOCH3), 7.55 (d, J = 7.7 Hz, 1H, ArH), 7.48 (m, 1H, ArH), 7.42 – 
7.35 (m, 2H, ArH), 7.33 – 7.27 (m, 2H, ArH), 7.23 (s, 1H, NCHC), 7.17 (ddd, J = 8.0, 7.0, 1.1 Hz, 
1H, ArH), 3.84 (s, 3H, NCH3), 3.31 (s, 3H, NHOCH3).  13C NMR (101 MHz, CDCl3; two doublet 
were not resolved) δ 166.6, 160.1 (d, J = 247.4 Hz),  136.8, 135.2, 129.2, 128.6 (d, J = 8.5 Hz), 
127.1, 125.0, 122.5, 120.4, 119.9 (d, J = 2.2 Hz), 118.01 (d, J = 23.3 Hz), 109.6, 105.9, 63.6, 33.1. 
19F NMR (376 MHz, CDCl3) δ -111.7. HR-ESI-MS 321.1008 ([M+Na]+, C17H15FN2NaO2+; calc. 
for 321.1010).  
4-Bromo-N-methoxy-2-(1-methyl-1H-indol-3-yl)benzamide (88) 
Starting from 4-bromo-N-methoxybenzamide 132 (69.0 mg, 0.300 mmol), 
4-bromo-N-methoxy-2-(1-methyl-1H-indol-3-yl)benzamide 88 (91.0 mg, 
0.253 mmol, 84% yield) was obtained as an orange oil. Rf: 0.35 
(Pentane:EtOAc 2:1). IR ν 3186 (w), 3063 (w), 2934 (w), 1656 (s), 1605 
(s), 1580 (m), 1480 (s), 1364 (w), 1331 (m), 1265 (s), 1195 (m), 1082 (w), 
1037 (m), 986 (w), 939 (w), 887 (m), 826 (m).  1H NMR (400 MHz, CDCl3) 
δ 8.04 (br s, 1H, NHOCH3), 7.75 (m, 1H, ArH), 7.67 (d, J = 8.0 Hz, 1H, ArH), 7.39 (d, J = 8.2 Hz, 
1H, ArH), 7.33 (m, 1H, ArH), 7.28 – 7.24 (m, 2H, ArH), 7.21 (m, 1H, ArH), 7.07 (td, J = 8.3, 2.6 
Hz, 1H, ArH), 3.85 (s, 3H, NCH3), 3.46 (s, 3H, NHOCH3). 13C NMR (101 MHz, CDCl3) δ 167.4, 
137.0, 134.6, 133.3, 131.2, 129.8, 128.4, 126.4, 125.2, 122.8, 120.7, 119.3, 112.3, 109.8, 63.9, 33.1 
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(one Carbon signal not resolved). HR-ESI-MS 381.0204 ([M+Na]+, C17H1579BrN2NaO2+; calc. for 
381.0209).  
N-Methoxy-5-methyl-2-(1-methyl-1H-indol-3-yl)benzamide (89) 
Starting from N-methoxy-3-methylbenzamide 133 (50.0 mg, 0.300 
mmol), N-methoxy-5-methyl-2-(1-methyl-1H-indol-3-yl)benzamide 
89 (44.0 mg, 0.149 mmol, 50% yield) was obtained as a yellow oil. Rf: 
0.40 (Pentane:EtOAc 2:1). IR ν 3181 (w), 2932 (w), 1713 (s), 1660 (s), 
1606 (m), 1538 (w), 1466 (w), 1437 (w), 1289 (m), 1262 (s), 1248 (s), 
1162 (w), 1128 (m), 1107 (m), 1038 (w). 1H NMR (400 MHz, CD2Cl2) 
δ 8.27 (s, 1H, ArH), 8.24 (s, 1H, NHOCH3), 8.13 (dd, J = 8.1, 1.9 Hz, 1H, ArH), 7.67 (dd, J = 9.9, 
8.0 Hz, 2H, ArH), 7.41 (dt, J = 8.3, 0.9 Hz, 1H, ArH), 7.34 (s, 1H, ArH), 7.29 (ddd, J = 8.2, 7.0, 
1.1 Hz, 1H, ArH), 7.18 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, ArH), 3.92 (s, 3H, NCH3), 3.85 (s, 3H, CH3), 
3.49 (s, 3H, NHOCH3). 13C NMR (101 MHz, CD2Cl2) δ 166.7, 138.2, 137.8, 133.1, 131.8, 131.2, 
131.0, 129.5, 128.6, 127.0, 123.1, 121.0, 119.9, 113.3, 110.4, 64.3, 52.7, 33.6. HR-ESI-MS 
317.1265 ([M+Na]+, C18H18N2NaO2+ calc. for 317.1260). 
 
N-Methoxy-2-(1-methyl-1H-indol-3-yl)-5-(trifluoromethyl)benzamide (90) 
Starting from N-methoxy-3-(trifluoromethyl)benzamide 134 (65.7 mg, 
0.300 mmol), N-methoxy-2-(1-methyl-1H-indol-3-yl)-5-
(trifluoromethyl)benzamide 90 (63.0 mg, 0.181 mmol, 60% yield) was 
obtained as a colorless oil. Rf: 0.37 (Pentane:EtOAc 2:1). IR ν 3187 
(w), 2978 (w), 2935 (w), 1657 (m), 1617 (w), 1549 (w), 1469 (w), 1331 
(s), 1274 (w), 1173 (m), 1159 (m), 1127 (s), 1092 (m), 947 (w), 911 
(w), 849 (w).   1H NMR (400 MHz, CDCl3) δ 8.00 (br s, 1H, NHOCH3), 7.91 (s, 1H, ArH), 7.70 – 
7.62 (m, 2H, ArH), 7.59 (d, J = 8.0 Hz, 1H, ArH), 7.33 (m, 1H, ArH), 7.27 (m, 1H, ArH), 7.24 (s, 
1H, NCHC), 7.14 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H, ArH), 3.79 (s, 3H, NCH3), 3.45 (s, 3H, NHOCH3). 
13C NMR (101 MHz, CDCl3) δ 167.1, 137.1, 136.4, 132.6, 130.9, 128.8, 128.7, 127.3, 126.7, 
126.4, 123.80 (q, J = 272.1 Hz, CF3), 122.8, 120.8, 119.2, 112.2, 109.9, 64.1, 33.1. 19F NMR (376 
MHz, CDCl3) δ -62.5. HR-ESI-MS 371.0979 ([M+Na]+, C18H15F3N2NaO2+ calc. for 371.0978).  
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5-Fluoro-N-methoxy-2-(1-methyl-1H-indol-3-yl)benzamide (91) 
Starting from 3-fluoro-N-methoxybenzamide 135 (50.7 mg, 0.300 
mmol), 4-bromo-N-methoxy-2-(1-methyl-1H-indol-3-yl)benzamide 91 
(84.0 mg, 0.225 mmol, 75% yield) was obtained as a yellow oil. Rf: 0.38 
(Pentane:EtOAc 2:1). IR ν 3179 (w), 3055 (w), 2932 (m), 2853 (w), 1662 
(s), 1586 (m), 1550 (w), 1479 (s), 1329 (w), 1256 (w), 1222 (w), 1163 
(w), 1089 (m), 1038 (m), 956 (w), 911 (m), 882 (m), 824 (w). 1H NMR 
(400 MHz, CDCl3) δ 8.00 (br s, 1H, NHOCH3), 7.72 (d, J = 2.0 Hz, 1H, ArH), 7.64 (t, J = 9.1 Hz, 
2H, ArH), 7.52 (dd, J = 8.2, 2.0 Hz, 1H, ArH), 7.40 (m, 1H, ArH), 7.32 (dd, J = 7.0, 1.2 Hz, 1H, 
ArH), 7.25 (s, 1H, NCHC), 7.21 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H, ArH), 3.85 (s, 3H, NCH3), 3.45 (s, 
3H, NHOCH3). 13C NMR (101 MHz, CDCl3) δ 167.6, 163.8 (d, J = 250.9 Hz), 137.0, 135.4, 135.3 
(d, J = 9.4 Hz), 131.8 (d, J = 9.5 Hz),  128.4, 128.3, 126.4, 122.7, 120.7, 117.10 (d, J = 21.5 Hz), 
113.79 (d, J = 21.9 Hz), 112.5, 109.8, 63.9, 33.1. 19F NMR (376 MHz, CDCl3) δ -109.3. HR-ESI-
MS 321.1011 ([M+Na]+, C17H15FN2NaO2+ calc. for 321.1010).  
 
5-Chloro-N-methoxy-2-(1-methyl-1H-indol-3-yl)benzamide (92) 
Starting from 3-chloro-N-methoxybenzamide 136 (55.7 mg, 0.300 
mmol), N-methoxy-2-(1-methyl-1H-indol-3-yl)-5-
(trifluoromethyl)benzamide 92 (70.9 mg, 0.225 mmol, 75% yield) was 
obtained as a yellow oil. Rf: 0.35 (Pentane:EtOAc 2:1). IR ν 3185 (w), 
3058 (w), 2931 (m), 2852 (w), 1656 (s), 1543 (w), 1482 (m), 1466 (m), 
1374 (w), 1330 (w), 1256 (w), 1163 (w), 1100 (m), 1041 (w), 943 (m), 
824 (w). 1H NMR (400 MHz, CDCl3) δ 7.81 (br s, 1H, NHOCH3), 7.64 (dd, J = 8.0, 1.3 Hz, 1H, 
ArH), 7.60 (d, J = 7.7 Hz, 1H, ArH), 7.45 – 7.37 (m, 2H, ArH), 7.35 (d, J = 7.9 Hz, 1H, ArH), 7.29 
(m, 1H, ArH), 7.19 (s, 1H, NCHC), 7.15 (t, J = 7.5 Hz, 1H, ArH), 3.87 (s, 3H, NCH3), 3.15 (s, 3H, 
NHOCH3). 13C NMR (101 MHz, CDCl3) δ 166.9, 137.0, 133.6, 132.7, 132.0, 131.1, 130.9, 129.5, 
128.2, 126.6, 122.7, 120.6, 119.3, 112.3, 109.8, 64.0, 33.1. HR-ESI-MS 337.0720 ([M+Na]+, 
C17H15ClN2NaO2+ calc. for 337.0714).  
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N-Methoxy-6-(1-methyl-1H-indol-3-yl)benzo[d][1,3]dioxole-5-carboxamide (93) 
Starting from N-methoxybenzo[d][1,3]dioxole-5-carboxamide 137 (58.6 
mg, 0.300 mmol), N-methoxy-6-(1-methyl-1H-indol-3-
yl)benzo[d][1,3]dioxole-5-carboxamide 93 (78.0 mg, 0.240 mmol, 80% 
yield) was obtained as a white oil. Rf: 0.48 (Pentane:EtOAc 2:1). IR ν 
3191 (w), 2967 (w), 2934 (w), 2899 (w), 1656 (m), 1628 (m), 1480 (m), 
1448 (s), 1374 (w), 1340 (m), 1250 (s), 1224 (w), 1132 (w), 1040 (s), 
1017 (w), 929 (m), 833 (w).  1H NMR (400 MHz, CD2Cl2) δ 7.49 (d, J = 8.0 Hz, 1H, ArH), 7.40 
(d, J = 8.3 Hz, 1H, IndoleH), 7.33 – 7.25 (m, 3H, IndoleH), 7.14 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H, 
ArH), 6.85 (d, J = 8.1 Hz, 1H, IndoleH), 6.01 (s, 2H, OCH2O), 3.84 (s, 3H, NCH3), 3.35 (s, 3H, 
NHOCH3). (NHOMe proton present at 8.2 ppm) 13C NMR (101 MHz, CD2Cl2; the signals of two 
aromatic carbons were not resolved) δ 166.8, 149.5, 146.1, 137.0, 129.4, 127.1, 126.9, 124.1, 122.4, 
120.2, 115.2, 109.8, 107.0, 106.8, 101.7, 63.6, 33.1.  
N-Methoxy-2-(1-methyl-1H-indol-3-yl)-1-naphthamide (94) 
Starting from N-methoxy-1-naphthamide 138 (60.4 mg, 0.300 mmol), 
N-methoxy-2-(1-methyl-1H-indol-3-yl)-1-naphthamide 94 (78.0 mg, 
0.236 mmol, 79% yield) was obtained as a colorless oil. Rf: 0.35 
(Pentane:EtOAc 2:1). IR ν 3186 (w), 3056 (w), 2958 (w), 2929 (m), 
2854 (w), 1651 (s), 1615 (m), 1545 (w), 1479 (m), 1384 (w), 1339 (w), 
1264 (w), 1230 (w), 1134 (w), 1101 (w), 1074 (m), 1019 (m), 892 (w), 
821 (s).  1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 8.5 Hz, 1H, ArH), 8.00 – 7.95 (m, 2H, ArH + 
NHOCH3), 7.89 (m, 1H, ArH), 7.80 (t, J = 8.6 Hz, 2H, ArH), 7.58 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H, 
ArH), 7.52 (ddd, J = 8.1, 6.9, 1.3 Hz, 1H, ArH), 7.41 (d, J = 9.7 Hz, 2H, ArH), 7.32 (m, 1H, ArH), 
7.22 (m, 1H, ArH), 3.86 (s, 3H, NCH3), 3.66 (s, 3H, NHOCH3). 13C NMR (101 MHz, CDCl3) δ 
168.3, 137.1, 131.8, 131.3, 131.1, 130.0, 128.9, 128.5, 128.0, 127.6, 127.4, 126.9, 126.0, 124.8, 
122.3, 120.2, 119.4, 113.1, 109.8, 64.0, 33.0. HR-ESI-MS 353.1256 ([M+Na]+, C21H18N2NaO2+ 
calc. for 353.1260).   
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5. Crystal Structure and DSC Measurements. 
 
A single crystal was grown by slow diffusion of the solution of 25 in MeOD/CCl4 mixture. 
Supplementary crystallographic data for this compound have been deposited at Cambridge 
Crystallographic Data Centre (1540821) and can be obtained free of charge via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
A single crystal was grown by slow diffusion of the solution of 37 in MeOD/CCl4 mixture. 
Supplementary crystallographic data for this compound have been deposited at Cambridge 
Crystallographic Data Centre (1541174) and can be obtained free of charge via 
www.ccdc.cam.ac.uk/data_request/cif. 
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DSC measurements of compound 21  
 
Integral
328.82 mJ
  normalized
61.12 Jg^
-1
Peak Height
0.34 mW
Peak
289.54 °C
Extrapol. Peak
289.56 °C
Peak W
idth
69.66 °C
Left Limit
220.94 °C
Right Limit
346.68 °C
Heating Rate
4.00 °Cmin^-1
Integral
24.01 mJ
  normalized
4.46 Jg^-1
Peak Height
0.10 mW
Peak
119.94 °C
Extrapol. Peak
113.21 °C
Peak W
idth
16.28 °C
Left Limit
103.95 °C
Right Limit
134.74 °C
Heating Rate
4.00 °Cmin^-1
Integral
1518.83 m
J
  normalized
282.31 Jg^-1
Peak Height
17.29 mW
Peak
182.78 °C
Extrapol. Peak
182.75 °C
Peak W
idth
3.69 °C
Left Limit
150.58 °C
Right Limit
202.03 °C
Heating Rate
4.00 °Cmin^-1
Method Name: 30-450°C 4°C per min
FBE-02534-01, 12.12.2016 16:55:17
FBE-02534-01, 5.3800 m
g
mW 20
min °C
50
100
150
200
250
300
350
400
0
10
20
30
40
50
60
70
80
90
100
^exo
STAR
e SW
 12.10
SYNGENTA: CPR Analytics
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DSC measurements of compound 35a  
 
Integral
265.81 mJ
  normalized
57.78 Jg^
-1
Peak Height
0.32 mW
Peak
319.00 °C
Extrapol. Peak
353.89 °C
Peak W
idth
53.48 °C
Heating Rate
4.00 °Cmin^-1
Integral
2640.75 m
J
  normalized
574.08 Jg^-1
Peak Height
41.06 mW
Peak
214.99 °C
Extrapol. Peak
214.87 °C
Peak W
idth
1.75 °C
Heating Rate
4.00 °Cmin^-1
FBE-02533-01, 12.12.2016 14:51:04
FBE-02533-01, 4.6000 m
g
mW 50
min °C
50
100
150
200
250
300
350
400
0
10
20
30
40
50
60
70
80
90
100
^exo
STAR
e SW
 12.10
SYNGENTA: CPR Analytics
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DSC measurements of compound 35b 
 
Integral
2994.97 mJ
  normalized
546.53 Jg^-1
Peak Height
26.82 mW
Peak
202.60 °C
Extrapol. Peak
202.58 °C
Peak Width
3.30 °C
Left Limit
165.53 °C
Right Limit
285.53 °C
Heating Rate
4.00 °Cmin^-1
Integral
149.68 mJ
  normalized
27.31 Jg^
-1
Peak Height
0.49 mW
Peak
79.43 °C
Extrapol. Peak
79.21 °C
Peak Width
22.52 °C
Left Limit
77.58 °C
Right Limit
108.37 °C
Heating Rate
4.00 °Cmin^-1
FBE-02532-01, 12.12.2016 12:46:42
FBE-02532-01, 5.4800 mg
mW 20
min °C
50
100
150
200
250
300
350
400
0
10
20
30
40
50
60
70
80
90
100
^exo
STAR
e SW 12.10
SYNGENTA: CPR Analytics
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7. Spectra of new compounds 
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1-(2-1-Methyl-1H-pyrrole)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ3-benzo[d][1,2]iodaoxole (16a) 
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1-(3-1-methyl-1H-pyrrole)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ3-benzo[d][1,2]iodaoxole (16b) 
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1-(3-1-Methyl-1H-indole)-3,3-bis(trifluoromethyl)-1,3-dihydro-1λ3-benzo[d][1,2]iodaoxole (17)  
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HMBC 2D (400 MHz, CDCl3) 
19F-NMR (376 MHz, CDCl3) 
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1-(3-1-Methyl-1H-indole)-3,3-dimethyl-1,3-dihydro-1λ3-benzo[d][1,2]iodoxole (23) 
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1-(2-1-Methyl-1H-pyrrole)-3,3-dimethyl-1,3-dihydro-1λ3-benzo[d][1,2]iodoxole (38a) and 1-(3-1-
methyl-1H-pyrrole)-3,3-dimethyl-1,3-dihydro-1λ3-benzo[d][1,2]iodoxole (38b) 
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1H-NMR (400 MHz, CD2Cl2) 
13C-NMR (101 MHz, CD2Cl2) 
S109 
 
5,6-Dimethoxy-1-(3-1-Methyl-1H-indole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one (39) 
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1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3) 
S110 
 
5,6-Dimethoxy-1-(2-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one (40a) 
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1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3) 
S111 
 
5,6-Dimethoxy-1-(3-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one (40b) 
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1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3) 
S112 
 
4-Fluoro-1-(2-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one (41a) 
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1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3) 
S113 
 
4-Fluoro-1-(3-1-methyl-1H-pyrrole)- 1H-1λ3 -benzo[b]iodo-3(2H)-one (41b) 
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1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3) 
S114 
 
5-Nitro-1-(2-1-Methyl-1H-pyrrole)-1H-1λ3-benzo[d][1,2]iodoxol-3-one (42a) 
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1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3) 
S115 
 
5-Nitro-1-(3-1-methyl-1H-pyrrole)-1H-1λ3-benzo[d][1,2]iodoxol-3-one (42b) 
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1H-NMR (400 MHz, CDCl3) 
13C-NMR (101 MHz, CDCl3) 
S116 
 
1-(2 D 1 methylindole)-1H-1λ3-benzo[b]iodo-3(2H)-one (49) 
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1H-NMR (400 MHz, CDCl3:AcOH 9:1) 
13C-NMR (101 MHz, CDCl3:AcOH 9:1) 
